Unnamed: 0,patient_filename,t,text,type,n,cmem_t_reasoning,cmem_t_ans_str,cmem_t_num_update
1260,TCGA-E2-A2P5.85E91C9F-9F61-4A25-B4D9-1BCBC7108F5E,1,"SPECIMENS: A. EXCISION RIGHT BREAST NEEDLE LOCALIZATION. B. LEFT BREAST AND AXILLARY CONTENTS. C. ADDITIONAL LEFT AXILLARY TISSUE. SPECIMEN(S): A. EXCISION RIGHT BREAST NEEDLE LOCALIZATION. B. LEFT BREAST AND AXILLARY CONTENTS. C. ADDITIONAL LEFT AXILLARY TISSUE. DIAGNOSIS: A. BREAST, RIGHT, NEEDLE LOCALIZATION EXCISIONAL BIOPSY: DUCTAL CARCINOMA IN SITU (DCIS), CRIBRIFORM TYPE, NUCLEAR. GRADE 2, WITH NECROSIS AND MICROCALCIFICATIONS. - DCIS IS PRESENT AT THE MEDIAL MARGIN, IS WITHIN 0.1 CM. OF THE POSTERIOR AND SUPERIOR MARGINS, AND IS WITHIN. 0.2 CM OF THE ANTERIOR MARGIN. - ATYPICAL INTRADUCTAL PAPILLOMAS, 0.1 CM FROM THE MEDIAL. MARGIN. - COMPLEX SCLEROSING LESION WITH EXTENSIVE LOBULAR CARCINOMA. IN SITU (LCIS), INTRADUCTAL PAPILLOMAS, SCLEROSING ADENOSIS,. APOCRINE METAPLASIA, AND MICROCALCIFICATIONS. NOTE: DCIS is present in 3 of 10 slides. On a single slide, DCIS measures 0.8 cm. Immunostains were. performed with appropriate positive and negative controls. SMMHC, p63, and calponin are positive,. showing no evidence of invasive carcinoma. B. BREAST, LEFT, AND AXILLARY CONTENTS, MODIFIED RADICAL MASTECTOMY: - INVASIVE LOBULAR CARCINOMA, NOTTINGHAM GRADE 3. - 3.3 CM IN SIZE. - EXTENSIVELY INVOLVES THE NIPPLE DERMIS. - LOBULAR CARCINOMA IN SITU (LCIS), PLEOMORPHIC TYPE, WITH. FOCAL NECROSIS. - MARGINS, NEGATIVE FOR CARCINOMA. - ATYPICAL DUCTAL HYPERPLASIA. - METASTATIC CARCINOMA IN 20 OF 24 LYMPH NODES WITH. EXTRANODAL EXTENSION, LARGEST METASTASIS IS 2.4 CM (20/24). C. ADDITIONAL AXILLARY TISSUE, LEFT, EXCISION: - METASTATIC CARCINOMA IN ONE LYMPH NODE AND TUMOR. IN FIBROADIPOSE TISSUE (1/1). NOTE: There is a 0.4 cm focus of invasive carcinoma in the fibroadipose tissue with no definite lymph. node adjacent to the focus and no breast parenchyma present. This focus is best interpreted as. extranodal extension. SYNOPTIC REPORT - BREAST. Specimens Involved. Specimens: A: EXCISION RIGHT BREAST NEEDLE LOCALIZATION. Specimen Type: Excision. Needle Localization: Yes - For mass. Laterality: Right. Invasive Tumor: Absent. Multifocality: N/A. WHO CLASSIFICATION. Intraductal proliferative lesions. Ductal carcinoma in situ 8500/2. DCIS present. Margins involved by DCIS: : medial margin. DCIS Type: Cribriform. DCIS Size (pure DCIS only): 0.8cm. Nuclear grade: Intermediate. Necrosis: Present. Location of CA++: DCIS. Benign epithelium. ER/PR/HER2 Results. ER: Positive. PR: Positive. Performed on Case: Pathological staging (pTN): pT is N X. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimens Involved. Specimens: A: EXCISION RIGHT BREAST NEEDLE LOCALIZATION. Specimen: Surgical Excision. Block Number: A2. ER: Positive. Allred Score: 8 = Proportion Score 5 + Intensity Score 3. PR: Positive. Allred Score: 8 = Proportion Score 5 + Intensity Score 3. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of. cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak. intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of staining), with a scoring. range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score. of less than or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed usina the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR. assay was not modified. Interpretation of the ER/PR immunohistochemical stain is guided by published. 136, 1:100) provided by. ) following the manufacturer S instructions. This. results in the medical literature, information provided by the reagent manufacturer and by internal. review of staining performance. SYNOPTIC REPORT - BREAST. Specimens Involved. Specimens: B: LEFT BREAST AND AXILLARY CONTENTS. C: ADDITIONAL LEFT AXILLARY TISSUE. Specimen Type: Mastectomy. Needle Localization: Laterality: Left. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive lobular carcinoma 8520/3. Tumor size: 3.3cm. Tumor Site: Central. Margins: Negative. Distance from closest margin: 0.9cm. deep. Tubular Score: 3. Nuclear Grade: 3. Mitotic Score: 2. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Absent. Lobular neoplasia: LCIS. Lymph nodes: Axillary dissection. Lymph node status: Positive 21/25 Extranodal extension. DCIS not present. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative by FISH. Performed on Case: Pathological staging (pTN): pT 2 N 3. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. GROSS DESCRIPTION: A. EXCISION RIGHT BREAST NEEDLE LOCALIZATION. Received fresh labeled with the patient's identification and ""right breast needle localization"" is an. oriented (short stitch-superior, long stitch-lateral, double stitch-deep), 35 g, 5.5 x 5.5 x 2.5 cm needle. localized lumpectomy with radiographs. Ink code: Anterior-yellow, posterior-black, medial-green, lateral-. red, superior-blue, inferior-orange. The specimen is serially sectioned from medial to lateral into 7 slices. revealing a 1.7 x 0.7 X 0.4 cm gritty, lobulated white tumor that is closest to the anterior margin at 0.1. cm. A clip is identified in slice 2. No additional lesions are noted. Representatively submitted: A1-medial margin. A2-slice 2, superior margin. A3-4-slice 2, anterior/posterior margins to tumor. A5-A8-slice 3, full cross-section/tumor. A9-slice 4, additional deep margin to firmer fibrous tissue. A10-lateral margin. B. LEFT BREAST AND AXILLARY CONTENTS. Received fresh labeled with the patient's identification and ""left breast and axillary contents"" is an. oriented 1150 g, 26 x 21 X 4 cm mastectomy with a 15 x 7 cm skin ellipse and 1.5 cm in diameter. inverted nipple. There is also 15 x 11 cm attached axillary tissue. Ink code: Posterior-black, anterior. superior-blue, anterior inferior-orange. The specimen is serially sectioned into 12 slices from medial to. lateral with nipple in slices 5/6 revealing a retroareolar, 3.3 x 3 x 2.7 cm infiltrative, gritty indurated,. lobulated tan to white tumor in slices 5 and 6, closest to the anterior margin (areolar skin) at 0.5 cm. No. additional lesions are identified. There are 24 possible lymph nodes identified, ranging from 0.2 cm to. 2.4 cm in greatest dimension. Representatively submitted: B1-deep margin closest to tumor, slice 5. B2-B3-entire nipple, slices5-6. B4-tumor to closest anterior (skin) margin, slice 6. B5-B7-additional tumor, slice 6. B8-UOQ, slice 9. B9-LOQ, slice 8. B10-UIQ, slice 4. B11-LIQ, slice 4. B12-superior skin margin, shave. B13-6 lymph nodes. B14-one trisected lymph node. B15-6 lymph nodes. B16-5 lymph nodes. B17-one bisected lymph node. B18-2 lymph nodes. B19-2 lymph nodes. B20-one lymph node. LH. C. ADDITIONAL LEFT AXILLARY TISSUE. Received in formalin labeled with patient's identification and ""additional left axillary tissue"" is adipose. tissue measuring 3 x 2.5 X 1 cm in aggregate. Representative sections submitted in C1. CLINICAL HISTORY: ; year-old female with multicentric left breast cancer; FNA-positive lymph nodes and right mass biopsy. shows atypia, left mass retroareolar, right atypical ductal hyperplasia at 12:00. PRE-OPERATIVE DIAGNOSIS: Invasive pleomorphic lobular carcinoma retroareolar, left breast. Microscopic/Diagnostic Dictation:,. Microscopic/Diagnostio Dictation:,. Final Review:., Pathologist,. Final:., Pathologisi.",BRCA,3,"The T stage is determined by the size of the primary tumor. In this report, the left breast and axillary contents show an invasive lobular carcinoma that is 3.3 cm in size. Therefore, the T stage is T2.",T2,0.0
1235,TCGA-E2-A1BD.DF746E32-AD2F-49CB-9AA6-4F8494C16B20,1,"SPECIMENS: A. SENTINEL NODE 1 RIGHT AXILLA. B. WLE RIGHT BREAST NEEDLE LOCALIZATION. SPECIMEN(S): A. SENTINEL NODE 1 RIGHT AXILLA. B. WLE RIGHT BREAST NEEDLE LOCALIZATION. GROSS DESCRIPTION: A. SENTINEL NODE 1 RIGHT AXILLA. Received fresh is a tan pink lymph node 1.8 x 1.1 x 0.5cm. The specimen is serially sectioned and three. touch preps are taken. Toto A1. B. WLE RIGHT BREAST NEEDLE LOCALIZATION. Received fresh labeled with the patient's identification and ""WLE right breast needle localization"" is an. oriented 98g, 8 x 4.5 x 4cm needle localized lumpectomy with radiograph. Ink code: anterior-yellow,. posterior-black, superior-blue, inferior-orange, medial-green, lateral-red. Specimen is serially sectioned. from superior to inferior into 11 slices revealing a tan white firm stellate mass 2.3 x 1.8 x 1.7cm, 0.4cm. from the closest medial margin and 0.5cm from the anterior margin in slices 8-10. A portion of the. specimen is submitted for tissue procurement. Representatively submitted: B1: superior margin slice 1. B2: slice 2. B3-B4: slice 3. B5-B7: slice 4. B8-B10: slice 5. B11-812: slice 6. B13-B16: slice 7. B17-B20: slice 8 with mass in B17. B21: mass slice 9. B22: superior margin slice 9. B23: anterior margin slice 9. B24: anterior margin slice 9. B25: inferior margin slice 9. B26: deep margin slice 9. B27: mass slice 10. B28-B29: slice 10. B30: perpendicular sections of inferior margin slice 11. DIAGNOSIS: A. SENTINEL NODE 1, RIGHT AXILLA: - ONE REACTIVE LYMPH NODE (1), NO METASTATIC CARCINOMA IS SEEN. B. WIDE LOCAL EXCISION, RIGHT BREAST, NEEDLE LOCALIZATION: - INVASIVE DUCTAL CARCINOMA, SEE SYNOPTIC REPORT. SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Laterality: Right. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 2.3cm. Additional dimensions: 1.8cm x 1.7cm. Margins: Negative. Distance from closest margin: Less than 0.2cm. anterior. Tubular Score: 2. Nuclear Grade: 2. Mitotic Score: 2. Modified Scarff Bloom Richardson Grade: 2. Necrosis: Absent. Vascular/Lymphatic Invasion: Indeterminate. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node. Lymph node status: Negative 0/1. Micrometastases: Non-neoplastic areas: fibrocystic disease. DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 2%. DCIS Type: Solid. Cribriform. DCIS Location: Associated with invasive tumor. Nuclear grade: Low. Necrosis: Absent. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative by FISH. Performed on Case: Pathological staging (pTN): pT2pNO pT 2 N. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. CLINICAL HISTORY: female with right breast mass, biopsy shows ? ductal carcinoma. PRE-OPERATIVE DIAGNOSIS: Right breast carcinoma. INTRAOPERATIVE CONSULTATION: TPA- SLN #1 right axilla: Negative for tumor cells. Diagnosis called to Dr. at. Dr. ADDENDUM: ONCOTYPE DX BREAST CANCER ASSAY. RESULTS: Recurrence Score: 10. CLINICAL EXPERIENCE: Patients with a recurrence score of: 10 in the clinical validation study. had an average rate of Distant Recurrence at 10 years of 7%. ER Score: 11.1 Positive. PR Score: 10 Positive. Her2 Score: 8.9 Negative. Interpretation: ER. Negative < 6.5. Positive >= 6.5. PR. Negative < 5.5. Positive >= 5.5. Her2 Negative <10.7 Positive 11.5 Equivocal = 10.7 - 11.4. >=. See separate. report for further information. Final Review:., Pathologist. Final:., Pathologist,. Addendum: Pathologist,. Addendum Final: Pathologist,.",BRCA,0,"The T stage is determined by the size of the primary tumor. According to the report, the size of the tumor is 2.3 cm, which falls under the T2 category of tumors that are more than 2.0 cm but not more than 5.0 cm in size.",T2,1.0
1193,TCGA-E2-A14N.C972EC08-E1AE-4FCB-B8A1-15000306CDE7,1,"SPECIMENS: A. SENTINEL NODE #1 RIGHT AXILLA. B. RIGHT BREAST. C. AXILLARY CONTENT. D. LEFT BREAST REDUCTION. SPECIMEN(S): A. SENTINEL NODE #1 RIGHT AXILLA. B. RIGHT BREAST. C. AXILLARY CONTENT. D. LEFT BREAST REDUCTION. INTRAOPERATIVE CONSULTATION DIAGNOSIS: TPA, FSA: Sentinel lymph node #1 right axilla: Smears (touch imprint)-Negative for tumor cells, (frozen section)-. Positive for carcinoma. By Dr, called to Dr. at. GROSS DESCRIPTION: A. SENTINEL LYMPH NODE #1, RIGHT AXILLA. Received fresh and labeled ""sentinel node #1 right axilla"" is a 2.8x1.0x1.2 2cm lymph node. There is blue dye staining. present. The specimen is sectioned and a touch prep is performed. A portion of the lymph node is submitted for. frozen section. The lymph node is submitted in toto as follows: FSA1: frozen section of portion of lymph node. A2-A4: remainder of lymph node. B. RIGHT BREAST,MASTECTOMY: Received is a 1,321gn right mastectomy specimen measuring 23x23x5.8c Margin of specimen oriented with a. stich indicating the lateral margin . In the medial portion of the specimen is an ellipse of tan skin measuring 6.7cm. in length with a diameter of 3.1cm. Eccentrically located on the skin is a healed scar measuring 5.5cm in length. The areola is present and measures 4.0cm in length with a width of 3.0cm. The nipple is everted and is 1.0cm. The. axillary tail is 6.5x5.0x1.5cm. The anterior surface of the specimen is inked blue, the posterior surface is inked black. and the specimen is serially sectioned. In the upper inner quadrant is a well circumscribed white-tan mass. measuring 3.8x3.2x2.9c which is located 0.5 cm from the nearest deep margin. The central portion of the mass. shows areas of hemorrhage and possible necrosis. 4.6cm lateral from the mass, located approximately 2.0cm from. the areola region, is a hemorrhagic white-tan firm mass measuring 2.5x2.0x1.8cm. It is located 2.5cm from the deep. margin. The remainder of the specimen consists of primarily adipose tissue. A few possible lymph nodes are found. within the axillary tail. Multiple sections are submitted and labelled as follows: follows: B1-10:sections from the larger tumor (medial). B11-14: sections from the smaller tumor near nipple area. B15-16 - sections from upper inner quadrant. B17-18: sections from upper outer quadrant. B19-20: sections from lower outer quadrant. B21-22: sections from lower inner quadrant. B23-24 sections from nipple and areolar area. B25-B26: possible lymph nodes. C. AXILLARY CONTENTS. Received in formalin and labeled ""axillary contents levels 1&2"" is a piece of adipose tissue, 7.3 x 5.6 x 0.9 cm. Multiple lymph nodes are found, ranging in size from 0.1 to 2.8cm. Lymph nodes are submitted in toto as follows: C1: 5 possible lymph nodes. C2-C6: 4 possible lymph nodes, each. C7: 2 possible lymph nodes. C8: 3 possible lymph nodes. C9-C10: 1 bisected lymph node, each. C11-C13: 1 lymph node each. D. LEFT BREAST REDUCTION: Received in formalin and labeled "", Left Breast Reduction mammoplasty"". The specimen consists of primarily. adipose tissue, little fibrous breast tissue is found. No masses or lesions are seen. Representative sections are. submitted as follows: D1 skin and subjacent adipose tissue, D2-D3 fibrous tissue. DIAGNOSIS: A. SENTINEL NODE #1, RIGHT AXILLA: METASTATIC CARCINOMA TO ONE OUT OF ONE LYMPH NODE, CONSISTENT WITH METASTASIS FROM. PRIMARY BREAST CARCINOMA. (1/1) see note. B. RIGHT BREAST, MASTECTOMY SPECIMEN: - INVASIVE DUCTAL CARCINOMA, SBR GRADE II WITH GEOGRAPHIC AREAS OF NECROSIS,. MULTICENTRIC. - SIZE OF TUMOR: MEDIAL ASPECT OF BREAST-3.8 x 3.2x2.9 CM. CENTRAL AREA - SIZE OF TUMOR-2.5 x 2.0 x 1.8 CM. - MARGINS OF RESECTION-NEGATIVE FOR TUMOR. - FOCAL COLUMNAR CELL CHANGE. - TWO AXILLARY LYMPH NODES-NEGATIVE FOR TUMOR (0/2). C. AXILLARY CONTENTS, RESECTION: - THIRTY-FIVE AXILLARY LYMPH NODES-NEGATIVE FOR TUMOR (0/35). D. LEFT BREAST REDUCTION: BREAST TISSUE WITH INCLUDED SKIN TISSUE-NO SPECIFIC PATHOLOGIC CHANGES-NEGATIVE FOR. TUMOR. NOTE: In specimen A,(A1) size of lymph node measured 2.8x1.0x1.2cm and metastatic tumor only seen on the. portion of lymphnode submitted for frozen and permanent section in an area measuring 5.0x2.5mm. The remainder. of the lymph node submitted as A2-A4 are negative for metastatic tumor. SYNOPTIC REPORT - BREAST. Specimens Involved. Specimens: A: SENTINEL NODE #1 RIGHT AXILLA. B: RIGHT BREAST. C: AXILLARY CONTENT. D: LEFT BREAST REDUCTION. Specimen Type: Mastectomy. Needle Localization: Laterality: Right. Invasive tumor: Present. Multifocality: Yes. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Specimen size: Size of Invasive focus 3.8cm. Additional dimensions: 3.2cm x 2.9cm. Tumor Site: Upper inner quadrant. Central. Margins: Negative. Distance from closest margin: 0.5cm. Margin: deep. Tubular score: 3 (<10% tubule). Nuclear grade: 3. Mitotic score (Olympus 40x): 3 (> -13/10 hpf). Modified Scarff Bloom Richardson Grade: III (8-9 points). Necrosis: Present. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node and axillary dissection. Lymph node status: Positive 1 / 38. Micrometastases: DCIS PRESENT?. Pathological staging (pTN): pT2N1. CLINICAL HISTORY: year old with right breast ca. PRE-OPERATIVE DIAGNOSIS: Right breast ca. ADDENDUM: BREAST ER/PR - 1. SPECIMEN. Type: Other. Mastectomy. Block Number: B9. HORMONE RECEPTOR STATUS. Laboratory: Estrogen Receptor: Negative. Allred Score: 0 = Proportion Score 0 + Intensity Score 0. Progesterone Receptor: Negative. Allred Score: 0 = Proportion Score 0 + Intensity Score 0. The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the proportion score (0. =. no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of cells staining, 4 = 31-60% of. cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak intensity of staining, 2 = intermediate. intensity of staining, 3 = strong intensity of staining), with a scoring range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score of less than or. equal to 2. Methodology: Fixation Type and Length: Tissue was fixed in 10% neutral buffered formalir. CT) for no less than 8 and TC longer than 24 hours. Antibody and Assay Methodology: Mouse anti-human ER ana. PR,. Comment: This assay can be used to select invasive breast cancer patients for hormone therapy (1). ER and PR analysis was performed on this case by immunohistochemistry utilizing the ER (ER 1D5, 1:100) and PR. (PGR 136, 1:100) antibody provided by. following the manufacturer's instructions listed in the package insert. This assay was not modified, and adherence to all instruction and guidelines were strictly followed. Interpretation of. the ER/PR immunohistochemical staining characteristics is guided by published results in the medical literature (1),. information provided by the reagent manufacturer and by internal review of staining performance within Pathology. Department. 1. Harvey JM, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for. predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 17:1474-1481, 1999. SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimens Involved. Specimens: B: RIGHT BREAST. HER2 Status Results, Immunohistochemistry Evaluation. SPECIMEN. Surgical Excision. Block Number: Block. B9. Interpretation: Negative. Intensity: 0. % Tumor Staining: 0%. FISH Ordered NO. METHODOLOGY. Methodology: Fixation Type and Length: Tissue was fixed in 10% neutral buffered formalin. for no less than 8 and no longer than 24 hours. Antibody and Assay Methodology: Rabbit anti-human HER2,. HerceptestTM (FDA-approved test kit), (. A). Control Slides Examined: External kit-slides. provided by manufacturer (cell lines with high, low and negative HER2 protein expression), and in-house known. HER2 amplified control tissue were evaluated along with the test tissue. These control slides run along side of this. patient's sample showed appropriate staining. Adequacy of Specimen: Adequate, well preserved, clear-cut invasive. carcinoma identified for HER2 evaluation. Scoring Criterion and Scoring System: IHC Level of Expression(Score /Tumor Cell Membrane Staining Pattern. Negative (0)/Absence of Staining. Negative (1+)/Faint Incomplete membrane Staining, >10% of Cells. Equivocal (2+)/Weak complete membrane Staining, >10% of Cells. Positive (3+)/Strong complete membrane Staining, >10% of Cells. Equivocal Category for HER2 IHC results: A HER2, 2+ staining result that is interpreted as equivocal may not. indicate gene amplification. A FISH test for HER2 gene amplification will be ordered for all HER2 IHC 2+ results. COMMENT. This assay can be used to select invasive breast cancer patients for Trastuzumab (Hereptin) therapy (1,2). Clinical. Trials have shown that Trastuzumab substantially increases the likelihood for an objective response and overall. survival for patients with metastatic HER2-positive breast cancer, regardless of whether HER2 tumor status was. determined as IHC 3+ or FISH positive. Trastuzumab added to adjuvant chemotherapy substantially increase. disease-free survival and decreases the risk of disease recurrence by about 50% for patients with early-stage HER2. protein over-expressed or gene amplified invasive breast cancer (3). HER2 analysis was performed on this case by immunohistochemistry utilizing the FDA approved Dako HercepTes. (TM) test kit following the manufacturer's instructions listed in the package insert. This assay was not modified, and. adherence to all instruction and guidelines were strictly followed. Interpretation of the HER2 immunohistochemical. staining characteristics is guided by published results in the medical literature (4), information provided by the. reagent manufacturer and by internal review of staining performance within the Pathology Department. HER2 TEST VALIDATION. This HER2 immunohistochemical assay has been validated according to the recently revised recommendations and. guidelines from the NCCN HER2 testing in Breast Cancer Task Force, and the jointly issued recommendations and. guidelines from ASCO and the CAP (5). 80 randomly selected breast cancer samples were tested for HER2 by IHC. as outline above and interpreted as, negative (score 0/1+) equivocal (score 2+) and positive (score 3+) without. knowledge of the previous reported results. These cases were also blindly read using two different FISH assay as amplified or non-amplified and the. HER2/CEP17 ratios were recorded. After analyzing these results, there was 100% concordance between the IHC. and FISH results for cases that were interpreted as either positive or negative by IHC. 9 of the 80 cases were. interpreted as equivocal by IHC and of these 3/9 (33%) were non-amplified by FISH and 6/9 (66%) were found to be. amplified. The Pathology Department Immunohistochemistry laboratory takes full responsibility for this tests performance. and has programs in place to regularly monitor the proficiency and the interpretation of HER2 assays. The. laboratory also participates in external quality assurance HER2 programs including the CAP proficiency testing. program. REFERENCE. 1. Carlson RW, Anderson BO, Burstein HJ, et al., NCCN breast cancer clinical practice guidelines in oncology. J. Natl Compr Canc Netw. 2005;3:238-289. 2. Carlson RW, Brown E, Burstein HJ, et al., NCCN Task Force Report: adjuvant therapy for breast cancer. J Natl. Compr Canc Netw. 2006;4:S1-S26. 3. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive. breast cancer. N Eng J Med 2005;353(16):1673-84. 4. Leong ASY, Formby M, Haffajee Z, et al. Refinement of immunohistologic parameters for Her2/neu scoring. validation by FISH and CISH. Appl Immunohistochem Mol Morphol. 2006;14:384-389. 5. Wolff AC, Hammond EH, Schwartz JN, et al., American Society of Clinical Oncology/College of American. Pathologists Guideline Recommendations for Human Epidermal Growth Factor Recepto 2 Testing in Breast Cancer. Arch of Path and Lab Med 2007; 131:18-43. Immunostain results done on the smaller second tumor (section B11) are as follows: ER: Negative (0%). PR: Negative (0%). SYNOPTIC REPORT - BREAST HER-2 RESULTS. HER2 Status Results, Immunohistochemistry Evaluation. SPECIMEN. Surgical Excision. Block Number: Block. B1. Interpretation: Equivocal. Intensity: 2+. % Tumor Staining: 20%. FISH Ordered YES DATE. METHODOLOGY. Methodology: Fixation Type and Length: Tissue was fixed in 10% neutral buffered formalin. d,. for no less than 8 and no longer than 24 hours. Antibody and Assay Methodology: Rabbit anti-human HER2,. HerceptestTM (FDA-approved test kit),. Control Slides Examined: External kit-slides. provided by manufacturer (cell lines witn nigh, low and negauve HER2 protein expression), and in-house known. HER2 amplified control tissue were evaluated along with the test tissue. These control slides run along side of this. patient's sample showed appropriate staining. Adequacy of Specimen: Adequate, well preserved, clear-cut invasive. carcinoma identified for HER2 evaluation. Scoring Criterion and Scoring System: IHC Level of Expression(Score)/Tumor Cell Membrane Staining Pattern. Negative (0)/Absence of Staining. Negative (1+)/Faint Incomplete membrane Staining, >10% of Cells. Equivocal (2+)/Weak complete membrane Staining, >10% of Cells. Positive (3+)/Strong complete membrane Staining, >10% of Cells. Equivocal Category for HER2 IHC results: A HER2, 2+ staining result that is interpreted as equivocal may not. indicate gene amplification. A FISH test for HER2 gene amplification will be ordered for all HER2 IHC 2+ results. COMMENT. This assay can be used to select invasive breast cancer patients for Trastuzumab (Hereptin) therapy (1,2). Clinical. Trials have shown that Trastuzumab substantially increases the likelihood for an objective response and overall. survival for patients with metastatic HER2-positive breast cancer, regardless of whether HER2 tumor status was. determined as IHC 3+ or FISH positive. Trastuzumab added to adjuvant chemotherapy substantially increase. disease-free survival and decreases the risk of disease recurrence by about 50% for patients with early-stage HER2. protein over-expressed or gene amplified invasive breast cancer (3). HER2 analysis was performed on this case by immunohistochemistry utilizing the FDA approved Dako HercepTest. (TM) test kit following the manufacturer's instructions listed in the package insert. This assay was not modified, and. adherence to all instruction and guidelines were strictly followed. Interpretation of the HER2 immunohistochemical. staining characteristics is guided by published results in the medical literature (4), information provided by the. reagent manufacturer and by internal review of staining performance within the Pathology Department. HER2 TEST VALIDATION. This HER2 immunohistochemical assay has been validated according to the recently revised recommendations and. guidelines from the NCCN HER2 testing in Breast Cancer Task Force, and the jointly issued recommendations and. guidelines from ASCO and the CAP (5). 80 randomly selected breast cancer samples were tested for HER2 by IHC. as outline above and interpreted as, negative (score 0/1+) equivocal (score 2+) and positive (score 3+) without. knowledge of the previous reported results. These cases were also blindly read using two different FISH assay as amplified or non-amplified and the. HER2/CEP17 ratios were recorded. After analyzing these results, there was 100% concordance between the IHC. and FISH results for cases that were interpreted as either positive or negative by IHC. 9 of the 80 cases were. interpreted as equivocal by IHC and of these 3/9 (33%) were non-amplified by FISH and 6/9 (66%) were found to be. amplified. The Pathology Department Immunohistochemistry laboratory takes full responsibility for this tests performance. and has programs in place to regularly monitor the proficiency and the interpretation of HER2 assays. The. laboratory also participates in external quality assurance HER2 programs including the CAP proficiency testing. program. REFERENCE. 1. Carlson RW, Anderson BO, Burstein HJ, et al., NCCN breast cancer clinical practice guidelines in oncology. J. Natl Compr Canc Netw. 2005;3:238-289. 2. Carison RW, Brown E, Burstein HJ, et al., NCCN Task Force Report: adjuvant therapy for breast cancer. J Natl. Compr Canc Netw. 2006;4:S1-S26. 3. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive. breast cancer. N Eng J Med 2005;353(16):1673-84. 4. Leong ASY, Formby M, Haffajee Z, et al. Refinement of immunohistologic parameters for Her2/neu scoring. validation by FISH and CISH. Appl Immunohistochem Moi Morphol. 2006;14:384-389. 5. Wolff AC, Hammond EH, Schwartz JN, et al., American Society of Clinical Oncology/College of American. Pathologists Guideline Recommendations for Human Epidermal Growth Factor Recepto 2 Testing in Breast Cancer. Arch of Path and Lab Med 2007; 131:18-43. Microscopic/Diagnostic Dictation: Pathologist. Final Review: Pathologist,. Microscopic/Diagnostic Dictation: Pathologist, i. Microscopic/Diagnostic Dictation: Pathologist, (. Final Review: Pathologist,. Final: Pathologist,. Addendum: Pathologist,. Addendum Review: Pathologist. Addendum Final: Pathologist,. Addendum: PATHOLOGIST,. Addendum Review: PATHOLOGIST. Addendum Final: PATHOLOGIST. Addendum: Pathologist. Addendum Review: Pathologist. Addendum Final: Pathologist,. Addendum: PATHOLOGIST, (. Addendum Review: PATHOLOGIST, {. Addendum Final: PATHOLOGIST, (.",BRCA,1,"Based on the report, the size of the larger tumor in the medial portion of the right breast is 3.8 x 3.2 x 2.9 cm, which falls within the T2 category of being more than 2.0 cm but not more than 5.0 cm in size.",T2,2.0
1035,TCGA-BH-A0HO.C9AD69EB-506A-4442-B1C2-C8F09B519CB2,0,"FINAL DIAGNOSIS: 1: BREAST, RIGHT, SEGMENTAL MASTECTOMY AT 10 O'CLOCK. PART. A. INVASIVE DUCTAL CARCINOMA, NO SPECIAL TYPE, WITH ABUNDANT CALCIFICATIONS. B. NOTTINGHAM GRADE 2 (TUBULE FORMATION: 2, NUCLEAR PLEOMORPHISM: 2, MITOTIC ACTIVITY: 2;. TOTAL SCORE = 6/9). C. THE INVASIVE TUMOR MEASURES 1.8 CM IN LARGEST DIMENSION. D. DUCTAL CARCINOMA IN SITU, NUCLEAR GRADE 2, CRIBRIFORM TYPE WITH CALCIFICATIONS. E. THE DUCTAL CARCINOMA IN SITU CONSTITUTES 5% OF THE TOTAL TUMOR VOLUME AND IS PRESENT. ADMIXED WITH THE INVASIVE COMPONENT. F. LYMPHOVASCULAR SPACE INVASION IS NOTED. G. RESECTION MARGINS ARE NEGATIVE FOR CARCINOMA. H. INVASIVE CARCINOMA IS 0.1 CM FROM THE NEAREST (ANTERIOR) MARGIN AND IS 0.2 CM FROM THE. POSTERIOR MARGIN (PLEASE SEE PART #2 FOR NEW ANTERIOR MARGIN). I. THE NON-NEOPLASTIC BREAST SHOWS FIBROCYSTIC CHANGES AND COLUMNAR CELL CHANGES. J. PREVIOUS BIOPSY SITE CHANGES. K. THE INVASIVE TUMOR CELLS ARE POSITIVE FOR ESTROGEN RECEPTORS (H SCORE OF 200),. PROGESTERONE RECEPTOR (H SCORE OF 290) AND NEGATIVE FOR HER-2 AS PER PREVIOUS. PART 2: BREAST, RIGHT, NEW ANTERIOR MARGIN, RE-EXCISION -. BENIGN BREAST TISSUE. PART 3: LYMPH NODES, RIGHT AXILLA, SENTINEL #1, EXCISION -. A. METASTATIC CARCINOMA INVOLVING ONE OF TWO LYMPH NODES (1/2). B. THE METASTATIC FOCUS MEASURES 0.1 CM IN LARGEST DIMENSION. C. NO EXTRACAPSULAR EXTENSION IS IDENTIFIED. PART 4: LYMPH NODES, RIGHT AXILLA, SENTINEL #2, EXCISION -. THREF I YMPH NODES, NEGATIVE FOR METASTATIC TUMOR (///). CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Segmental. Upper outer quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 1.8 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 2. Mitouc acurity -. Total Nottingham score: 6. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: Not applicable. CALCIFICATION: Yes, malignant zones. TUMOR TYPE, IN SITU: Cribriform. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPH NODES POSITIVE: 1. LYMPH NODES EXAMINED: 5. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain, Keratin stain. SENTINEL NODE METASTASIS: SIZE OF NODAL METASTASES: Diameter of largest lymph node metastasis: 1 mm. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: NON-NEOPLASTIC BREAST TISSUE: FCD. T STAGE, PATHOLOGIC: pT1c. N STAGE, PATHOLOGIC: pNX. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: zero or 1+. Comment: The tumor N stage is at least pN1mi. If a sentinel node is positive, then a final ""N. stage"" can be assigned only after complete lymph node dissection.",BRCA,1,"The report states that the maximum dimension of the invasive component of the tumor is 1.8 cm. According to the rules provided, T1 tumors are 2.0 cm or less in size. Therefore, the T stage for this patient is T1.",T1,2.0
1382,TCGA-GM-A2DF.CA6B733A-6030-422C-9DE9-B9718CBB2FDC,0,"ACC # 26. A) ADDITIONAL MARGIN OF MOST MEDIAL TUMOR, EXCISION: Benign breast tissue, no tumor present. (B). LEFT BREAST, SEGMENTAL MASTECTOMY: MULTIFOCAL INVASIVE DUCTAL CARCINOMA WITH ASSOCIATED LYMPHOCYTIC. INFILTRATE, HIGH NUCLEAR GRADE, NOTTINGHAM HISTOLOGIC GRADE. 3. (SEE COMMENT). LARGEST FOCUS OF INVASIVE CARCINOMA MEASURES 1.2 CM IN GREATEST. DIMENSION IN THE MEDIAL ASPECT OF THE SPECIMEN. MULTIPLE SATELLITE FOCI OF INVASIVE CARCINOMA ARE LATERAL TO THE. MAIN FOCUS AND MEASURE 5 MM (X 2), 4 MM, 3 MM AND 1 MM. LYMPHOVASCULAR INVASION IDENTIFIED. DUCTAL CARCINOMA IN SITU (DCIS), HIGH GRADE, PREDOMINANTLY. CRIBRIFORM AND CLINGING TYPES WITH CANCERIZATION OF LOBULES. AND ASSOCIATED LYMPHOCYTIC INFILTRATE. DCIS EXTENDS IN AN APPARENT IRREGULAR DISTRIBUTION OVER A 4 CM AREA. DCIS EXTENDS TO LESS THAN 1 MM FROM THE ANTERIOR MARGIN, TO 1 MM. FROM THE INFERIOR MARGIN, AND TO 2 MM FROM THE SUPERIOR AND. POSTERIOR MARGINS. INVASIVE CARCINOMA EXTENDS TO 2 MM FROM THE ANTERIOR MARGIN. (SEE. COMMENT). (C) ADDITIONAL CENTRAL ANTERIOR INFERIOR MARGIN, EXCISION: Benign breast tissue, no tumor present. (D) LEFT AXILLARY CONTENTS, DISSECTION: METASTATIC CARCINOMA IN ONE OF THIRTY LYMPH NODES (1/30); METASTASIS. MEASURES 7 MM; NO EXTRANODAL EXTENSION IDENTIFIED. (E) ADDITIONAL LEVEL I LEFT AXILLARY TISSUE, EXCISION: Two lymph nodes, no tumor present (0/2). Entire report and diagnosis completed by. COMMENT. Additional tissue was re-excised, and invasive carcinoma does not approach the final margins. However, I. with involvement of lobules is 1 mm from the final inferior margin and 2 mm from. the final superior and posterior margins. Tumor marker studies will be performed and reported in an addendum. GROSS DESCRIPTION. (A) ADDITIONAL MARGIN OF MOST MEDIAL TUMOR - Received is a piece of fibroadipose. tissue (1.8 x 1.2 x 0.5 cm) with clips on the true margin. The true margin inked black. The. specimen is serially sectioned and entirely submitted in A. (B) LEFT SEGMENTAL MASTECTOMY - A segmental mastectomy specimen (8.0 x 6.5 X 5.5. cm) with a short stitch at the superior aspect, long stitch at the lateral aspect, and multiple clips. on the anterior aspect. The specimen is serially sliced from medial to lateral into 11 slices. A. well-circumscribed tan-pink tumor 1.4 x 1.1 x 1.0 cm, with an associated biopsy clip is identified in. slice #3, which is 0.7 cm from the closest anterior margin. Multiple smaller nodules are identified. lateral to the main tumor. One of these is very close to the anterior margin in the central anterior. inferior aspect of the specimen, and additional tissue is requested from this margin. INK CODE: Anterior - yellow, posterior - black, superior - blue, inferior - green, medial. and lateral - red. SECTION CODE: B1, medial perpendicular margin; B2, tissue adjacent to tumor from. slice #2 ; B3-B7, tumor and margins from slice #3 (B3 and B4, tumor with anterior margin in area. of clip; B5, inferior margin; B6, posterior margin; B7, superior margin); B8, fibrous tissue adjacent. to the tumor from slice #4; B9, one small nodule, 1.2 cm from superior margin and 1.8 from. anterior margin of slice #4; B10, one small nodule 1.0 cm from anterior margin and 1.2 cm from. superior margin of slice #5; B11, one small nodule, 1.5 cm from anterior margin, 2.0 cm from. superior margin of slice #5; B12, B13, one small nodule, 0.1 cm from anterior margin and 1.2 cm. from inferior margin of slices #6 and #7; B14, one small nodule 0.4 cm from posterior margin and. 1.5 cm from inferior margin of slice #4; B15-818, remainder of margins of slice #4, entirely. submitted (B15, anterior margin; B16, superior margin; B17, posterior margin; B18, inferior. margin); B19, representative section from slice #8; B20, lateral perpendicular margin. (C) ADDITIONAL CENTRAL ANTERIOR INFERIOR MARGIN, LEFT BREAST - A portion of. fibroadipose tissue (2.0 x 1.3 x 0.5 cm) with clips on the true margin. The true margin is inked. black. The specimen is serially sectioned and entirely submitted in C1-C2. (D) LEFT AXILLARY CONTENTS - Adipose tissue (11.0 x 7.5 x 3.0 cm). Multiple lymph nodes. are identified ranging from 0.2 x 0.2 x 0.2 cm to 2.5 x 1.5 x 0.8 cm. SECTION CODE: D1-D3, each containing six lymph nodes; D4, four lymph nodes; D5,. four. lymph nodes; D6, one lymph node, trisected; D7, one lymph node, serially sectioned: n8. one lymph node, serially sectioned; D9 and D10, one lymph node, serially sectioned. (E) ADDITIONAL LEVEL I LEFT AXILLARY TISSUE - Two lymph nodes (0.2 x 0.2 x 0.2 cm and. 0.8 x 0.4 x 0.4 cm), entirely submitted. SECTION CODE: E1, one lymph node; E2, one lymph node, trisected. CLINICAL HISTORY. Left breast cancer. SNOMED CODES. T-04050, M-85003, M-85002 T-C4710, M-85006. ""Some tests reported here may have been developed and performance characteristics. determined by. These tests have not been. specifically cleared or approved by the U.S. Food and Drug Administration."". Released by: Start of ADDENDUM #1. ADDENDUM. Addendum completed by. This report is issued to give immunohistochemistry results. Immunohistochemical staining is performed on a representative formalin-fixed, paraffin-. embedded section of INVASIVE DUCTAL CARCINOMA, left breast, block B3. MARKER. % POSITIVE. SCORE. Estrogen Receptor. Negative. 0 %. Progesterone Receptor. Negative. < 1 %. N/A. HER-2/neu. overexpression. Negative. Focal 1+. Due to the above HER-2/neu immunohistochemical staining result, gene. copy level (HER-2/neu: CEP17 signal ratio) will be evaluated by FISH. and a separate report will be issued. FOOTNOTE. Estrogen receptor was assessed by immunohistochemistry using antibody 6F11 (. Progesterone receptor was assessed by immunohistochemistry using antibody PgR1294(. HER-2/neu was assessed by immunohistochemistry using antibody AB8 (I. Released by: Start of ADDENDUM #2. ADDENDUM #2. This modified report is being issued to report the results of HER-2/neu FISH. Addendum completed by. SPECIMEN SOURCE. Left breast. SUMMARY. Tissue section of the invasive carcinoma. B3 was evaluated for HER-2/neu gene. amplification by interphase fluorescence in situ hybridization technique using the -. HER-2/neu DNA Probe Kit (LSI HER-2/neu. /CEP17. Slide adequacy is satisfactory. Sixty tumor nuclei were counted and showed an average of 1.57. copies of LSI HER-2/neu gene per nucleus and an average of 1.40 copies of CEP17 per nucleus. Negative and positive controls (established by. 1 with this batch are. appropriate. Two representative images have been archived. INTERPRETATION. The tumor cells demonstrated no amplification of the HER-2/neu gene copy levels (HER-2/neu: CEP17 signal ratio: 1.12). The following guideline has been established for HER-2/neu testing: Normal HER-2/neu levels: < 1.80; equivocal HER-2/neu levels: 1.80 - 2.20; amplified HER-2/neu. levels: > 2.20. (Ref: Arch Patholo Lab Med. 2007; 131:18-43). NOTES. The LSI HER-2/neu probe is specific for the HER-2/neu gene Locus (17q 11.2-q12) and the CEP. 17 DNA probe is specific for the alpha satellite DNA sequence at the centromeric region of. Chromosome 17 (17 p11.1-q11.2). This test has been cleared and approved for specific uses by the U.S. Food and Drug. Administration. Its system is operating within the performance specifications stated in the product. insert. Released by:",BRCA,1,"The largest focus of invasive carcinoma measures 1.2 cm in greatest dimension, which falls under T1 tumors that are 2.0 cm or less in size.",T1,3.0
632,TCGA-A8-A07R.FD75D315-EED7-4350-A890-8FB94648E9FC,1,"Diagnosis: 1. Left breast segment at 2 o'clock with a poorly differentiated invasive ductal carcinoma,. max. 4.6 cm in size, with concomitant high-grade DCIS III with comedo necroses. Tumor classification based on the preliminary findings: pT2 (4.6 cm), pN3a (15/22), MX, R1. (peripheral invasive carcinoma), G3, (L1, V1).",BRCA,3,"The T stage is determined by the size of the primary tumor. The report states that the size of the largest focus of invasive carcinoma is 4.6 cm, which falls in the T2 category of being more than 2.0 cm but not more than 5.0 cm in size.",T2,3.0
1420,TCGA-LD-A9QF.E8601979-AE05-4E4D-BB39-6B9C5E67D050,0,"DATE OBTAINED: DATE RECEIVED: SUBMITTING MD: DIAGNOSIS. 1. LEFT AXILLARY ""SENTINEL"" LYMPH NODES: NEGATIVE (0/3); NEGATIVE CUTDOWNS SECTIONS. 2. LEFT AXILLARY ""PALPABLE"" LYMPH NODES: NEGATIVE (0/4); NEGATIVE CUTDOWNS SECTIONS. 3. LEFT AXILLARY ""SENTINEL"" LYMPH NODE: NEGATIVE (0/1); NEGATIVE CUTDOWNS SECTIONS. 4. LEFT AXILLARY ""SENTINEL"" LYMPH NODES #3: NEGATIVE (0/6); NEGATIVE CUTDOWNS SECTIONS. 5. LEFT TOTAL MASTECTOMY: INVASIVE AND INTRADUCTAL MAMMARY DUCT CARCINOMA. SIZE (INVASIVE): 1.6 cm (additional incidental < 1mm microinvasion). SIZE (DCIS COMPONENT): -11 cm scattered foci (subareolar region to 11 cm from nipple @ 12-1 o'clock). LATERALITY: Left. TUMOR FOCALITY: Unifocal gross reference mass; incidental microinvasive lesion. LESIONAL SITE: Subareolar (both reference mass and incidental microinvasion). HISTOLOGIC TYPE: Invasive ductal carcinoma, apocrine type. NUCLEAR GRADE: III of III. HISTOLOGIC GRADE:(EEmSBR). III of III (Tubules score 3 + NG score 3 + mitoses score 3). IN-SITU COMPONENT: DCIS (variable histology). comedo NG3 subareolar. cribriform non-apocrine with comedonecrosis NG2-3 UOQ. cribriform apocrine without comedonecrosis NG2 UOQ. LYMPH NODE SAMPLING: Negative (0/14); see specimen #1 - #4. AJCC CATEGORIES: Stage I (assuming ""cM0"" status). pTNM: pT1c. pNO. cTNM: cT1. cNO. cMO. INTEGRITY/ORIENTATION: Intact specimen with designated margins. MARGINS (invasive and DCIS): Negative; 3 cm to nearest margins (anterior & posterior locations). LYMPHOVASCULAR INVASION: Focal. MICROCALCIFICATIONS: Present (associated with comedo-DCIS). NIPPLE/SKIN: (if applicable). Negative nipple; numerous pigmented seborrheic keratoses & simple lentigines. SKELETAL MUSCLE. Not present. OTHER: Two core biopsy sites (1 o'clock subareolar; 12-1 o'clock UOQ); focal microcysts,. mammary duct stasis/ectasia and focal usual duct hyperplasia. COMMENT. 1-88329,88307 2-88333,88307 3-88333,88307 4-88307 5-88309. Clinical Diagnosis and History: ear old female with left invasive CA/DCIS ? extensive DCIS 12-1:00. cT1,cNo,cMo clinical stage I. Tissue(s) Submitted: 1: LEFT AXILLARY SENTINEL LYMPH NODES #1. 2: LEFT AXILLARY PALPABLE LYMPH NODES. 3: LEFT AXILLARY SENTINEL LYMPH NODE #2. 4: LEFT AXILLARY SENTINEL LYMPH NODE #3. 5: LEFT TOTAL MASTECTOMY SUTURE IN AXILLARY TAIL. Gross Description: Specimen #1 is received fresh for intraoperative consultation labeled left axillary sentinel lymph nodes, and consists of three lymph. nodes with attached fat, ranging from 0.2 cm to 2.4 cm in greatest dimension. The lymph nodes are submitted in their entirety for. permanent microscopy as follows: 1A: two lymph nodes. 1B: one lymph node serially sectioned. Specimen #2 is received fresh for intraoperative consultation labeled left axillary palpable lymph nodes, and consists of four lymph. nodes,. ranging from 0.8 cm to 1.5 cm in greatest dimension. The lymph nodes are serially sectioned to reveal predominantly pink-. tan. cut surfaces, one of which displays a white focus. A smear preparation from the lymph node with the white focus is performed. The lymph nodes are submitted in their entirety for permanent microscopy as follows: 2A-D: one lymph node per cassette. Specimen#3 is received fresh for intraoperative consultation labeled left axillary lymph node, sentinel #2, and consists of one, 0.9. cm lymph node, which is serially sectioned and submitted in its entirety labeled 3A. Specimen #4 is received in formalin labeled left axillary sentinel lymph node #3, and consists of six lymph nodes ranging from 0.2. cm to 0.7 cm in greatest dimension. The largest lymph node is bisected and the lymph nodes are submitted in their entirety as. follows: 4A: five lymph nodes. 4B: one lymph node, bisected. Specimen #5 is received fresh labeled left total mastectomy, suture in axillary tail, and consists of an 858 gm, 25 x 23 x 5 cm left. total mastectomy specimen, with a suture marking the axillary tail. There is a 24 x 17 cm, ovoid to elliptical portion of brown skin. on the anterior aspect, displaying a 2 X 2 X 1 cm everted nipple. The skin displays multiple brown-black, flat to raised,. predominantly keratotic skin lesions, ranging from 0.1 cm to 1.0 cm and 0.6 to 0.2 cm. The largest lesion is located at 12 o'clock,. 1.7 cm from the nearest 12 o'clock margins. One of the smaller lesions appears to be transected at the 5 d'clock margin. The. specimen is inked as follows: superoanterior - blue, inferoanterior - green, posterior - black. The posterior margin is intact. The. specimen is serially sectioned to reveal a 1.6 x 1.2 x 1.2 cm tan-white, ovoid, lobulated, indurated mass located retroareolar, 6 cm. from the deep margin and 3 cm from the overlying skin. Sectioning of the mass reveals a clip. Anterior to the mass is some dense. fibrosis, displaying possible comedonecrosis. Sectioning of the remaining fibrous tissue reveals a 1.2 x 1.0 x 0.6 cm rubbery,. but. stellate area of fibrosis at 1-2 o'clock, 11 cm from the nipple. Sectioning of this area reveals a clip. The clip is located 3 cm from. the. deep margin, and 6.5 cm from the overlying skin. No definitive gross tumor is associated with this clip. The remaining breast. parenchyma consists of approximately 90% yellow, lobulated adipose tissue, and 10% scattered white, rubbery fibrous tissue. A. small portion of tumor and normal are submitted for TCGA studies. Representative sections are submitted as follows: 5A: nipple. 5B-5D: mass with clip, no margin. 5E-5G: representative fibrous tissue anterior to mass, no margin. 5H: representative deep margin to mass. 5I-5K: stellate area of fibrosis with clip. 5L: posterior margin and anterior skin to stellate area of fibrosis with clip. 5M-50: representative fibrous tissue at 12-1 o'clock. 5P: representative upper inner quadrant. 5Q: representative lower inner quadrant. 5R: representative lower outer quadrant. 5S: representative upper outer quadrant. 5T: representative margin in second largest skin lesion. 5U: representative medium five skin lesions. 5V: representative smaller skin lesions. Time in formalin: 1 p.m, submitted same day. Intraoperative Consult Diagnosis. 1A. THREE NEGATIVE LYMPH NODES (BY GROSS). 2A. FOUR LYMPH NODES IDENTIFIED; THREE NEGATIVE (BY GROSS); ONE NEGATIVE (BY GROSS AND. SMEAR). 3A. ONE NEGATIVE LYMPH NODE (BY GROSS AND SMEAR).",BRCA,0,"The T stage is based on the size of the largest focus of invasive carcinoma. In this report, the size of the largest focus of invasive carcinoma is 1.6 cm, which falls under the T1 category. More specifically, it is T1c as the size is more than 1 cm but not more than 2 cm.",T1c,4.0
691,TCGA-A8-A0AB.E4D30B42-383A-40BF-BB91-511A90227655,1,"Diagnosis: Skin and fatty tissue with small foci of resorptive inflammatory reactions and also incipient. scarring. But no evidence of carcinoma. A regional R0 status is therefore likely to have been attained. Diagnosis: Invasive lobular breast carcinoma (maximum tumor diameter 2.7 cm, malignancy grade 2). with an invasive satellite node and multicentric, in parts confluent LIN formations (grade I). Remaining glandular body fibrolipomatous and with cystic duct ectasia, also small focal areas. of adenosis. Submitted tissue samples of cutaneous/subcutaneous tissue histologically. unremarkable. Tumor-free resection margins. Minimum width of dorsal safety margin 0.6 cm. Tumor classification: pT2m (maximum diameter 2.7 cm), pNO sn (0/2) (compare xxxxx),. MX, R0, G2 (L0, V0).",BRCA,0,"The report indicates that the maximum tumor diameter is 2.7 cm, which falls within the range for T2 tumors (more than 2.0 cm but not more than 5.0 cm).",T2,5.0
1011,TCGA-BH-A0E1.891F4C63-8207-4CB8-AB59-A970CC6F1A1A,1,"P.24/33. FINAL DIAGNOSIS. PART 1: LEFT AXILLARY SENTINER. CARCINOMA, EACH DEPOSIT. A. TWO LYMPH. (274). MEASURING LESSTHAD. B. NO EXTRACAPSULARIEXTENSIS. PART 2: LEFT AXILLARY SENTINEL: #2, BIOPSY. TWO LYMPH NODES, NEGATIVE FOR NEOPLASM (0/2)-. PART 3: LEFT BREAST.TOTAL MASTECTOMY. A. INFILTRATING DUCTAL CARCINOMA, NOTTINGHAM GRADE 2 (NUCLEAR GRADE 2, TUBULE SCORE 3. MITOTIC ACTIVITY SCORE 2; TOTAL SCORE 7/9). B. TUMOR MEASURES 4.5 CM IN GREATEST DIMENSION. C. LYMPHOVASCULAR SPACE INVASION IS PRESENT. D. TUMOR IS PRESENT IN THE LOWER INNER QUADRANT. E. MARGINS ARE NEGATIVE FOR NEOPLASM; TUMOR APPROACHES MOST CLOSELY TO THE ANTERIOR. MARGIN (1.5 MM). F. FIBROCYSTIC CHANGES. G. NIPPLE SKIN IS NEGATIVE FOR NEOPLASM. H. PATHOLOGIC STAGE: pT2 pN1mi pMX. CASE SYNOPSIS: SYNOPTIC . PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Simple mastectomy. Lower inner quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 4.5 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 2. Total Nottingham score: 7. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 1.5 mm. LYMPH NODES POSITIVE: 2. LYMPH NODES EXAMINED: 6. METHOD(S) OF LYMPH NODE EXAMINATION: H/F. stain. SENTINEL NODE METASTASIS: ONLY KERATIN POSITIVE CELLS ARE PRESENT: SIZE OF NODAL METASTASES: Diameter of largest lymph node metastasis: 1 mm. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: T STAGE, PATHOLOGIC: N STAGE, PATHOLOGIC: pN1mi. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: 2+.",BRCA,1,"The T stage is determined by the size of the primary tumor. The report states that the size of the tumor is 4.5 cm in greatest dimension (part 3, section B). According to the rules provided, T2 tumors are more than 2.0 cm but not more than 5.0 cm in size. Therefore, the T stage for this patient is T2.",T2,6.0
1150,TCGA-D8-A1XQ.33B6269D-1D59-4184-A786-2BEB73F6D3A8,1,"page 1 / 1. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breast with axillary tissues. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the right breast. Specimen from a modified radical mastectomy using. technique. Macroscopic description: Right breast sized 20 x 16 x 5 cm removed along with axillary tissues sized 9 x 11 x 3 cm and a skin flap of 20 x 8 cm. Weight 880. g. Tumour sized 2.2 x 2.0 x 1.5 cm on the border of the outer quadrants, located 3.0 cm from the lower boundary, 1.2 cm from the. base and 1.6 cm from the skin. Lymph nodes of 1.0 cm in length. Microscopic description: Carcinoma ductale invasivum, basal-like NHG3 (3 + 3 +2/15 mitoses/10 HPF - visual area 0.55 mm). Reactio lymphocytaria peritumoralis. Mamilla sine laesionibus. Axillary lymph nodes: Lymphonodulitis reactiva No VII. Histopathological diagnosis: Invasive ductal carcinoma of the right breas)(NHG3, pT2, pNO). Results of immunohistochemical examination: No estrogen receptors found in neoplastic cell nuclei. Progesterone receptors found in less than 10% of neoplastic cell nuclei. HER2 protein stained with HercepTestM by DAKO. Negative reaction in invasive cancerous cells ( Score = 1+). Tests performed. twice. Compliance vali.",BRCA,0,"The report states that the tumor size is 2.2 x 2.0 x 1.5 cm, which is more than 2.0 cm but not more than 5.0 cm. This falls under the T2 category according to the rules provided.",T2,7.0
514,TCGA-A2-A0SY.8E6902A6-A673-46CC-9AEB-3A71EF11099F,2,"Lab No.: Sex: F. Date Collected: Date Received: Doctor: M.R. No.: Room No: Account No: CLINICAL HISTORY: PREOPERATIVE DIAGNOSIS: LEFT BREAST CA. POSTOPERATIVE DIAGNOSIS: LEFT BREAST CA. OPERATION: LEFT SIMPLE MASTECTOMY, SENTINEL LYMPH. NODE BIOPSY, F.S. SPECIMENS: A. LEFT SENTINEL LYMPH NODE #1, F.S. B. LEFT SENTINEL LYMPH NODE #2, F.S. C. SENTINEL LYMPH NODE #3, F.S. D. LEFT BREAST SIMPLE MASTECTOMY. FROZEN SECTION DIAGNOSIS: A. LEFT SENTINEL LYMPH NODE #1 -. NUMEROUS HISTIOCYTES WITH ATYPICAL CELLS. DEFER FOR PERMANENT SECTION. B. LEFT SENTINEL LYMPH NODE #2 -. ONE NEGATIVE LYMPH NODE (0/1). C. SENTINEL LYMPH NODE #3 -. ONE NEGATIVE LYMPH NODE (0/1). FINAL DIAGNOSIS: A. LEFT SENTINEL LYMPH NODE #1 -. POSITIVE FOR METASTATIC CARCINOMA (1/1); THE TUMOR. INVOLVES THREE-FOURTHS OF THE NODE WHICH MEASURES .6. CM. IN DIAMETER, NO PERICAPSULAR SOFT TISSUE EXTENSION. B. LEFT SENTINEL LYMPH NODE #2 -. ONE REACTIVE LYMPH NODE (0/1). Lab No.: C. SENTINEL LYMPH NODE #3 -. ONE REACTIVE LYMPH NODE (0/1). D. LEFT BREAST MASTECTOMY -. INVASIVE LOBULAR CARCINOMA (7 CM.). TUMORAL CALCIFICATION/NECROSIS: NONE IDENTIFIED. DCIS/LCIS: NONE IDENTIFIED. SURGICAL MARGINS/NIPPLE, SKIN AND AREOLA: UNINVOLVED. NON-NEOPLASTIC BREAST: FIBROCYSTIC CHANGES TO INCLUDE DUCTAL EPITHELIAL. HYPERPLASIA. PTNM CLASSIFICATION: T3 N1 MX; STAGE IIIA. COMMENT: The multiple sections from the tumor reveal patchy areas of tumor infiltration. extending up to lactiferous ducts. In addition, the tumor cells also display unfavorable. nuclear features in many areas. The ER, PR and Her-2/neu have been performed on the. previous biopsy. The PanKeratin Immunostain is performed on specimens A, B. and C. GROSS: A. The container is received fresh unfixed labele. eft sentinel lymph node #1. for frozen section"". The specimen consists of an ovoid mass of pink-tan soft rubbery. tissue mixed with fatty tissue measuring 0.6 cm. in greatest dimension. Frozen section is. obtained by. The entire specimen including frozen section in one block. B. The container is received fresh unfixed labele. left sentinel lymph node #2. for frozen section"". The specimen consists of an ovoid mass of tan-gray soft rubbery. tissue with attached fat. Frozen section is obtained by. The entire specimen. including frozen section in one block. Lab No.: C. The container is received fresh unfixed labele. sentinel lymph node #3 for. frozen section"". The specimen consist of an ovoid mass of pink-tan soft rubbery tissue. measuring 1.3 cm. in diameter in the aggregate. Frozen section is obtained by. The entire specimen including frozen section in one block. D. The container is received fresh unfixed labeled. ""left breast"". The specimen. consists of an 809 gm. apparent left breast which is 23 x 15 x 4 cm. in greatest overall. dimension. There is an inverted nipple. The attached skin ellipse is 21 x 9.5 cm. Sectioning through the breast stroma reveals dense gray-white fibrous tissue varying up. to 7.5 cm. in greatest dimension. This area has been previously marked with blue dye. There are scattered cystic spaces varying up to 0.1 cm. in greatest dimension filled with. an amber-colored fluid. Sectioning also reveals a firm tan-gray striated tumor mass. which is 7 x approximately 5.5 cm. in greatest overall dimension and is approximately. 0.7 cm. from the deep/underlying resection margin. The specimen is submitted in ten. blocks. Key Note Block Summary: 1-nipple, 2 through 4-cystic spaces, 5-random,. 6. through 10-tumor mass. MICROSCOPIC EXAMINATION: MICROSCOPIC EXAMINATION CONDUCTED BY PATHOLOGIST CONFIRMS FINAL DIAGNOSIS. SPECIAL STAINS PERFORMED: PanKeratin (specimens A,B,C).",BRCA,1,"The report states that the largest tumor size in the left breast is 7 cm, which falls under the category of T3 tumors, which are more than 5.0 cm in size. The specific sub-staging information is not provided, but the minimum size of 7 cm is sufficient to determine the T stage as T3.",T3,8.0
556,TCGA-A2-A3XX.770EEADF-19CD-4AB9-A7FA-1A05EE17984C,1,"Specimen #: (Age. Race. SPECIMEN: A: SENTINEL NODE #1 B: LEFT BREAST TISSUE. FINAL DIAGNOSIS: A. LYMPH NODE, SENTINEL #1, BIOPSY: - ONE (1) LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA BY H&E AND. IMMUNOSTAINS. B. BREAST, LEFT, MASTECTOMY: - TUMOR TYPE: INFILTRATING DUCTAL CARCINOMA. - NOTTINGHAM GRADE: 3 OUT OF 3. - NOTTINGHAM SCORE: 8 OUT OF 9 (Tubules= 3, Nuclei= 2, Mitoses= 3. mitotic count 22 per 10 HPF at 40x power). TUMOR SIZE (GREATEST DIMENSION) : 2.2 CM (MEASURED GROSSLY). - TUMOR NECROSIS: PRESENT IN BOTH THE INVASIVE AND IN SITU COMPONENTS. - MICROCALCIFICATIONS: ABSENT. - VENOUS / LYMPHATIC INVASION: ABSENT. - MARGINS NEGATIVE. DISTANCE OF TUMOR FROM NEAREST MARGIN IS 0.1 CM, FROM THE. SUPERFICIAL (GREEN INKED) MARGIN. (MEASURED MICROSCOPICALLY) (SLIDE. B6). - INTRADUCTAL COMPONENT: PRESENT. DUCTAL CARCINOMA; HIGH NUCLEAR GRADE. (GRADE III) SOLID SUBTYPE WITH CENTRAL NECROSIS. - LYMPH NODES: ONE (1) NEGATIVE FOR TUMOR. (SEE PART A). - NIPPLE INVOLVEMENT: ABSENT. - SKIN INVOLVEMENT: ABSENT. - MULTICENTRICITY: ABSENT. - ESTROGEN RECEPTORS: NEGATIVE (SEE CASE. - PROGESTERONE RECEPTORS : NEGATIVE (SEE CASE. - HER 2 NEU by IHC: NEGATIVE (SEE CASE. - PATHOLOGIC STAGE: pT2 NO (i-) MX. - ADDITIONAL PATHOLOGIC CHANGES. INTRADUCTAL PAPILLOMA. FIBROADENOMATOUS CHANGES. FIBROCYSTIC CHANGES. COMMENT: Cytokeratin staining of part A supports the above diagnosis. This case received prospective intradepartmental peer review. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY ACT OF. FOR OFFICIAL US ONLY - PERSONAL DATA - PRIVACY ACT or. Specimen #. FINAL DIAGNOSIS (continued). CLINICAL DIAGNOSIS AND HISTORY: yr old. with left breast cancer. PRE-OPERATIVE DIAGNOSIS: none provided. POST-OPERATIVE DIAGNOSIS: none provided. GROSS DESCRIPTION: A: Received fresh, labeled with the patient's name,. Id. designated ""Sentinel Node #1 with markings; suture marks hottest point at. 1152 hours"" is a 2.5 x 2.5 x 0.7 cm irregular portion of soft tissue. Sectioning reveals a 2.5 x 1.5 x 0,5 cm pink-tan lymph node with attached. adipose tissue. The specimen is entirely submitted as follows: Cassette Summary: A1- sentinel lymph node; A2- adipose tissue. At the time of submission the specimen will have been in formalin for. approximately 23 hours Matched sections of cassette A1 are. submitted in OCT for. Protocol. B: Received fresh, labeled with the patient's name,. and. designated ""Left Breast Tissue, long-lateral, short-superior 1 pm' is. a. 468 gm left mastectomy specimen oriented with a short stitch at the. superior aspect and long stitch at the lateral aspect. The specimen. measures 20.0 cm from superior to inferior by 18.0 cm from medial to. lateral by 3.0 cm from anterior to posterior. The darkly pigmented skin. ellipse measures 9.5 x 3.5 cm and displays a 1.5 cm centrally located,. everted nipple free of discharge. The deep margin is inked in black, and. the left outer quadrant superficial margin is inked in green. Serial. sectioning reveals a 11-circumscribed 2.2 x 2. x 1.8 cm mass in the. lower outer quadrant located 0.3 cm from the superficial margin and 0. cm. from the deep margin. The cut surface is firm gritty pink-red and focally. congested. The remainder of the specimen is composed of evenly. distributed pink-tan fibrous tissue admixed adipose tissue. No additional. lesions are identified. No lymph nodes are identified within the specimen. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY ACT OF. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY ACT or. specimen #: GROSS DESCRIPTION (continued) : Representative sections are submitted. At the time of submission the. specimen has fixed in formalin for approximately 21 hours. Cassette Summary: B1- - skin; B2-B3 - lower outer quadrant deep margin;. B4-B6- mass with superficial margin; B7 - representative section of grossly. normal breast parenchyma from the upper outer quadrant; B8- representative. section of grossly normal breast parenchyma from the upper inner quadrant;. B9 representative section of grossly normal breast parenchyma from the. lower inner quadrant; B10- representative section of grossly normal breast. parenchyma from the lower outer quadrant; B11- - representative section of. grossly normal breast parenchyma from the central area; B12-. representative section of nipple with associated subcutaneous tissue. Matched sections of cassette B1, B4-B5, B7-B11 are submitted in OCT for. ) Protocol. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY.",BRCA,0,"The report states that the 'tumor size (greatest dimension)' is 2.2 cm, and T2 tumors are defined as being 'more than 2.0 cm but not more than 5.0 cm in size'. Therefore, the T stage for this patient is T2.",T2,9.0
1373,TCGA-EW-A6SC.315A77B4-1A2E-468D-9E44-FF0B07697943,1,"x. Pathologic Interpretation: A. LEFT BREAST SENTINEL NODE 1. One lymph node, negative for carcinoma (0/1). Immunohistochemistry for keratin is pending. B. LEFT BREAST SENTINEL NODE 2. One lymph node, negative for carcinoma (0/1). Immunohistochemistry for keratin is pending. C. LEFT BREAST LUMPECTOMY: INVASIVE LOBULAR CARCINOMA, moderately differentiated, Nottingham grade 2 (3+2+1=6), 2.1 cm. in. greatest dimension. Immunohistochemistry performed on previous core needle biopsy demonstrated the following staining. pattern in the lesional cells: ER: POSITIVE (> 50%). PR: POSITIVE (10-50%). HER2: NEGATIVE (0). E-Cadherin: NEGATIVE (0). Resection margins are negative for carcinoma. Prior biopsy site changes present. Atypical ductal hyperplasia. See Surgical Pathology Cancer Case Summary. Surgical Pathology Cancer Case Summary. Procedure. Excision without wire-guided localization. Lymph Node Sampling. Sentinel lymph node(s). Specimen Laterality. Left. Tumor Site: Invasive Carcinoma. Position: 1 o'clock. Histologic Type of Invasive Carcinoma. Invasive lobular carcinoma. Tumor Size: Size of Largest Invasive Carcinoma. Greatest dimension of largest focus of invasion >1 mm: 21 mm. Histologic Grade: Nottingham Histologic Score. Glandular (Acinar)/Tubular Differentiation. Score 3: <10% of tumor area forming glandular/tubular structures. Nuclear Pleomorphism. Score 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate. variability in both size and shape. Mitotic Rate. Score 1 (<3 mitoses per mm). Overall Grade. Grade 2: scores of 6 or 7. Tumor Focality (required only if more than 1 focus of invasive carcinoma is present). Single focus of invasive carcinoma. Ductal Carcinoma In Situ (DCIS) (select all that apply). No DCIS is present. Lobular Carcinoma In Situ (LCIS). Not identified. Margins. Invasive Carcinoma. Margins uninvolved by invasive carcinoma. Distance from closest margin: 2.5 mm. Specify margin: Anterior. Lymph Nodes (required only if lymph nodes are present in the specimen). Number of sentinel lymph nodes examined: 2. Total number of lymph nodes examined (sentinel and nonsentinel): 2. Number of lymph nodes with macrometastases (>2 mm): 0. Number of lymph nodes with micrometastases (>0.2 mm to 2 mm and/or >200 cells): 0. Method of Evaluation of Sentinel Lymph Nodes (select all that apply). Hematoxylin and eosin (H&E), 1 level. H&E, multiple levels. Immunohistochemistry to follow. Treatment Effect: Response to Presurgical (Neoadjuvant) Therapy. In the Breast. No known presurgical therapy. In the Lymph Nodes. No known presurgical therapy. Lymph-Vascular Invasion. Not identified. Dermal Lymph-Vascular Invasion. No skin present. Pathologic Staging (based on information available to the pathologist) (pTNM). Primary Tumor (Invasive Carcinoma) (pT). pT2: Tumor >20 mm but <50 mm in greatest dimension. Regional Lymph Nodes (pN). Modifier (required only if applicable). (sn): Only sentinel node(s) evaluated. pNO: No regional lymph node metastasis identified histologically. Distant Metastasis (pM). Not applicable. Ancillary Studies. (required only if available at time of report completion) (select all that apply). Performed on another specimen. Specify specimen (accession number): --. Estrogen Receptor (ER). Results and interpretation: Positive Immunoreactive tumor cells present (>50%). Progesterone Receptor (PgR). Results and interpretation: Positive Immunoreactive tumor cells present (10-50%). HER2. Immunoperoxidase Studies. Negative (Score 0). Microcalcifications (select all that apply). Present in invasive carcinoma. AJCC Classification (7th edition): pT2, (sn)pNo, pMn/a. Final AJCC classification will be issued after the keratin immunostain. Procedures/Addenda. Addendum. Date Complete: Addendum Diagnosis. A. Immunohistochemistry for keratin is negative. B. Immunohistochemistry for keratin is negative. Final AJCC pT2 sn NO (i-) Mn/a. Intraoperative Consultation. A. Sentinel node 1,. FS: No malignancy seen. However, final diagnosis pending Immunohistochemical. stains. B. Sentinel node 2,. FS: No malignancy seen. However, final diagnosis pending Immunohistochemical. stains. Clinical History: Lobular carcinoma, ER+, RR+, HER (-). Operation Performed. Left lumpectomy with sentinel node biopsy and possible axillary dissection. Pre Operative Diagnosis: None Provided. Specimen(s) Received/Processing Information: Codes: A: LEFT BREAST SENTINEL NODE 1. Frozen section x 1, FS Perm x 1, Touch. Prep Histology x 1, Cytokeratin Cocktail (KER) x 1. A: B: B: LEFT BREAST SENTINEL NODE 2. Frozen section x 1, FS Perm x 1, Touch. Prep Histology x 1, Cytokeratin Cocktail (KER) x 1. C: LEFT BREAST LUMPECTOMY 1 SUPERIOR 2 LATERAL 3 DEEP H&E, Initial x 1,. H&E, Initial x 1, H&E, Initial x 1, H&E, Initial X 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x. 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial. x 1. Gross Description: A. Received fresh labeled ""Sentinel lymph node count 1 containing 1.3 x 1.0 x 1.0 cm pale yellow soft. lymph node. Bisected and submitted in toto in one cassette for frozen section. B. Received fresh labeled ""Sentinel node 2 count containing 1.3 x 1.0 x 1.0 cm pale yellow, soft lymph. node. It is. bisected and submitted in toto in one cassette for frozen section. C. Received in formalin labeled ""Left breast lumpectomy, 1 superior, 2 lateral 3 deep"" is a lumpectomy. specimen of the breast weighing 180 grams. It is oriented with sutures by the surgeon. It measures 7.5 cm. in superior to inferior, 7.0 cm medial to lateral surface, 3.5 cm anterior to the posterior surface. The. specimen is inked as follows: Blue superior, green inferior, red medial, orange lateral, black posterior,. yellow anterior. Upon sectioning, there is a 2.0 x 1.6 x 1.2 cm tan-white, firm gritty mass with stellate. borders. It is approximately round to oval in shape. The mass contains a metallic clip measuring 3 mm. The mass is closest to the anterior margin which is 0.7 cm away. It is 3.0 cm away from the posterior. margin, 2.0 cm from the superior margin, 2.6 cm from the inferior margin, 4.0 cm from the medial margin and. 2.5 cm from the lateral margin. The rest of the breast parenchyma is yellow and soft with fat to stroma ratio. 90's to 30. A piece of tumor measuring approximately1.0 x 1.0 cm is submitted to the tissue bank. Sections. are submitted as follows: Cassettes #1-6. Mass in toto (cassette 1 mass with clip). Cassette #7. Anterior margin. Cassette #8. Posterior margin. Cassette #9. Medial margin. Cassette #10. Lateral margin. Cassette #11. Superior margin. Cassette #12. Inferior margin. Cassette #13. Stroma.",BRCA,0,"The report states that the size of the largest focus of invasive carcinoma is greater than 2.0 cm but not more than 5.0 cm (2.1 cm). According to the rules provided, this corresponds to a T2 stage.",T2,10.0
1335,TCGA-EW-A1IZ.F5EF4698-364C-4A5B-A8EC-1CF231BEEF31,1,"F. Pathologic Interpretation: A. Right breast short stich superior long lateral right single mastectomy: - Benign mammary parenchyma, no malignancy seen. B. Left breast and level I and II of axilla to tumor short superior, left lateral: - Invasive ductal carcinoma, Nottingham grade 3 (3+3+2), 2.8 cm in greatest linear dimension, focally presert at the. anterior specimen margin. - Ductal carcinoma in situ, high grade (DIN 3) solid type. - Organizing previous biopsy cavity. - Lymphovascular space invasion is present. - Metastatic carcinoma in four out of nine lymph nodes (4/9). - Receptors to follow. C. Additional fat above left breast tumor: - No malignancy seen in adipose tissue. D. Left level III axilla: - No malignancy seen in four lymph nodes (0/4). Tumor Summary (Invasive Carcinoma of the Breast): Specimen Type: Total breast (including nipple and skin). Procedure: Total mastectomy (including nipple and skin). Lymph Node Sampling: Axillary dissection (partial or complete dissection). Specimen Integrity: Single intact specimen (margins can be evaluated). Specimen Laterality: Left. Tumor Site: Lower outer quadrant; Lower inner quadrant. Tumor Size: Size of Largest Invasive Carcinoma: Greatest dimension of largest focus of invasion: 2.8 cm. Tumor Focality: Single focus of invasive carcinoma. Macroscopic and Microscopic Extent of Tumor: Skin: Invasive carcinoma does not invade into the dermis or epidermis. Nipple: DCIS does not involve the nipple epidermis. Skeletal Muscle: No skeletal muscle present. Ductal Carcinoma in Situ: DCIS is present. Architectural Patterns: Solid. Nuclear Grade: Grade III (high). Lobular Carcinoma in Situ: Not identified. Histologic Type of Invasive Carcinoma: Invasive ductal carcinoma (no special type or not otherwise specified). Histologic Grade: Glandular (Acinar)/Tubular Differentiation: Score 3. Nuclear Pleomorphism: Score 3. Mitotic Count: Score 2. Overall Grade: Grade 3. Margins: Uninvolved by invasive carcinoma. Distance from posterior margin: 2 cm. Uninvolved by DCIS (if present). Lymph-Vascular Invasion: Present. Dermal Lymph-Vascular Invasion: Not identified. Lymph Nodes: Number of sentinel lymph nodes examined: 0. Total number of lymph nodes examined (sentinel and nonsentinel): 13. Number of lymph nodes with macrometastases: 4. Size of largest metastatic deposit: 2.0 cm. Extranodal Extension: Not identified. SURGICAL PATHOL Report. Method of Evaluation of Sentinel Lymph Nodes: Hematoxylin and eosin (H&E), one level. Pathologic Staging (pTNM). TNM Descriptore: m (multiple foci of invasive carcinoma). Primary TumorpT2. Regional Lymph Nodes: pN2. Distant Metastasis: Not applicable. Anciliary Studies: Estrogen Receptor: Pending. Progesterone Receptor: Pending. Her2: Pending. NOTE: Some immunohistochemical antibodies are analyte spectific reagents (ASRs) validated by our laboratory (Her 2, Pervo, H. pylori, HBcore). These ASRs are clinically indicators that do. not require FDA approval. These clones are used: ID5=ER, POR 636=PR, A485HER2, H-11=EGFR, CCH2/DDG9=CMV, F39.4 1=AR and HPV by ISH. All immunohistochemidelt stains are used. with formalin or molecular fixed, paraffin embedded fissue. Detection is by LSAB. The results are read by a pathologist as positive or negative. As the attending pathologist, / attest that 1: (i) Exemined the relevent. preperation(s) for the specimen(s); and (i) Rendered the diagnosis(es). Procedures/Addenda. Addendum. Date Complete: Addendum Diagnosis. The tumor cells are positive for ER and PR and negative for HER2 by immunohistochemistry. Immunohistochemistry for p63 was. used in the evaluation of the specimen. Clinical History: female with left breast cancer. Pre Operative Diagnosis: Left breast cancer. Specimen(s) Received: A: Right breast short stich superior long lateral right single mastectomy (fresh). B: Left breast and level 1 and Il of axilla to tumor short superior, left lateral (fresh). C: Additional fat above left breast tumor (perm). D: Left level III axilla (perm). Gross Description: A. Received fresh and labeled ""right breast short stich superior long lateral right single mastectomy (fresh)"" is a breast. specimen measuring 18.0 x 15.0 x 5.0 cm. It has a white-tan ellipse of skin measuring 4.0 x 1.0 cm. The nippl measures. 1.0 x 1.0 cm. The skin is unremarkable and nipple is unremarkable. Deep margin is smooth, facial plane without any. SURGICAL PATHOL Report. skeletal muscle. Deep margin is inked in black. Serial sectioning of the mastectomy specimen does not reveal any gross. lesion. Specimen submitted as follows: 1&2. Sections from upper outer quadrant. 3&4. Representative section from lower outer quadrant. 5&6. Representative section from upper inner quadrant. 7&8. Representative section from lower inner quadrant. 9&10. Representative section from central quadrant. 11. Representative section from nipple. B. Received fresh and labeled ""left breast and level 1 and II of axilla to tumor short superior, left lateral (fresh)"" is a. mastectomy specimen measuring 19.0 x 17.0 x 3.0 cm. It has a white-tan ellipse of skin measuring 2.5 x 2.0 cm. The. axillary tail measures 13.0 x 9.0 cm. The skin and nipple are unremarkable. Deep margin is smooth, facial plane without. any skeletal muscle. Deep margin is inked black, superior margin is inked blue, medial margin is inked red and inferior. margin is inked green. Serial sectioning of the mastectomy specimen reveals a 2.8 x 2.0 x 1.5 cm firm gray mass located. in the lower outer quadrant, less than 0.1 cm from the inked anterior specimen margin. There is also a 1 x 1 1 cm. mass. in the lower inner quadrant. The mass is well defined. It has a clip in it. in the upper inner quadrant, there is an area of. necrosis measuring 2.0 x 2.0 x 1.0 cm. it is brown in color and soft in consistency. Remainder of the breast parenchyma is. predominantly white and firm with small cyst measuring up to 0.3 cm in greatest dimension. The axillary tail is yellow and. soft. There are 13 possible lymph nodes. The largest measures 3.0 cm in greatest dimension. Sections submitte as. follows: 1-8. Mass in the lower inner quadrant. 9&10. Area of necrosis. 11&12 Representative section from upper outer quadrant. 13&14 Representative section from lower outer quadrant. 15&16 Representative section from upper inner quadrant. 17&18 Representative section from lower inner quadrant. 19820. Representative section from the central quadrant. 21. Representative section from the nipple. 22-24. Contains representative section from the largest lymph node. 25-37. One fymph node per cassette. 38-41. Additional section of mass in lower outer quadrant. C. Received in formalin and labeled ""additional fat above left breast tumor"" is a soft fragment measuring 2.5 x 1.0x 1.0 cm. Submitted in toto in three cassettes. D. Received in formalin and labeled ""left level III axilla"" is a pale yellow, soft tissue fragment measuring 4.0 x 3.0 x 2.0 cm. Four possible lymph nodes are bisected and submitted in toto in four cassettes. ICD-9(s);. 174.5 174.3 196.3.",BRCA,2,"Based on the report, the size of the largest focus of invasive carcinoma is 2.8 cm, which falls in the T2 category of 'more than 2.0 cm but not more than 5.0 cm in size'. The T stage is based on the size of the largest tumor, regardless of the number or size of other tumors present, and is not affected by the presence of in situ carcinoma or the number of tumors.",T2,10.0
1208,TCGA-E2-A153.06D417E8-68C2-408C-8ABC-B3042566C976,1,"Path Site Code : breast, central prtiar. SPECIMENS: A. NON-SENTINEL LYMPH NODE #1. B. RIGHT BREAST. C. LEFT BREAST WITH AXILLARY CONTENTS. SPECIMEN(S): A. NON-SENTINEL LYMPH NODE #1. B. RIGHT BREAST. C. LEFT BREAST WITH AXILLARY CONTENTS. INTRAOPERATIVE CONSULTATION DIAGNOSIS: TPA/FSA-non sentinel lymph node #1: Touch prep is negative for tumor; frozen section positive for metastatic. carcinoma (0.4 cm). Diagnosis called by Dr. to Dr. GROSS DESCRIPTION: A. NON-SENTINEL LYMPH NODE #1. Received fresh, labeled with matching patient identifiers, are 2 lymph nodes, 1.1 x 1 x 0.5 cm (A2) and 1.3 x 0.7 x. 0.4 cm (A1). A1 contains a 0.4 cm white area of discoloration. A2 is used for touch prep; A1 is submitted for frozen. section. Specimen is submitted entirely. FSA1: frozen A1. A2: A2. B. RIGHT BREAST, NORMAL BREAST. Received fresh, labeled with the patient's identification and ""right breast, normal breast"" is an oriented 1154 g, 27 x. 17 x 7 cm mastectomy with 25 x 9.5 cm skin ellipse and 1.7-cm flat nipple. Ink code: Anterior/superior-blue,. anterior/inferior-orange, posterior-black. The specimen is serially sectioned into 12 slices with from medial to lateral. with nipple in slice 6; no masses or lesions are identified. No lymph nodes are found. Representatively submitted. B1: slice 3, upper inner quadrant. B2: slice 4, upper inner quadrant. B3: slice 5, upper inner quadrant. B4: slice 7, upper outer quadrant. B5: slice 8, upper outer quadrant. B6: slice 10, upper outer quadrant. B7: slice 10, lower outer quadrant. B8: slice 9, lower outer quadrant. B9: slice 6, lower outer quadrant. B10: slice 5, lower inner quadrant. B11: slice 2, lower inner quadrant. B12: slice 1, lower inner quadrant. B13-B14: nipple and skin. C. LEFT BRESAST WITH AXILLARY CONTENTS. Received fresh labeled with the patient's identification and ""left breast with axillary contents"" is an oriented 1457. g,. 29 x 22 x 7 cm mastectomy with 24 x 11.5 cm skin ellipse and 1.2-cm inverted nipple; there is a 0.7-cm nodule. adjacent to the nipple and multiple skin lesions ranging from 0.2 to 0.4 cm. Ink code: Anterior/superior-blue,. anterior/inferior-orange, posterior-black. Specimen is serially sectioned into 12 slices from medial to lateral with. nipple and slice 6 revealing, in slices 5-7 a 2.5 x 2 x 1.8 cm firm tan lesion located in the mid upper region which is. 3.2 cm from the deep margin and 1.7 cm from the anterior margin (#1), 2.4 cm inferior to lesion #1, in slice 8, is a 1.7. x. 1.7 x 1.5 cm firm tan mass located in the mid section, 5 cm from the deep margin and 1 cm from the anterior. margin (#2), 3 cm superior to lesion #2 is a firm 0.7 cm nodule located in the upper mid-quadrant in slice 8 which is. 4.3 cm from the deep margin and 1.3 cm from the anterior margin. Clips are identified in slices 6, 7, and 8; multiple. axillary lymph nodes are identified. Representative sections. C1-C3: slice 6, lesion #1 including both margins (clip). C4: slice 7, connecting tissue between lesions #1 and #2. C5: slice 7, lesion #2 (clip). C6: slice 8, lesion #2 (clip). C7: slice 8, tissue connecting lesion #2 and #3 (including #3). C8: slice 11, upper outer quadrant. C9: slice 10, upper outer quadrant. C10: slice 10, lower outer quadrant. C11: slice 4, lower inner quadrant. C12: slice 3, lower inner quadrant. C13-C15: nipple and adjacent nodule. C16: skin lesions. C17: 5 lymph nodes. C18: 3 lymph nodes. C19-C22: 1 lymph node each. C23-C24: 1 lymph node. DIAGNOSIS: A. LYMPH NODE, NON-SENTINEL, LEFT AXILLA, EXCISION: - METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1), MEASURING 0.25-CM WITH FOCAL. EXTRANODAL EXTENSION. B. BREAST, RIGHT, MASTECTOMY: LOBULAR CARCINOMA IN SITU (E-CADHERIN NEGATIVE). - FIBROADENOMA (0.6-CM), COLUMNAR CELL CHANGES AND HYPERPLASIA WITHOUT ATYPIA, USUAL. DUCTAL HYPERPLASIA WITHOUT ATYPIA, MICROCALCIFICATIONS IN BENIGN DUCTS, FIBROCYSTIC. CHANGES WITH FIBROSIS AND APOCRINE METAPLASIA. C. BREAST, LEFT, MASTECTOMY WITH AXILLARY NODE DISSECTION: - MULTIPLE FOCI OF INVASIVE DUCTAL CARCINOMA, SBR GRADE 2, LARGEST FOCUS MEASURING 2.5-CM. INTERMEDIATE NUCLEAR GRADE, DUCTAL CARCINOMA IN SITU, SOLID AND CRIBRIFORM TYPES WITH. CENTRAL NECROSIS AND MICROCALCIFICATIONS. - SURGICAL RESECTION MARGINS NEGATIVE FOR TUMOR. - METASTATIC CARCINOMA TO TWO OF FORTEEN LYMPH NODES (2/14), LARGEST MEASURING 1.3-CM. WITH EXTRANODAL EXTENSION. BIOPSY SITE CHANGES WITH FIBROSIS, GRANULATION TISSUE AND FOREIGN BODY GIANT CELL. REACTION. - SEE SYNOPTIC REPORT AND SEE NOTE. NOTE: Multiple foci of invasive ductal carcinoma identified around the central region. One focus of tumor involves. nipple without skin ulceration. SYNOPTIC REPORT - BREAST. Specimens Involved. Specimens: A: NON-SENTINEL LYMPH NODE #1. C: LEFT BREAST WITH AXILLARY CONTENTS. Specimen Type: Mastectomy. Needle Localization: Laterality: Left. Invasive Tumor: Present. Multifocality: Yes. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 2.5cm. Tumor Site: Central. Margins: Negative. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 1. Modified Scarff Bloom Richardson Grade: 2. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: LCIS. Lymph nodes: Sentinel lymph node and axillary dissection. Lymph node status: Positive 3/15 Extranodal extension. Micrometastases: DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 5%. DCIS Type: Solid. Cribriform. DCIS Location Both associated and separate from invasive tumor mass. Nuclear grade: Intermediate. Necrosis: Present. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative. Performed on Case: Pathological staging (pTN): pT 2N1a. CLINICAL HISTORY: None given. PRE-OPERATIVE DIAGNOSIS: Left breast cancer. Microscopic/Diagnostic Dictation: Pathologist,. Final Review: Pathologist,. Final: Pathologist,.",BRCA,1,"The largest focus of invasive carcinoma in the left breast measures 2.5 cm, which falls under the T2 category of tumors that are more than 2.0 cm but not more than 5.0 cm in size.",T2,10.0
979,TCGA-BH-A0BJ.A3CDF051-4162-47EC-BE8A-1519A5564518,1,"FINAL DIAGNOSIS: PART 1: BREAST, LEFT, SEGMENTAL MASTECTOMY -. A. INFILTRATING DUCTAL CARCINOMA, NOS TYPE, MODERATELY DIFFERENTIATED. B. THE TUMOR MEASURES 2.5 CM (GROSS MEASUREMENT), NOTTINGHAM SCORE 6/9 (TUBULE 2,. NUCLEAR GRADE 2, MITOSIS 2; OVERALL GRADE 2/3). C. NO LYMPHOVASCULAR INVASION IS IDENTIFIED. D. DUCTAL CARCINOMA IN-SITU, SOLID AND CRIBRIFORM SUBTYPES, NUCLEAR GRADE 2, COMPRISES. 25% OF THE TOTAL TUMOR VOLUME AND IS PRESENT IN ASSOCIATION WITH INVASIVE CARCINOMA. E. MARGINS: ALL MARGINS OF RESECTION ARE FREE OF IN-SITU OR INVASIVE CARCINOMA. THE. CLOSEST POSTERIOR MARGIN IS 1 MM AWAY (SLIDE 1B). F. FIBROCYSTIC CHANGES, DUCTAL EPITHELIAL HYPERPLASIA, COLUMNAR CELL HYPERPLASIA,. ATYPICAL DUCTAL HYPERPLASIA, SCLEROSING ADENOSIS, AND PREVIOUS BIOPSY SITE CHANGES. G. ESTROGEN RECEPTOR POSITIVE. PROGESTERONE RECEPTOR POSITIVE, HER-2/NEU NEGATIVE (IHC. SCORE 1+), CROSS REFER. PART 2: BREAST, LEFT, LATERAL MARGIN, EXCISION -. A. NO IN-SITU OR INVASIVE CARCINOMA IDENTIFIED. B. FIBROCYSTIC CHANGES, DUCTAL EPITHELIAL HYPERPLASIA, SCLEROSING ADENOSIS, AND. COLUMNAR CELL CHANGE. PART 3: SENTINEL LYMPH NODE #1, LEFT AXILLA, BIOPSY -. ONE BENIGN LYMPH NODE, NO TUMOR SEEN (0/1). PART 4: SENTINEL LYMPH NODE #2, LEFT AXILLA, BIOPST -. A. ONE OUT OF TWO LYMPH NODES POSITIVE FOR METASTATIC CARCINOMA (1/2), THE METASTATIC. FOCUS MEASURES 1 CM (ON GLASS SLIDE). B. EXTRACAPSULAR EXTENSION IS IDENTIFIED. PART 5: SENTINEL LYMPH NODE #3, LEFT AXILLA, BIOPSY -. TWO BENIGN LYMPH NODES, NO TUMOR SEEN (0/2). CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Not specified. SIZE OF TUMOR: Maximum dimension invasive component: 2.5 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 2. Mitotic activity score: 2. Total Nottingham score: 6. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: TUMOR TYPE, IN SITU: Cribriform. Solid. DCIS admixed with invasive carcinoma. Percent of tumor occupied by in situ component: 25 %. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 1 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: Distance of in situ disease to closest margin: 1 mm. PAGET'S DISEASE OF NIPPLE: 1. LYMPH NODES POSITIVE: LYMPH NODES EXAMINED: 5. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: ONLY KERATIN POSITIVE CELLS ARE PRESENT: SIZE OF NODAL METASTASES: Diameter of largest lymph node metastasis. IU mm. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: METASTASES TO IPSILATERAL INTERNAL MAMMARY LYMPH NODE (IF APPLICABLE): SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST TISSUE: ADH, FCD. T STAGE, PATHOLOGIC: pT2. N STAGE, PATHOLOGIC: pN1. as STAGE DATUOI neir. PMY.",BRCA,1,"Based on the report, the size of the largest focus of invasive carcinoma is 2.5 cm, which falls under the T2 category of 'more than 2.0 cm but not more than 5.0 cm in size'.",T2,10.0
897,TCGA-AR-A2LN.128D4F7D-017D-459F-9664-AF509AE4555E,1,"Final Diagnosis. A. Breast, right, mastectomy: Infiltrating lobular carcinoma, Nottingham grade II (of III). [tubules 3/3, nuclei 2/3, mitoses 1/3; Nottingham score 5/9], forming a 2.8 x 2.0 x 1.2 cm mass. located in the upper outer quadrant of the breast [AJCC, 7th ed., pT2]. Angiolymphatic invasion. is present. The non-neoplastic breast parenchyma shows proliferative fibrocystic changes. Biopsy site changes present. The tumor does not involve the nipple, overlying skin, or underlying. chest wall. A seborrheic keratosis is identified in the skin. All surgical resection margins,. including deep margin, are negative for tumor (minimum tumor free margin, 2.0 cm, anterior-. superior margin). B. Lymph node, right axillary, sentinel biopsy: One (of1) axillary sentinel lymph node is. positive for metastatic carcinoma, the largest measuring 2.0 cm. Extranodal extension is present. [AJCC, 7th ed., pN1]. C. Breast, left, mastectomy: Infiltrating lobular carcinoma, Nottingham grade II (of III) [tubules. 3/3, nuclei 2/3, mitoses 1/3; Nottingham score 6/9], and lobular carcinoma in situ, forming a 4.1. x 3.8 x 2.4 cm mass located in the upper subareolar aspect of the breast [AJCC, 7th ed., pT2]. Angiolymphatic invasion is absent. The non-neoplastic breast parenchyma shows proliferative. fibrocystic changes. Biopsy site changes present. The tumor involves the nipple. The overlying. skin and underlying chest wall are uninvolved. All surgical resection margins, including deep. margin, are negative for tumor (minimum tumor free margin, 1.6 cm, anterior-superior margin). D. Lymph node, left axillary, sentinel biopsy: One axillary sentinel lymph node is negative for. metastatic carcinoma. Blue dye is identified. Immunohistochemical cytokeratin stain was. performed on the paraffin embedded sentinel lymph node tissue and confirms the H&E. impression. E. Lymph node, left axillary #2, sentinel biopsy: One axillary sentinel lymph node is negative. for metastatic carcinoma. Blue dye is not identified. Immunohistochemical cytokeratin stain was. performed on the paraffin embedded sentinel lymph node tissue and confirms the H&E. impression. [AJCC, 7th ed., pN0(i-)(sn)]. F. Lymph nodes, right axillary, dissection: Multiple (14) axillary lymph nodes are negative for. metastatic carcinoma.",BRCA,0,"Based on the report, the right breast tumor measures 2.8 x 2.0 x 1.2 cm, which falls within the T2 category of being more than 2.0 cm but not more than 5.0 cm in size. The left breast tumor is also T2, measuring 4.1 x 3.8 x 2.4 cm. However, we select the highest T stage for the overall T stage, which is T2.",T2,11.0
914,TCGA-B6-A0IE.DFCA9C6E-710E-4645-9CFC-A908AAD583F3,2,"Surgical Pathology: Final. CLINICAL HISTORY: Inflammatory breast ca. Breast cancer. GROSS EXAMINATION: A. ""Left breast biopsy, received fresh. A fragment of skin which is 3.3 cm. long and 0.4 cm in diameter attached to underlying fibroadipose tissue which. is 2.7 cm thick x 3.5 x 1 cm in greatest dimensions. The specimen has been. previously partially sectioned revealing a poorly defined area of pink tissue. measuring approximately 2.5 x 1.5 x 1 cm in greatest dimensions. This does. not represent the true sides of the lesion. Portions of the tissue have. submitted for ER/PR evaluation. It is noted that this is a representative. fragment of larger lesion and margins are not require for the specimen. Representative sections are submitted in Blocks A1 and A2. DIAGNOSIS: A. BREAST, LEFT, INCISIONAL BIOPSY: POORLY DIFFERENTIATED CARCINOMA WITH EXTENSIVE VASCULAR INVASION. IN SITU CARCINOMA IS NOT PRESENT. NOTE: THE TUMOR HAS FEATURES OF LOBULAR CARCINOMA, BUT AN IN SITU COMPONENT. IS NOT PRESENT. eBrowser Result for: 1 of 1.",BRCA,1,"The report states that the largest focus of invasive carcinoma measures approximately 2.5 x 1.5 x 1 cm in greatest dimensions. According to the rules provided, T2 tumors are more than 2.0 cm but not more than 5.0 cm in size. Therefore, the T stage for this patient's cancer is T2.",T2,12.0
783,TCGA-AO-A03P.0BFAB667-8B40-46AE-A224-535573E268C7,1,"Clinical Diagnosis & History: y/o female with two foci of carcinoma right breast 10:00/subareolar (FNA. malignant) and 11:00/UOQ (core biopsy invasive ductal carcinoma) . For right. wide excision, SLNB, possible ALND. Specimens Submitted: 1: SP: Sentinel node #1 level one right axilla (fs). 2: SP: Sentinel node #2, level one right axilla (fs). 3: SP: Wide excision of tumor right breast 10:00 (. DIAGNOSIS: 1). SENTINEL LYMPH NODE #1, LEVEL I, RIGHT AXILLA; BIOPSY: - ONE BENIGN LYMPH NODE. - DEEPER LEVEL RECUTS AND SPECIAL STAINS HAVE BEEN ORDERED. THE. RESULTS WILL BE REPORTED IN AN ADDENDUM. 2). SENTINEL LYMPH NODE #2, LEVEL I, RIGHT AXILLA; BIOPSY: ONE BENIGN LYMPH NODE. - DEEPER LEVEL RECUTS AND SPECIAL STAINS HAVE BEEN ORDERED. THE. RESULTS WILL BE REPORTED IN AN ADDENDUM. 3). BREAST, RIGHT, 10:00; WIDE EXCISION: - INVASIVE DUCTAL CARCINOMA, NOS TYPE, HISTOLOGIC GRADE III/III (SLIGHT. OR. NO TUBULE FORMATION). NUCLEAR GRADE III/III (MARKED VARIATION IN SIZE AND. SHAPE), PRESENT AS THREE SEPARATE NODULES, RANGING IN SIZE FROM 1.0 CM UP TO. 3.7 CM. - DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID TYPE WITH HIGH. NUCLEAR GRADE AND MINIMAL NECROSIS. - THE DCIS CONSTITUTES <= 25% OF THE TOTAL TUMOR MASS, AND IS PRESENT. ADMIXED WITH AND AWAY FROM THE INVASIVE COMPONENT. - NO CALCIFICATIONS ARE IDENTIFIED IN EITHER THE INVASIVE OR IN SITU. CARCINOMA. NO VASCULAR INVASION IS NOTED. - INVASIVE CARCINOMA IS 0.15 CM FROM THE NEAREST (SUPERIOR) MARGIN AND 0.4. CM FROM THE POSTERIOR MARGIN. - THE NON-NEOPLASTIC BREAST TISSUE IS UNREMARKABLE. - RESULTS OF SPECIAL STAINS (ER, PR, HER2-NEU) WILL BE REPORTED AS AN. ADDENDUM. Page 2 or 5'. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL), AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Special Studies: Special Stain. Comment. POSITIVE. AE1:AE3. NEG CONT. IMM RECUT. AE1:AE3. AE1:AE3. NEG CONT. IMM RECUT. ER-C. PR-C. HER2-. NEG CONT. NEG-HER2. IMM RECUT. 1). The specimen is received fresh for frozen section diagnosis, labeled,. ""Sentinel node #1, level one, right axilla"". It consists of a single lymph. node, measuring 0.8 x 0.7 x 0.5 cm. The lymph node is bisected and entirely. frozen. Summary of Sections: FSC frozen section control. 2). The specimen is received fresh for frozen section diagnosis, labeled,. ""Sentinel node #2, level one, right axilla"". It consists of a single lymph. node, measuring 0.5 x 0.5 x 0.5 cm. Bisected and entirely submitted. Summary of Sections: FSC frozen section control. 3). The specimen is received fresh, labeled, ""Wide excision of tumor. right breast 10:00 (short stitch superior, long stitch lateral)"" It. consists of an ovoid to irregular piece of yellow lobulated adipose tissue,. measuring about 9.5 x 7.5 x 4.0 cm in greatest dimension. The specimen is. oriented with a short stitch at the superior aspect and a long stitch at the. lateral margin. The specimen is inked as follows: superior-blue,. Page 3 of. inferior-red, posterior-black, anterior-yellow. Serial sections of the. breast reveal large centrally located 3.7 x 2.5 x 2.0 cm fairly. ell-circumscribed, tan lesion, located about 1.0 cm from the superior,. inferior, and medial margins. The tumor is closest to the anterior and. posterior margin and is at a distance of 0.5 cm from either of them. Cut. surface of the tumor reveals a tan, slightly granular appearance About 1.0. cm superior and lateral to the main mass are two smaller well-circumscribed. nodules, the larger of which measures 2.2 x 1.3 x 1.0 cm. This fairly. ell-circumscribed nodule is < 0.2 cm from the superior margin and is. located about 1.0 cm from the lateral and 0.5 cm from the posterior margin. About 0.5 cm lateral to this nodule is the smallest nodule measuring about. 1.0 cm in diameter. The smallest nodule is located 0.2 cm from the superior. and 0.5 cm from the lateral margin. The remaining portion of the breast. parenchyma is composed of yellow lobulated adipose tissue. Representative. sections of the specimen are submitted as follows. Summary of Sections: MM medial margin. LM lateral margin. T1 largest centrally located nodule. T2 larger of the smaller nodules located lateral to the main mass. T3 the smallest nodule. R. representative sections of the remaining breast tissue. Summary of Sections: Part 1: SP: Sentinel node #1 level one right axilla (fs). Block. Sect. Site. PCs. 1. FSC. 1. Part 2: SP: Sentinel node #2, level one right axilla (fa). Block. Sect. Site. PCs. 1. FSC. 1. Part 3: SP: Wide excision of tumor right breast 10:00. Block. Sect. Site. PCs. 3. LM. 9. 2. MM. 6. 2. R. 3. 5. T1. 5. 2. T2. 2. 3. T3. 3. Procedures/Addenda. Addendum. Date Complete: Addendum Diagnosis. ADDENDUM. SITE: SENTINEL LYMPH NODE, RIGHT AXILLA. PART #1, AND 2. PART #1. METASTATIC CARCINOMA IN THE FORM OF MICROSCOPIC CLUSTERS AND SINGLE CELLS. MEASURING LESS THAN 2MM (MICROMETASTASIS). IS IDENTIFIED ON CYTOKERATIN. IMMUNOHISTOCHEMICAL STAINS ONLY. PART #2. ONE ISOLATED CYTOKERATIN-POSITIVE CELL IS PRESENT. THESE CELLS ARE NOT. IDENTIFIED ON THE H&E STAINED SECTIONS. Addendum. Sigmed out. Date Complete: Addendum Diagnosis. ADDENDUM. SITE: RIGHT BREAST. ER: >95% OF NUCLEAR STAINING WITH STRONG INTENSITY. PR: 40% OF NUCLEAR STAINING WITH MODERATE INTENSITY. HER2/NEU (HERCEPTEST) : NEGATIVE (STAINING INTENSITY OF 0) . CONTROLS ARE SATISFACTORY. M.D. Intraoperative Consultation: Note: The diagnoses given in this section pertain only to the. tissue sample examined at the time of the intraoperative. consultation. 1). FROZEN SECTION DIAGNOSIS: NO TUMOR IDENTIFIED. PERMANENT DIAGNOSIS: SAME. 2). FROZEN SECTION DIAGNOSIS: NO TUMOR IDENTIFIED. PERMANENT DIAGNOSIS: SAME.",BRCA,1,"The largest focus of invasive carcinoma is 3.7 cm, which falls under T1 tumors being 2.0 cm or less in size. It is further divided into T1c as it is greater than 1 cm but not more than 2 cm.",T1,13.0
1265,TCGA-E2-A572.5CED2FBF-42DB-4D17-95C0-DEAE27BBFD02,1,"SPECIMEN(S): A. LEFT BREAST AND AXILLARY CONTENTS. B. ADDITIONAL AXILLARY CONTENTS. C. LEFT BREAST SKIN AND TISSUE. D. RIGHT BREAST NEEDLE LOCALIZATION. E. ADDITIONAL RIGHT BREAST RETROAREOLAR TISSUE. MARGIN. CLINICAL HISTORY: yo female with left clinical T2N1 IDC, 3.5 cm retroareolar (note ER + primary and ER. negative axillary mets) here for L MRM. Also, right breast mass bx shows ADH. Here. for R excisional biopsy. PRE-OPERATIVE DIAGNOSIS: Left - IDC, Right - ADH. INTRAOPERATIVE CONSULTATION. FSD: Right breast needle localization- Representative section of mass-no invasive. carcinoma on frozen. At least atypical ductal hyperplasia-cannot rule out DCIS-lesion. near anterior margin. Diagnosis called to Dr. at by Dr. DIAGNOSIS: A. BREAST, LEFT, AND AXILLARY CONTENTS, MODIFIED RADICAL. MASTECTOMY: - INVASIVE DUCTAL CARCINOMA, NOTTINGHAM GRADE 2, WITH. LOBULAR FEATURES, INVOLVING THE NIPPLE DERMIS. - 3.4 CM IN SIZE. - DUCTAL CARCINOMA IN SITU (DCIS), CRIBRIFORM AND SOLID. TYPES,. NUCLEAR GRADE 2, WITH NECROSIS AND MICROCALCIFICATIONS. - MARGINS, NEGATIVE FOR CARCINOMA. METASTATIC CARCINOMA IN SEVEN OF EIGHT LYMPH NODES. WITH. EXTRANODAL EXTENSION (7/8). B. ADDITIONAL AXILLARY CONTENTS, LEFT, DISSECTION: - METASTATIC CARCINOMA IN ONE OF FIVE LYMPH NODES (1/5). C. BREAST, LEFT, SKIN AND TISSUE, EXCISION: - SKIN AND ADIPOSE TISSUE, NEGATIVE FOR CARCINOMA. D. BREAST, RIGHT, NEEDLE LOCALIZATION EXCISIONAL BIOPSY: - DUCTAL CARCINOMA IN SITU (DCIS), CRIBRIFORM AND PAPILLARY. TYPES, NUCLEAR GRADE 1. - DCIS IS WITHIN 0.2 CM OF THE DESIGNATED RETROAREOLAR. MARGIN AND 0.3 CM FROM THE ANTERIOR MARGIN. - SEVERAL FOCI OF ATYPICAL DUCTAL HYPERPLASIA (ADH). - COLUMNAR CELL CHANGE, COMPLEX SCLEROSING LESION WITH. USUAL DUCTAL HYPERPLASIA, INTRADUCTAL PAPILLOMAS,. CYSTIC. APOCRINE METAPLASIA, MICROCALCIFICATIONS AND PREVIOUS. BIOPSY SITE CHANGES. NOTE: DCIS is present in two slides and measures 0.4 cm on a single slide. E. BREAST, RIGHT, ADDITIONAL RETROAREOLAR TISSUE MARGIN,. EXCISION: SMALL INTRADUCTAL PAPILLOMA WITH USUAL DUCTAL. HYPERPLASIA. AND FOCAL PREVIOUS BIOPSY SITE CHANGES. SYNOPTIC REPORT - BREAST. Specimens Involved. Specimens: A: LEFT BREAST AND AXILLARY CONTENTS. B: ADDITIONAL AXILLARY CONTENTS. C: LEFT BREAST SKIN AND TISSUE. Specimen Type: Mastectomy. Needle Localization: Laterality: Left. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 3.4cm. Tumor Site: Central. Margins: Negative. Distance from closest margin: Greater than 2cm. deep. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 1. Modified Scarff Bloom Richardson Grade: 2. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Axillary dissection. Lymph node status: Positive 8 / 13 Extranodal extension. Non-neoplastic areas: complex sclerosing lesion, intraductal papillomas, usual ductal hyperplasia. DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 10%. DCIS Type: Solid. Cribriform. DCIS Location: Both associated and separate from invasive tumor mass. Nuclear grade: Intermediate. Necrosis: Present. Location of CA++: DCIS. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative. Performed on Case: Pathological staging (pTN): pT 2 N 2. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimens Involved. Specimens: A: LEFT BREAST AND AXILLARY CONTENTS. Specimen: Surgical Excision. Block Number: A21 (lymph node). ER: Positive. Allred Score: 8 = Proportion Score 5 + Intensity Score 3. PR: Positive. Allred Score: 3 = Proportion Score 2 + Intensity Score 1. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-. 30% of cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score. (1 = weak intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of. staining), with a scoring range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score. of less than or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR. (PGR 136, 1:100) provided by. bllowing the manufacturer s. instructions. This assay was not modified. Interpretation of the ER/PR immunohistochemical stain. is guided by published results in the medical literature, information provided by the reagent. manufacturer and by internal review of staining performance. SYNOPTIC REPORT - BREAST. Specimens Involved. Specimens: D: RIGHT BREAST NEEDLE LOCALIZATION. E: ADDITIONAL RIGHT BREAST RETROAREOLAR TISSUE MARGIN. Specimen Type: Excision. Needle Localization: Laterality: Right. Invasive Tumor: Absent. Multifocality: N/A. WHO CLASSIFICATION. Intraductal proliferative lesions. Ductal carcinoma in situ 8500/2. DCIS present. Margins uninvolved by DCIS : see above. DCIS Type: Cribriform. Papillary. Nuclear grade: Low. Necrosis: Absent. Location of CA++: Benign epithelium. Pathological staging (pTN): pT is N X. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. GROSS DESCRIPTION: A. LEFT BREAST AND AXILLARY CONTENTS. Received fresh with the patient's identification and designated ""left breast and axillary. contents"" is an oriented 1143g, 19 x 19 x 3.6 cm mastectomy with 14 X 6 cm attached. tan-brown skin ellipse and a centrally located, non-retracted 1.2 x 1.4 cm nipple. Ink. code: posterior-black, anterior superior-blue, anterior inferior-orange. Serial sectioning. from medial to lateral into 14 slices reveals two lesions: Lesion 1: 3.4 x 3 x 2 cm white-tan, firm, irregular mass at 12:00 in slices 5 and 6, 3 cm. from the deep margin. Lesion 2: 8 x 7 X 3 cm ill-defined nodular and cystic area, involving the LIQ, mid to LOQ. and central area in slices 4-9, 2 cm from the deep margin, and inferior and adjacent to. lesion 1. In the axillary tail, there is a 4 x 3.2 x 2 cm mass consistent with tumor involving lymph. node(s) as well as several other grossly positive lymph nodes. Representatively submitted. as per the attached diagram: A1-A2: lesion 1 (mass), slice 5, 12:00. A3-A5: lesion 1 (mass), slice 6, 12:00 (biopsy clip in cassette A3). A6: deep margin, slice 5. A7: lesion 2, slice 4, LIQ. A8: lesion 2, slice 5, central lower. A9: lesion 2, slice 6, central lower. A10: lesion 2, slice 7, LOQ. A11: lesion 2, slice 8, LOQ. A12: lesion 2, slice 8, mid outer quadrant. A13: lesion 2, slice 9, LOQ. A14: deep margin, slice 9. A15: UIQ. A16: UOQ. A17-A19: nipple. A20: skin. A21-A22: representative sections of largest lymph node. A23: one lymph node, representative section. A24: one lymph node, bisected. A25: one possible lymph node, bisected. A26: two lymph nodes. A27: one lymph node, bisected. A28: two lymph nodes. A29-A32: additional axillary tissue. B. ADDITIONAL AXILLARY CONTENTS. Received fresh labeled with patient identification and designated ""additional axillary. contents"" is a tan-pink to tan-red and hemorrhagic, fibrofatty soft tissue fragment, 3.5 x. 2.5 x 1 9 cm. Examination reveals 8-10, firm, tan-white to tan-pink possible lymph nodes. ranging in size from 0.2 x 0.2 x 0.2 cm to 0.4 x 0.2 x 0.2 cm. The specimen is entirely. submitted as follows: B1: Possible lymph nodes. B2-B3: The remaining soft tissue. C. LEFT BREAST SKIN AND TISSUE. Received fresh with patient's identification and designated ""left breast skin and tissue"" are. 1) an unoriented, tan-pink to tan-yellow, partially skin covered soft tissue fragment. measuring 9.5 x 6.5 x 1.8 cm, serial sectioning reveals no grossly visible/possible. masses/lesions. The deep surface of the specimen is inked in black and representatively. submitted in C1-C3. 2) A fragment of tan-brown skin (the central part is missing), 2-1.5 x 7.5 x 1 cm,. examination reveals no grossly visible lesions, representatively submitted in C4-C5. D. RIGHT BREAST NEEDLE LOCALIZATION. Received fresh labeled with the patient's identification and ""right breast needle. localization"" is an oriented 31g, 7 x 5 x 3cm needle localized lumpectomy with. radiograph. Ink code: retroareolar - purple, anterior-yellow, posterior-black, superior-. blue, inferior-orange, medial-green, lateral-red. Specimen is serially sectioned from. lateral to medial into 7 slices revealing a 1.4 x 1 x 1cm tan white irregular mass, 0.1cm. from the anterior-retroareolar margin in slices 3-4. A 0.5 x 0.5 x 0.3cm tan white firm. area is also identified, at the anterior-lateral-inferior margin of slice 1. A biopsy clip is. identified in slice 2 adjacent to the firm area in slice 1. A portion of the 1.4 cm mass is. submitted for frozen section in FSD. Representatively submitted: FSD: 1.4 cm mass slice 3. D2-D4: lateral margin with 0.5 cm firm area in D4. D5-D8: slice 2 with clip ID in D8. D9: superior margin slice 3. D10: posterior margin slice 3. D11-D12: inferior margin slice 3. D13-D14: superior margin slice 4. D15: mass with anterior margin slice 4. D16: posterior margin slice 4. D17: inferior margin slice 4. D18-D19: anterior margin slice 5. D20-D21: posterior margin slice 5. D22: superior margin slice 6. D23: anterior margin slice 6. D24: posterior margin slice 6. D25: inferior margin slice 6. D26-D27: medial margin slice 7. E. ADDITIONAL RIGHT BREAST RETROAREOLAR TISSUE MARGIN. Received fresh labeled with the patient's identification and 'additional right breast. retroareolar tissue' is an oriented 5g, 4.5 x 3.8 x 1.4cm tan pink fibrofatty tissue. Final. margin is inked blue. Serial sectioning reveals no discrete lesions. Entirely submitted in. E1-E4.",BRCA,2,"The report states that the largest focus of invasive carcinoma is 3.4 cm in size, which falls under the T2 category of tumors that are more than 2.0 cm but not more than 5.0 cm in size. The presence of ductal carcinoma in situ (DCIS) or the number of tumors does not affect the T stage, as per the rules.",T2,14.0
1162,TCGA-D8-A1Y3.E8D4229D-5049-4991-BDE0-AFC2CBC1827E,1,"page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breast. Unit in charge: I. Material collected on: I. aterial received on: Expected time of examination: up to 8 working days. Clinical diagnosis: Macroscopic description: Right breast Sized 20 x 14 x 5 cm removed along with axillary tissues sized 10 x 5 x 3 cm and a skin flap of 18 x 10 cm. Tumour. found in the upper outer quadrant, located 3 cm from the upper boundary, 1 cm from the base and 1.5 cm from the skin. Microscopic description: Carcinoma ductale invasivum NHG3 (3+3+3: 20 mitoses/10 HPF - visual area: 0.55mm). Invasio carcinomatosa vasorum massiva. Mamilla sine laesionibus. Glandular tissue showing mastopathia fibrosa. Axillary lymph nodes: Metastases carcinomatosae in lymphonodis (No V/ VIII). Infiltratio telae perinodalis. Emboliae carcinomatosae vasorum. Histopathological diagnosis: Carcinoma ductale invasivum mammae dextrae. Invasive ductal carcinoma of the right breast. Metastases carcinomatosae in lymphonodis axillae (No V / VIII). Cancer metastases in axillary lymph nodes (No V/VIII). (NHG3, pT2, pN2a). Invasio carcinomatosa vasorum massiva. Massive vascular invasion. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell nuclei. HER2 protein stained with Ventana's Pathway HER-2/neu (4B5) rabbit antibody. Score=2+, FISZ verification recommended. UDD:E8D4229D-5849-4991-BDE@-AFC2C8C1827E. Examination: Histopathological examination. I. Gender: F. Result of immunohistochemical examination: RESULT OF HER2/neu GENE AMPLIFICATION with the FISH method by Path Vysion HER2 DNA Probe Kit. HER-2 GENE AMPLIFICATION NOT FOUND. Supplementary information: Size of the tumour 3.5 x 2.5 x 2.0 cm.",BRCA,2,"According to the report, the size of the largest focus of invasive carcinoma is 3.5 x 2.5 x 2.0 cm. Based on the rules provided, T2 tumors are more than 2.0 cm but not more than 5.0 cm in size. Therefore, the T stage for this patient is T2.",T2,15.0
1130,TCGA-D8-A1JN.021DF0B3-A535-4AD4-9545-1B9A7BC3E1E6,2,"page 1 / 2. copy No. Examination: Histopathological examination. PESEL: Gender: F. Material: Multiple organ resection - left breast. Expected time of examination: up to 8 working days. Clinical diagnosis: Results of immunohistochemical examination: Estrogen receptors found in 75% of neoplastic cell nuclei. Progesterone receptors found in 10% of neoplastic. cell nuclei. HER2 protein stained with HercepTest by DAKO. Score = 2+, verification by the FISH method recommended. Macroscopic description: Left breast sized 17.8 x 11.3 x 4.8 cm removed with axillary tissues sized 9 x 5 x 3 cm. Weight 400 g. Skin flap. 21.7 x 9.2 cm in size. Tumour sized 3.9 x 6.6 x 2.8 cm found in the central part, placed 1.4 cm from the upper. edge, 0.9 cm from the base and 0.0 cm from the skin. Status after blopsy (test No. Microscopic description: Carcinoma lobulare invasivum (G2 acc. to Elston: 3+2+1; 0 mitoses /10 HPF diam. 0.55 mm) Infiltratio. carcinomatosa cutis et mammillae. Glandular tissue showing parenchyma atrophy. Invasive lesions are placed 0.1 cm from the base of the surgical specimen. Axillary lymph nodes: Metastases. carcinomatosae in lymphonodo (No XI/XIII). Histopathological diagnosis: (including test No. Ca rei nom alobulare invasivum mammae sinistrae. Invasive lobular carcinoma of the left breast. Metastases carcinomatosae in lymphonodis axillae (XI/XIII) Cancer metastases in axillary lymph nodes (XI/XIII). (NHG2, pT3, pN3a). Examination: Histopathological examination page 2 / 2. PESEL: Gender: F. Results of immunohistochemical examination: RESULT OF HER2/neu GENE AMPLIFICATION with the FISH method by Path Vysion HER2 DNA Probe Kit. HER-2 GENE AMPLIFICATION NOT FOUND.",BRCA,3,"The report states that the size of the largest focus of invasive carcinoma is 3.9 x 6.6 x 2.8 cm. According to the rules provided, T3 tumors are more than 5.0 cm in size. However, the exact measurement of the tumor size in a single dimension is not explicitly stated in the report. Given that the largest dimension of the tumor is 6.6 cm, which is more than 5.0 cm, the T stage would be T3.",T3,16.0
843,TCGA-AR-A0TX.4FC34715-9004-4F53-B914-F0004AEA88C8,0,"Breast, left, wide local excision: Infiltrating ductal carcinoma, Nottingham grade II (of III), forming a. multilobulated mass (1.5 x 1.2 x 1.0 cm) adjacent to the prior core biopsy site (AJCC pTlc). Ductal. carcinoma in-situ, solid type, high nuclear grade, is present outside the main tumor mass. No. angiolymphatic invasion is identified. The skin is without diagnostic abnormality. All surgical resection. margins, after re-excision of the deep margin (skeletal muscle), are negative for tumor (minimum tumor. free margin, 0.4 cm, superior margin). Lymph nodes, left axillary, dissection: Multiple (3 of 25) left axillary lymph nodes are positive for. metastatic carcinoma with extranodal extension (AJCC pN1). Two positive lymph nodes are matted. together. Her-2/NEU has been ordered on paraffin embedded tissue.",BRCA,1,"The report states that the largest focus of invasive carcinoma is a multilobulated mass with dimensions of 1.5 x 1.2 x 1.0 cm. Based on the rules provided, T1 tumors are 2.0 cm or less in size, and are further divided into T1a (0.1-0.5 cm), T1b (0.5-1 cm), and T1c (>1 cm but not more than 2 cm) based on size. The mass in this report falls into the T1c category.",T1c,17.0
772,TCGA-AN-A0XP.80E9B7CE-0D5D-4C01-A8E3-E6345BE145EC,1,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 2. T Stage: 2 N Stage: 1 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,2,"The report specifies that the patient is a female with a diagnosis of breast cancer, specifically infiltrative ductal carcinoma. The T stage is provided as T2, which means the tumor is more than 2.0 cm but not more than 5.0 cm in size. The T stage is not affected by the presence of in situ carcinoma or the number of tumors, and is determined by the size of the largest tumor. The report also mentions that the tumor grade is 2, but this information is not relevant to the T stage prediction.",T2,18.0
876,TCGA-AR-A24Q.CCE8E855-2582-4214-B9B1-25F0431065CB,2,"Final Diagnosis. Yeast, left, simple mastectomy: Invasive ductal carcinoma, Nottingham grade III (of III), is identified forming a 6.0 x 4.0 x 3.5. cm tumor (AJCC pT3) in the central-upper inner region of the breast. The deep and lateral margins of resection are. negative. for. tumor. The closest margin is deep and is free by 1.0 cm. The overlying skin and nipple are not involved by carcinoma. Breast, right, simple mastectomy: Invasive ductal carcinoma, Nottingham grade III (of III), is identified forming a 1.7 x. 1.3. x. 1.0. cm tumor (AJCC pTlc) in the upper outer region of the breast. The deep and lateral margins of resection are negative for tumor. The closest margin is deep and is free by 2.8 cm. The overlying skin and nipple are negative for involvement by carcinoma. Lymph nodes, left axillary sentinel, excision: Multiple (2) left axillary sentinel lymph nodes, both containing blue dye, are. negative for metastatic carcinoma [(AJCC pNO (i-)]. Immunohistochemical cytokeratin stain was performed on the paraffin. embedded sentinel lymph node tissue and confirms the H&E impression. Lymph nodes, right axillary sentinel, excision: Multiple (4) right axillary sentinel lymph nodes are negative for tumor [(AJCC. pN0) (i-)]. A single lymph node (1A) contains blue dye. Immunohistochemical cytokeratin stains were performed on the paraffin. embedded sentinel lymph node tissue and confirm the H&E impression. Her-2/NEU has been ordered on paraffin-embedded tissue on the left breast.",BRCA,0,"The T stage is determined by the size of the largest tumor. In this report, the largest tumor is found in the left breast, measuring 6.0 x 4.0 x 3.5 cm (AJCC pT3), which is larger than the 5.0 cm threshold for T3 tumors.",T3,19.0
850,TCGA-AR-A0U4.6424BA69-DA2B-4CCD-ADDF-DB1BEDA11EBF,1,"Breast, right, simple mastectomy: Breast parenchymal tissue is negative for tumor. Focal calcifications. identified. The nipple is negative for tumor. A single intraparenchymal lymph node is negative for. tumor. Breast, left, simple mastectomy: Infiltrating ductal carcinoma, Nottingham grade III (of III), [tubules 3. (of 3), nuclei 3 (of 3), mitoses 2 (of 3); Nottingham score 7-8 (of 9) forming a 4.7 x 4.0 x 2.7 cm mass,. located in the upper outer quadrant of the breast (AJCCpT2). Ductal carcinoma in situ is absent. Angiolymphatic invasion is absent. No calcifications are present. The tumor does not involve the nipple,. overlying skin, or underlying chest wall. All surgical resection margins, including deep margin, are. negative for tumor (minimum tumor free margin, 1.7 cm, deep margin). Lymph nodes, left axillary sentinel, excision: Multiple (10) sentinel lymph nodes are negative for tumor. AJCC PN0(1-)(sn). Immunohistochemical stains were performed on paraffin embedded tissue from the breast tumor using. antibodies to ER, PR, and HER2/neu. Estrogen is negative, 0% nuclear staining. Progesterone is. negative, 0% nuclear staining. HER2/neu protein overexpression is negative, score of 0, according to the. interpretation guidelines in the FDA-approved HercepTest. ER (Estrogen Receptor) test was developed and its performance characteristics determined by. It has not been cleared or approved by the U.S. Food. and Drug Administration.",BRCA,0,"The report states that the patient has 'infiltrating ductal carcinoma, Nottingham grade III forming a 4.7 x 4.0 x 2.7 cm mass' in the left breast. The T stage is determined by the size of the largest tumor, and in this case, the tumor measures 4.7 cm, which falls under the T2 category of tumors that are more than 2.0 cm but not more than 5.0 cm in size.",T2,20.0
811,TCGA-AO-A129.DD973A0E-3CC3-4ED7-BE2C-7E5E3C55032B,1,"Clinical Diagnosis & History: Patient with left breast cancer IFDC on core left MRM and right prophylactic. TM and SLNB. Specimens Submitted: 1: SP: Left breast & axillary contents levels 1, with tags attached. 2: SP: Right breast. 3: SP: Level 3 axillary contents. 4: SP: Sentinel node #1, level one right axilla. 5: SP: Sentinel node #2. lovel one right axilla. DIAGNOSIS: 1). BREAST, LEFT AND AZILLARY CONTENTS, LEVELS I AND II; EXCISION: - INVASIVE DUCTAL CARCINOMA, WITH MEDULLARY FEATURES, HISTOLOGIC GRADE. II/ILI (MODERATE TUBULE FORMATION), NUCLEAR GRADE III/III (MARKED VARIATION. IN SIZE AND SHAPE) MEASURING 2.3 CM IN LARGEST DIMENSION MICROSCOPICALLY. - DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID TYPE WITH HIGH. NUCLEAR GRADE AND EXTENSIVE NECROSIS. -THE DCIS CONSTITUTES <- 25% OF THE TOTAL TUMOR MASS, AND IS PRESENT ADMIXED. WITH THE INVASIVE COMPONENT. - THE INVASIVE CARCINOMA IS LOCATED IN THE LOWER OUTER QUADRANT. THE DCIS. IS LOCATED IN THE LOWER OUTER QUADRANT. - NO INVOLVEMENT OF THE NIPPLE BY EITHER IN SITU OR INVASIVE CARCINOMA IS. IDENTIFIED. - NO CALCIFICATTONS ARE IDENTIFIED IN EITHER THE INVASIVE OR IN SITU. CARCINOMA. - NO VASCULAR INVASION IS NOTED. - NO INVOLVEMENT OF THE SURGICAL MARGINS BY EITHER INVASIVE OR IN SITU. CARCINOMA IS IDENTIFIED. - NO SKIN INVOLVEMENT BY CARCINOMA IS IDENTIFIED. - THE NON-NEOPLASTIC BREAST TISSUE IS UNREMARKABLE. - THE LYMPH NODE STATUS IS AS FOLLOWS (EXPRESSED AS THE NUMBER OF. POSITIVE LYMPH NODES IN RELATION TO THE TOTAL NUMBER OF LYMPH NODES. EXAMINED) : LEVEL I: 2/13; LEVEL II: 0/4. - THERE IS EXTRANODAL EXTENSION OF CARCINOMA. RESULTS OF SPECIAL STAINS (ER, PR, HER2-NEU) WILL BE REPORTED AS AN. ADDENDUM. 2). BREAST, RIGHT; EXCISION: - BENIGN BREAST PARENCHYMA WITH SECRETORY CHANGE. 3). LYMPH NODES, LEFT AXILLA, LEVEL III; EXCISION: - TWO BENIGN LYMPH NODES (0/2). 4). LYMPH NODES, SENTINEL #1, LEVEL I, RIGHT AXILLA; EXCISION: - TWO BENIGN LYMPH NODES (0/2) DEEPER LEVEL RECUTS AND SPECIAL. STAINS HAVE BEEN ORDERED. THE RESULTS WILL BE REPORTED IN AN ADDENDUM. 5). LYMPH NODE, SENTINEL #2, LEVEL I, RIGHT AXILLA; EXCISION: - BENIGN BREAST TISSUE. NO LYMPH NODE IDENTIFIED. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL), AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Special Studies: Special Stain. Comment. HER2-C. ER-C. PR-C. NEG CONT. IMM RECUT. NEG-HER2. AE1:AE3. CAM 5.2. AE1:AE3. CAM 5.2. NEG CONT. IMM RECUT. NEG CONT. IMM RECUT. Gross Description: 1). The specimen is received fresh, labeled, ""Left breast & axillary. contents levels 1,2 with tags attached"". It is a product of left modified. mastectomy, consisting of an ellipse of tan skin, breast tissue and axillary. tail designated as levels one and two. The skin measures 15.0 x 4.0 cm. The breast tissue measures 23.0 x 23.0 x 6.5 cm. The axillary tail site. measures 14.0 x 6.5 x 2.0 cm. The nipple is everted. No visible scars are. present on the skin surface. A scanty amount of skeletal muscle tissue is. present at the deep margin which is inked. The breast tissue was sectioned. to reveal an ill-defined pink-gray focally hemorrhagic rubbery tumor. completely surrounded by thickened fibrous tissue situated in the lower. outer quadrant, 3.5 em from the deep surgical margin. The fibrous tissue. surrounding the tumor abuts the deep surgical margin. The rest of the tissue. is. predominantly fibrous. Serial sectioning of the axillary tail reveals. ?age 3 of 5. multiple lymph nodes, ranging from 0.3 up to 1.5 cm in greatest dimension. Representative sections were submitted, portion of the tumor was given to. TPS. Summary of Sections: N nipple. T tumor. DM deep margin closest to the tumor. UOQ upper outer quadrant. LOQ lower outer quadrant. LIQ lower inner quadrant. LN1 lymph nodes level one. LN2 lymph nodes level two. 2). The specimen is received fresh, labeled, ""Right breast, (stitch marks. axillary tail)"" It is a product of right modified mastectomy consisting of. an. ellipse of tan skin with breast tissue. The skin measures 15.5 x 5.0 cm. The breast tissue measures 16.0 x 16.0 x 6.0 cm. The nipple is everted. Grossly no visible scars are present on the skin surface. There is a scanty. amount of skcletal muscle tissue present at the deep margin which is inked. The breast tiscue was sectioned to reveal fibrofatty tissue. The fibrous. tissue counts to approximately 55% of the entire breast tissue. Grossly. evert lesions were identified. No lymph nodes were present at the axillary. tail site. Representative sections were submitted. Summary of Sections: N nipple. OUQ upper outer quadrant. LOW lower outer quadrant. UIQ upper inner quadrant. LIQ lower inner quadrant. DM deep margin. AXT axillary tail site. 3). The specimen is received in formalin, labeled, ""Level 3 axillary. contents' It consists of three piece of fibroadipose tissue measuring in. aggregate 1.5 x 1.0 x 0.6 cm. Entirely submitted. Summary of Sections: U undesignated. 4). The specimen is received in formalin, labeled, ""Sentinel node #1,. level onc, right axilla"". It consists of a single piece of adipose tissue. meacuring 2.5 x 2.0 x 0.5 cm. Entirely submitted. Summary of Sections: U undesignated. 5). The specimen is received in formalin, labeled, Sentinel node #2,. level one right axilla"". It consists of a single piece of fibroadipose. tissue with embedded lymph node, measuring 0.8 cm in its greatest dimension. Entirely submitted. Summary of Sections: LN lymph node. Summary of Sections: Part 1: SP: Left breast & axillary contents levels 1,2 with tags attached. Block. Secr. Site. PCs. 5. ALN. 13. 2. BLN. 7. 1. DM. 3. 2. LIQ. 2. 2. LOQ. 2. 2. N. 2. 4. 4. 2. UIQ. 2. 2. UOQ. 2. Part 2: SP: Right breast. Block. Sect. Site. PCs. 1. AXT. 2. 1. DM. 3. 4. LIQ. 4. 4. LOQ. 4. 2. N. 2. 4. UIQ. 4. 4. UOQ. 4. Part 3: SP: Level 3 axillary contents. Block. Sect. Site. PCs. 1. U. 3. Part 4: SP: Sentinel node #1, level one right axilla. Block. Sect. Site. PCs. 2. 2. Part 5: SP: Sentinel node #2, level one right axilla. Block. Sect. Site. PCs. 1. LN. 1. Procedures/Addenda: Addendum. Date Complete. Addendum Diagnosis. ADDENDUM. SITE: LEFT BREAST. - ER-ICA: NEGATIVE. - PR-ICA: NEGATIVE. - HER2/NEU (HERCEPTEST) : NEGATIVE (STAINING INTENSITY OF 0) . CONTROLS ARE SATISFACTORY. Addendum. Date Complete: Addendum Diagnosis. ADDENDUM. SITE: SENTINEL LYMPH NODE, RIGHT AXILLA. PART #4. ADDITIONAL H&E STAINED SECTIONS AND IMMUNOHISTOCHEMICAL STAINS FOR. CYTOKERATINS (AE1:AE3 AND CAM 5.2) SHOW NO EVIDENCE OF METASTATIC TUMOR.",BRCA,1,"The report states that the largest focus of invasive carcinoma measures 2.3 cm in size. According to the rules provided, T1 tumors are 2.0 cm or less in size. Therefore, the T stage for this patient is T1.",T1,21.0
1252,TCGA-E2-A1LB.A868EC86-9CB6-445E-B961-5D4C57263548,1,"SPECIMENS: A. WLE RIGHT BREAST. B. RIGHT AXILLARY CONTENTS. SPECIMEN(S): A. WLE RIGHT BREAST. B. RIGHT AXILLARY CONTENTS. INTRAOPERATIVE CONSULTATION DIAGNOSIS: Part A, WLE Right breast, gross examination: Tumor 0.2-cm from posterior margin. Called to Dr. at. by Dr. GROSS DESCRIPTION: A. WLE RIGHT BREAST. Received fresh labeled with matching patient identifiers is an oriented (short-superior, long-lateral) 124. g, 9.7 (medial to lateral) x 9 x 3 cm lumpectomy with a slender fragment of tan skin 2.8 x 0.3 cm. The. specimen is inked as follows: anterior - blue, posterior - black, superior - red, inferior - orange, medial. green, lateral - yellow. The specimen is serially sectioned from medial to lateral into 7 slices revealing. a 2.8 x 2.5 x 1.4 cm ill defined firm tan mass approaching the closest posterior margin at 0.2 cm, and. superior margin at 0.5 cm. A portion of the specimen is submitted for tissue procurement. Representative sections are submitted as follows: A1-A2: Perpendicular sections medial margin. A3-A4: Section 2 anterior. A5: Section 2 posterior. A6: Section 3 inferior. A7: Section 3 anterior/superior. A8-A9: Section 3 superior. A10-A11: Section 4 lesion and posterior. A12: Section 4 anterior/inferior. A13-A16: Section 5, lesion and nearest posterior. A17-A18: Section 6, lesion and posterior/anterior. A19-A20: Section 6, lesion and superior. A21-A22: Perpendicular sections lateral margin. A23-A26: Medial margin. A27: Section 6, inferior aspect. A28: Lateral margin. A29: Lateral margin. A30: Section 5, superior margin. A31: Section 2, superior aspect. A32: Section 2, inferior aspect. A33: Section 5, inferior margin. A34: Section 2, superior aspect. B. RIGHT AXILLARY CONTENTS. Received in formalin in a container labeled with matching patient identifiers is a portion of red yellow. fibroadipose tissue measuring 10.7 x 5.9 x 2.5 cm. Multiple possible lymph nodes are identified ranging. in size from 0.3 x 0.3 x 0.3 up to 4 x 3.5 x 2 cm. Cassette summary: B1-B3: Representative sections, largest lymph node. B4: Two possible lymph nodes. B5: Two possible lymph nodes. B6: Four possible lymph nodes. B7: Four possible lymph nodes. B8: Two possible lymph nodes. B9: Two possible lymph nodes. B10: Three possible lymph nodes. B11-B15: Additional possible lymph nodes. DIAGNOSIS: A. BREAST, RIGHT, WIDE LOCAL EXCISION: - INVASIVE DUCTAL CARCINOMA, POORLY DIFFERENTIATED. (SBR GRADE 3), WITH APOCRINE FEATURES, AND SEVERAL FOCI OF. MICROINVASION ASSOCIATED WITH DCIS. - TUMOR MEASURES AT LEAST 3 CM IN GREATEST DIMENSION. INVASIVE CARCINOMA IS 2 MM FROM THE DEEP MARGIN. - EXTENSIVE LYMPHVASCULAR INVASION IS PRESENT. DUCTAL CARCINOMA IN SITU (DCIS), SOLID TYPE, NUCLEAR GRADE 3,. WITH NECROSIS AND ASSOCIATED LYMPHOID INFILTRATE, INVOLVING. LOBULES. DCIS IS PRESENT AT THE LATERAL MARGIN, IS WITHIN 1 MM OF THE. ANTERIOR/MEDIAL AND ANTERIOR MARGIN, AND IS WITHIN 2 MM. OF THE DEEP MARGIN. B. AXILLARY CONTENTS, RIGHT, DISSECTION: - METASTATIC CARCINOMA TO 2 OF 25 LYMPH NODES WITH LARGEST. METASTASIS MEASURING 4 CM (2/25). - NO EXTRACAPSULAR EXTENSION IS SEEN. SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Laterality: Right. Invasive Tumor. Present. Multifocality: Yes. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 3cm. Tumor Site: Upper outer quadrant. Margins: Negative. Distance from closest margin: deep. Tubular Score: 3. Nuclear Grade: 3. Mitotic Score: 2. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Absent. Vascular/Lymphatic Invasion: Present. Lobular neoplasia: None. Lymph nodes: Axillary dissection. Lymph node status: Positive 2/25. DCIS present. Margins involved by DCIS: lateral margin. DCIS Quantity: Estimate 25%. DCIS Type: Solid. DCIS Location: Both associated and separate from invasive tumor mass. Nuclear grade: High. Necrosis: Present. ER/PR/HER2 Results. ER: Negative. PR: Negative. HER2: Positive by IHC. Performed on. Case: This case - the largest lymph node with metastasis. Pathological staging (pTN): pT 2N1. SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: B2 (Lymph node with metastasis). ER: Negative. Allred Score: 0 = Proportion Score 0 + Intensity Score 0. PR: Negative. Allred Score: 0 = Proportion Score 0 + Intensity Score 0. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of. cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak. intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of staining), with a scoring. range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score. of less than or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed usina the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR. 136, 1:100) provided by. following the manufacturer s instructions. This. assay was not modified. Interpretation of the ER/PR immunohistochemical stain is guided by published. results in the medical literature, information provided by the reagent manufacturer and by internal. review of staining performance. SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Surgical Excision. Block Number: B2 (Lymph node with metastasis). Interpretation: POSITIVE. Intensity: 3+. % Tumor Staining: 100%. Fish Ordered: METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Her2 analysis was performed using the FDA approved. HercepTest (TM) test kit. using rabbit anti-human HER2. This assay was not modified. External kit-slides. provided by the manufacturer (cell lines with high, low and negative HER2 protein expression) and in-. house known HER2 amplified control tissue were evaluated along with the test tissue. Adequate, well. preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of the HER2. immunohistochemical stain is guided by published results in the medical literature, information provided. by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the 2007 joint recommendations and guidelines from. ASCO and CAP and from the NCCN HER2 testing in Breast Cancer Task Force. Pathology. Department takes full responsibility for this test's performance. CLINICAL HISTORY: :year-old woman, right breast, upper outer 4 cm mass, IDC, ER/PR negative; HER-2/neu positive,. with palpable adenopathy, here for lumpectomy and axillary lymph node dissection. PRE-OPERATIVE DIAGNOSIS: Right breast cancer. Microscopic/Diagnostic Dictation; Pathologist,. Final Review: Pathologist,. Final Review: Pathologist,. Final: Pathologist.",BRCA,1,"The report states that the invasive ductal carcinoma measures at least 3 cm in greatest dimension, which falls under the T2 category. The specific sub-staging information (T2a, T2b, etc.) is not provided in the report.",T2,22.0
640,TCGA-A8-A084.6A49B3F9-6B43-4D74-A28B-C83BFE61EC7B,1,"Diagnosis: Poorly differentiated invasive ductal carcinoma (tumor diameter: 3.5 cm) with focally. marked intraductal patterns of spread. Concluding tumor classification: NOS, G III, pT2N1aLOV0RX. IGA-A8-A0S4-01A-PR.",BRCA,1,"The report specifies that the tumor diameter is 3.5 cm, which falls within the range for T2 tumors (>2.0 cm but not more than 5.0 cm).",T2,23.0
1477,TCGA-OL-A5RY.C8297152-7551-49A1-8C9D-6B411391AC77,0,"FINAL PATHOLOGIC DIAGNOSIS. A. Right axillary sentinel lymph node #1, biopsy: - Metastatic ductal carcinoma (1.3cm) involving single lymph node (1/1). B. Right axillary sentinel lymph node #2, biopsy: - One lymph node, no tumor (0/1). C. Right axillary sentinel lymph node #3, biopsy: - One lymph node, no tumor (0/1). D. Right axillary non sentinel lymph node, biopsy: - One lymph node, no tumor (0/1). E. Right breast, wire-guided lumpectomy: - Invasive ductal carcinoma, SBR III, multiple foci (largest 1.3cm). - Ductal carcinoma in situ high grade, solid, cribriform and micropapillary. types with central necrosis and associated calcifications; DCIS spans entire. specimen (8cm in greatest dimension). F. Right breast, new inferior lateral margin, excision: - Ductal carcinoma in situ, intermediate grade, microscopic foci (largest 5mm). - Microscopic foci (each 1mm) of DCIS present at outer medial aspect of specimen. G. Right breast, new outer lateral margin, excision: - Ductal carcinoma in situ, rare microscopic foci (largest 1mm). - DCIS >1cm from nearest new margin. Breast Pathologic Parameters. 1. Invasive carcinoma: A. Microscopic measurement: Multifocal; largest focus (measures 1.3cm). B. Composite histologic (modified SBR) grade: III (largest focus). - Architecture: 2. - Nuclear grade: 3. - Mitotic count: 3. C. Associated intraductal carcinoma in situ (DCIS): - High grade, solid, cribriform and micropapillary types. - DCIS involves entire specimen and spans 8cm in greatest dimension. 2. Excisional biopsy margins: Positive. - DCIS present at medial margin, <1mm from anterior, posterior, lateral,. superior, and inferior margins (tumor approaches margins at multiple foci. throughout specimen). - Invasive carcinoma at inferior and 1mm from posterior margin; additional. margins greater than 2mm away. 3. Blood vessel and lymphatic invasion: Present in breast parenchyma. 4. Axillary lymph nodes: Positive (1/4). - Size of largest metastatic deposit: 13 mm. - Extranodal extension: absent. 5. Special studies. - ER: Weak expression in 10% of invasive tumor nuclei. - PR: No expression. - Her2/neu antigen (FISH): Amplified (ratio: 7.6). 6. pTNM (AJCC, 7th edition, 2010): pT1c(m), N1(sn), MX. Effective. is Checklist utilizes the 7th edition TNM staging. system for breast of the American Joint Committee on Cancer (AJCC) and the. International Union Against Cancer (UICC). has1. Interpretation performed by the Attending Pathologist and reviewed with the. Resident/Fellow. Clinical History: Patient is a. -year-old female with right breast IDC undergoing lumpectomy and. sentinel lymph node biopsy. Specimens Received: A: Sentinel lymph node #1. B: Sentinel lymph node #2. C: Sentinel lymph node #3. D: Non-sentinel lymph node. E: Right wire-guided lumpectomy. F: Right breast new inferior lateral margin. G: New outer lateral margin. Gross Description: The specimens are received in seven containers each labeled with the patient's. name and medical record number. A. The first container is additionally identified as, 'sentinel lymph node #1'. Received fresh and placed in formalin the specimen consists of a 1.5x1x1cm. lymph node which is serially sectioned and entirely submitted in cassette A1. B. The second container is additionally identified as, 'sentinel lymph node. #2'. Received fresh and placed in formalin the specimen consists of a 1x 0.5 X. 0.3 cm lymph node which is bisected and is entirely submitted in cassettes B1. C. The third container is additionallyidentified as, 'sentinel lymph node #3'. Received fresh and placed in formalin the specimen consists of a 0.7 x 0.3 x 0.3. cm lymph node which is entirely submitted in cassette C1. D. The fourth container is additionally identified as, 'non-sentinel lymph. node'. Received fresh and placed in formalin the specimen consists of a 0.5 X. 0.3 x 0.3 cm lymph node which is entirely submitted in cassette D1. E. The fifth container is additionally identified as, 'right wire guided. lumpectomy'. Received fresh on a radiographic grid is a 102 gm lumpectomy. specimen measuring 8 cm from medial to lateral, and 8 in cm from superior to. inferior and 3 cm from anterior to posterior. The specimen is oriented with a. short suture designating the superior pole and a long suture designating the. lateral pole. There is a wire entering the antero-lateral aspect of the specimen. through grid coordinate E5. Accompanying the specimen is an x-ray demonstrating. a metallic clip located in grid coordinate E3. There is a circled mass in grid. positions C3, C4, D3, D4, centered on the clip. The wire enters the specimen in. grid coordinates E5 terminates in E3. 2 other areas of calcifications are. circled in grid coordinates D6 (#2) and F4-F5 (#3). The margins are inked as follows: anterior - black;. posterior - red;. superior - blue;. inferior - green;. medial - yellow;. lateral - violet. The specimen is serially sectioned from medial to lateral into 8 slices. The. area of calcifications noted in grid D6 begins in the slides #2 and extends. laterally the tumor the main to mass and measures 3 X 2 x 1.5 cm. is found in. the slices #2 and 3 adjacent to the red and green ink. The main mass, which is. irregular and firm, is present in slices #5 to #7 and measures 3.5 X 2.5 X 2 cm. It is present adjacent to red ink and is 1 cm from black ink, 3 cm from green. ink, 1.5 cm away from blue ink. The area of calcification noted in grid F4 and. F5 is present in the slices numbers 7 and activated ink measuring 1.5 X 1.1 x 1. cm and is continuous with the main mass. The metallic clip is identified in. slice 6. The wire enters the specimen in slice 5 and terminates in slice 5. The. remainder of the breast parenchyma is white-yellow and lobulated with no. additional masses or lesions. Entire mass including both calcified area was has a largest dimension of 5 cm. Specimen is submitted in toto. Block summary: E1-E4: medial margin, slice 1. E5-E9: slice 2, area of calcification. E10-E23: slice 3, area of calcification. E24-E31: slice 4. E32-E44; slice 5. E45-E62: slice 6, clip in E49-E50. E63-E78: slice 7. E79-E86: lateral margin, slice 8. F. The sixth container is additionally identified as, 'right breast, new. inferior lateral margin'. Received fresh on the radiographic grid is a 13.5 gm,. 6.5 X 4 X 1.2 cm medial inferior lateral margin which is oriented as follows: - new outer lateral margin is marked with a long black stitch (violet). - new outer medial margin is designated with a short black stitch (yellow). - new outer anterior margin is designated with a short blue stitch (black). - new outer posterior margin is designated with a long blue stitch. (red). Inner cauterized margin is inked green. An area of calcification is noted on the. accompanying x-ray in grid D4-D5-E5. Specimen is a serially sectioned from. lateral to medial in to 14 slices. An area of calcification is present in slice. #6 and measures 1 X 0.5 X 0.3 cm. No other lesions are identified. The specimen. is entirely submitted from lateral to medial. F1: slice 1-3. F2: slice 4-5. F3: slice 6. F4: slice 7. F5-F6: slice 8. F7: slice 9. F8: slice 10. F9: slice 11. F10: slice 12. F11: slice 13-14. G. The seventh container is additionally identified as, 'new outer lateral. margin'. Received fresh ona radiographic grid is a 20 gm, 8 x 3.5 X 1 cm new. outer lateral margin. Specimen is oriented as follows. - new outer superior is designated with a short black stitch (blue). - new outer inferior is designated with a long black a stitch (green). - new outer anterior is designated with a short blue stitch (black). - new outer posterior is designated with a long blue stitch (red). Inner cauterized margin is inked violet. Specimen is serially sectioned from. lateral to medial into 14 slices and does not contain any distinct masses or. lesions. Specimen is submitted in toto in cassettes G1-14.",BRCA,1,"The T stage is determined by the size of the largest focus of invasive carcinoma. The largest focus of invasive carcinoma measures 1.3 cm, which falls in the T1c category (>1 cm but not more than 2 cm). This is further supported by the statement in the report that the mass including both calcified areas has a largest dimension of 5 cm.",T1c,24.0
885,TCGA-AR-A250.16BE833B-E17B-4B8A-9D71-B0D83D73D9DE,1,"left, wide local excision and simple mastectomy: Infiltrating ductal carcinoma, Nottingham grade III (of III), [tubules 3/3,. nuclei 2/3, mitoses 3/3; Nottingham score 8/9], forming a 2.4 x 2.0 x 1.6 cm mass (in the wide local excision specimen). [AJCCpT2]. Extensive ductal carcinoma in-situ, high nuclear grade, present within (> 25%) and outside the invasive. component. involving an area measuring at least 3.8 x 2.2 x 2.0 cm. Angiolymphatic invasion is absent. The non-neoplastic breast. parenchyma shows proliferative fibrocytic changes and multiple small intraductal papillomas. Biopsy site changes present. Multiple margins on the wide local excision specimen, including the separately submitted inferior margin, are positive. for. tumor. There is residual in-situ carcinoma in the mastectomy specimen adjacent to the biopsy cavity which is located in the outer. quadrant. The. tumor does not involve the nipple, overlying skin, or underlying chest wall. All surgical margins, mastectomy, are. negative for tumor (minimum tumor free margin, 1.7 cm, deep margin). Lymph. nodes, left axillary sentinel, excision: Multiple (3) left axillary sentinel lymph nodes are negative for metastatic carcinoma. [AJCC pNO (i-) (sn)]. Blue dye is identified in left axillary sentinel lymph nodes No. 1 and No. 2. Blue dye is not identified in. left axillary sentinel lymph node No. 3. Lymph. node, left axillary non-sentinel, excision: A single left axillary non-sentinel lymph node (adjacent to left axillary sentinel. lymph node No. 1) is negative for metastatic carcinoma. Estrogen and progesterone receptor analysis and Her-2/NEU have been ordered on paraffin-embedded tissue.",BRCA,0,"The T stage is determined by the size of the largest focus of invasive carcinoma. In this report, the invasive carcinoma forms a 2.4 x 2.0 x 1.6 cm mass, which is larger than 2.0 cm but not more than 5.0 cm, classifying it as T2.",T2,25.0
822,TCGA-AO-A1KQ.EB5199BA-6164-4CFB-AFAA-B41544B83103,3,"Clinical Diagnosis & History: y/o male with left breast cancer (invasive ductal carcinoma (IDC)). Specimens Submitted: 1: SP: Sentinel node #1, level 1, left axilla (fs). 2: SP: Left breast with levels one and two axillary contents. DIAGNOSIS: 1). LYMPH NODE, LEFT AXILLA, SENTINEL LYMPH NODE #1; LEVEL 1; BIOPSY: METASTATIC CARCINOMA IN ONE LYMPH NODE (1/1). - THE METASTATIC DEPOSIT IS SEEN ONLY ON THE ACTUAL FROZEN SECTION AND. MEASURES AT LEAST. 2 MM. NO EXTRANODAL EXTENSION IDENTIFIED. - THE LYMPH NODE EXHIBITS INCIDENTAL BENIGN CAPSULAR NEVUS CELL. AGGREGATES. 2). BREAST. LEET: MASTECTOMY: - INVASIVE DUCTAL CARCINOMA. NOS TYPE. HISTOLOGIC GRADE III/III (SLIGHT. OR NO TUBULE FORMATION), NUCLEAR GRADE III/III (MARKED VARIATION IN SIZE AND. SHAPE) MEASURING 2.2 CM IN LARGEST DIMENSION MICROSCOPICALLY. - DUCTAL CARCINOMA IN-SITU (DCIS) IS ALSO IDENTIFIED, SOLID, CRIBRIFORM TYPE. WITH HIGH NUCLEAR GRADE AND MODERATE NECROSIS. - THE DCIS CONSTITUTES <= 25% OF THE TOTAL TUMOR MASS, AND IS PRESENT. ADMIXED WITH AND AWAY FROM THE INVASIVE COMPONENT. - THE INVASIVE CARCINOMA IS LOCATED IN THE LOWER INNER QUADRANT AND CENTRAL. AREA (RETROAREOLAR). - THE NIPPLE IS INVOLVED BY INVASIVE CARCINOMA. - A FOCUS OF PERINEURAL INVASION BY CARCINOMA IS SEEN IN THE DERMIS OF. THE NIPPLE REGION. THERE IS ALSO FOCAL LYMPHATIC INVASION IN THE NIPPLE. REGION. - CALCIFICATIONS ARE PRESENT IN THE IN SITU CARCINOMA. - NO INVOLVEMENT OF THE SURGICAL MARGINS BY EITHER INVASIVE OR IN SITU. CARCINOMA IS IDENTIFIED. THE ION-NEOPLASTIC BREAST TISSUE IS UNRENORKAELE. - THE LYMPH NODE STATUS IS AS FOLLOWS (EXPRESSED AS THE NUMBER OF. POSITIVE LYMPH NODES IN RELATION TO THE TOTAL NUMBER OF LYMPH NODES. EXAMINED) : METASTATIC CARCINONA IN ONE OF EIGHT LYMPH NODES (1/8). THIS IS A MACROMETASTASIS (1.8 CM). - THERE IS NO EXTRANODAL EXTENSION OF CARCINOMA. Nc. - RESULTS OF SPECIAL STAINS (ER, PR, HER2-NEU) WILL BE REPORTED AS AN. ADDENDUM. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL), AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Special Studies: Special Stain. Comment. ER-C. PR-C. HER2-0. NEG CONT. NEG-HER2. IMM RECUT. Gross Description: 1) The specimen is received fresh for frozen section consultation labeled,. Sentinel node #1, level 1, left axilla"", and consists of one lymph node. measuring 1.5 x 1.0 x 0.8 cm. The lymph node is bisected and submitted for. frozen section diagnosis. Summary sections: FSC - frozen section control. 2) The specimen is received fresh labeled, ""Left breast with levels one and. two axillary contents, stitch marks axillary tail"" and consists of a breast. measuring 19 x 18 x 3.5 cm with overlying skin ellipse measuring 19 x 11 cm,. attached axillary contents measuring 11 x 10 x 3 cm. The axillary tail is. marked with a black suture. Situated centrally on the skin surface is. a. flattened nipple measuring 0.8 x 0.8 em and areola measuring 2.5 x 2.5 cm. There are no scars or lesions noted on the skin. A suture demarcates the. axillary aspect. The posterior surface of the breast is inked black and the. specimen is serially sectioned to reveal a well circumscribed stony hard. white-tan tumor measuring 2.0 x 2.0 x 1.7 cm, and located 1.8 cm from the. deep margin. The tumor is located subjacent to the nipple The remainder. of. the breast tissue is yellow tan fatty and lobulated. The specimen is. submitted for lymph node dissection. Representative sections are submitted. A sample of the tumor is given to. Summary of sections: N nipple. NB - nipple base. DM - deep margin. T - tumor. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. LN-lymph nodes. Summary of Sections: Part 1: SP: Sentinel node #1, level 1, left axilla (fs). Block. Sect. Site. PCs. 1. FSC. 1. Part 2: SP: Left breast with levels one and two axillary contents. Block. Sect. Site. PCs. 1. dm. 1. 1. lig. 1. 5. LN. 8. 1. log. 1. 1. n. 1. 1. nb. 1. 6. 6. 1. uiq. 1. uog. Procedures/Addenda: Addendum. Date Complete: Addendum Diagnosis. ADDEN. SITK: #2, LEFT BREAST. ER: >95% OF NUCLEAR STAINING WITH STRONG INTENSITY. - PR: >80% OF NUCLEAR STAINING WITH STRONG TO NODERATE INTENSITY. - HER-2/NEU. (Hexcep Test) : NEGATIVE (STAINING INTENSITY OF FOCAL 1+). - CONTROLS ARZ SATISFACTORY. Intracperative Consultation: Note: The diagnoses given in this section pertain only to the tissue sample. examined at the time of the intraoperative consultation. 1). FROZEN SECTION DIAGNOSIS: METASTATIC CARCINOMA. PERMANENT DIAGNOSIS: SAME.",BRCA,1,"The report states that the largest focus of invasive carcinoma measures 2.2 cm in largest dimension, which falls within the T2 category of being more than 2.0 cm but not more than 5.0 cm in size.",T2,26.0
1110,TCGA-D8-A142.7D2C880F-6897-44A0-9470-5A5B5429A9C0,2,"page 1 / 2. copy No. Examination: Histopathological examination. Patien. PESEL: Gender: F. Material: Multiple organ resection - left breast. Expected time of examunation: up to 8 working days. Clinical diagnosis: Cancer of the left breast. Results of immunohistochemical examination: Estrogen receptors in neoplastic cell nuclei not found. Progesterone receptors in neoplastic cell nuclei not. found. HER2 protein stained with HercepTest by DAKO. Score = 2+, verification by the FISH method recommended. Macroscopic description: Left breast, sized 20 x 19 x 7 cm, removed along with axillary tissues sized 12 x 14 x 4 cm and a skin flap of 22. x 13 cm. Weight 1,527 g. Tumour sized 6 x 4.5 x 2.5 cm in the outer lower quadrant, placed 4 cm from the lower edge, 2.5 cm from. the base and 1.3 cm from the skin. Lymph nodes of 2.3 cm in length. Microscopic description: Carcinoma ductale invasivum - NHG3 (3 + 2 +3: 28 mitoses/10 HPF, visual area diameter 0.55 mm). Mamilla sine laesionibus. Glandular tissue showing lesions of the type mastopathia fibrosa. AXILLARY LYMPH NODES. Lymphonodulitis chronica et sinus histiocytosis et lipomatosis lymphonodorum (No XIV). Examination result: Carcinoma ductale invasivum mammae sinistrae. (NHG3, pT3, pNO). Examination: Histopathological examination. page 2 / 2. PESEL: Gender: F. Results of immunohistochemical examination: RESULT OF HER2/neu GENE AMPLIFICATION with the FISH method by Path Vysion HER2 DNA Probe Kit. HER-2 Gene AMPLIFICATION NOT FOUND. Chromosome 17 polisomy.",BRCA,0,"The report states that the tumor size is 6 x 4.5 x 2.5 cm, which is more than 5.0 cm in size. According to the rules, T3 tumors are more than 5.0 cm in size. Therefore, the T stage for this patient is T3.",T3,27.0
1348,TCGA-EW-A1P3.042304AE-706A-4033-A97F-3765A6AEC649,1,"F. Pathologic Interpretation: A. Sentinel node #1, left side, CT. ouch prep: - No tumor seen in one lymph node (0/1). - Immunohistochemistry for Keratin to follow. B. Left/breast 1 stitch superior, 2 stitches lateral: - Invasive, moderately differentiated ductal carcinoma, intermediate nuclear grade, 0.5 cm. - Specimen margins are negative (see tumor summary). - Fibroadenoma, 0.5 cm. C. Sentinel node #1, right side CT. - No tumor seen in two lymph nodes (0/2). - Immunohistochemistry for Keratin to follow. D. Non-sentinel lymph node right side: - No tumor seen in one lymph node (0/1). E. Sentinel lymph node #2, right side, CT #. touch prep: - No tumor seen in one lymph node (0/1). - Immunohistochemistry for Keratin to follow. F. Right breast additional superior flap: - No tumor seen in adipose tissue. G. Right breast 1 stitch superior, 2 stitches lateral: - Invasive, moderately differentiated ductal carcinoma, intermediate nuclear grade, 2.5 cm, extending within 0.1 cm of the. anterior specimen margin (see tumor summary). TUMOR SUMMARY ""B"": Specimen Type: Mastectomy. Lymph Node Sampling: Sentinel lymph node(s) only. Laterality: Left. Tumor Site: Upper inner quadrant. Size of Invasive Component: Greatest dimension: 0.5 cm. Histologic Type: Invasive ductal carcinoma. Histologic Grade: Tubule Formation: Moderate 10% to 75% (score =2). Nuclear Pleomorphism: Moderate increase in size, etc (score =2). Mitotic Count: 10 to 20 mitoses per 10 HPF (score = 2). Total Nottingham Score: Grade II: 6-7 points. Pathologic Staging (pTNM). Primary Tumor: pT1a. Regional Lymph Nodes: pNO. Number examined: 1. Number Involved: 0. Distant Metastasis: pMX. Margins: Margins uninvolved by invasive carcinoma. Venous/Lymphatic Invasion: Absent. TUMOR SUMMARY ""G"": Specimen Type: Mastectomy. Lymph Node Sampling: Sentinel lymph node with axillary dissection. Laterality: Right. Tumor Site: Lower outer quadrant. SURGICAL PATHOL Report. Size of Invasive Component: Greatest dimension: 2.5 cm. Histologic Type: Invasive ductal carcinoma. Histologic Grade: Tubule Formation: Minimal less than 10% (score =3). Nuclear Pleomorphism: Moderate increase in size, etc (score = 2). Mitotic Count: Less than 10 mitoses per 10 HPF (score =1). Total Nottingham Score: Grade II: 6-7 points. Pathologic Staging (pTNM). Primary Tumor: pT2. Regional Lymph Nodes: pNO. Number examined: 4. Number Involved: 0. Distant Metastasis: pMX. Margins: Margins uninvolved by invasive carcinoma. Distance from closest margin: 1.0 mm. Specify which margin: Anterior. Venous/Lymphatic Invasion: Absent. not with require formain or molecular freed, paramfn embedded tissue Detection is by LSAB. The results are read by a pathologier as positive or negative. NOTE: Some FDA immunohistochemical approval. These clones are used: ID5-ER, PgR 636-PR, A486-HER2, H-11=EGFR, CCH2/DOG9=CMV, F39.4. 1-AR and HPV by ISH. AII immunohistochemical. antibodies are analyte specific reagents (ASRs) validated by our laboratory (Her 2. Parvo, H. pylori, HScore). These ASRs are clinically useful indicatora stains are that used do. , MD. As the attending pathologiet, I attest that I: (0 Examined the relevant. preparation(s) for the specimen(s); and (ii) Rendered the diagnosis(es). Procedures/Addenda. Addendum. Date Complete: Addendum Diagnosis. A. Immunohlstochemistry for Keratin is negative for tumor. C. Immunohistochemistry for Keratin is negative for tumor. E. Immunohistochemistry for Keratin is negative for tumor. MD. Intraoperative Consultation. A (FS): No malignancy seen in one lymph node (0/1). C (FS): No malignancy seen in two lymph nodes examined (0/2). E (FS): No malignancy seen in one lymph node examined (0/1). MD. Clinical History: SURGICAL PATHOL Report. Patient is a. female with right infiltrate ductal carcinoma. Specimen(s) Received: A: Sentinel node #1, left side, ct ;. ouch prep (FS). B: Left Breast 1 stitch superior, 2 stitches lateral, fresh. C: Sentinel node #1, right side ct 1 (FS). D: Non-sentinel lymph node right side. E: Sentinel lymph node #2, Right side, ct #. touch prep (FS). F: Right breast additional superior flap - perm. G: Right breast 1 stitch superior, 2 stitches lateral fresh. Gross Description: A. Received fresh and labeled ""sentinel node #1, left side, ct. touch prep (FS)"" is a segment of tan-yellow, fibroadipose. tissue measuring 2.5 x 1.1 x 0.5 cm. Cassettes are submitted as follows: 1. One lymph node bisected submitted in toto for frozen section. 2. Remainder adipose tissue submitted in toto in one cassette. B. Received fresh and labeled ""left breast 1 stitch superior, 2 stitches lateral"" is a mastectomy specimen, which measures. 22.0 x 19.0 x 4.0 cm and weighs 790.0 grams. The specimen has an attached ellipse of paie-tan skin with areola and. nipple measuring 9.0 x 4.5 cm. The skin and nipple are unremarkable. The specimen is oriented by one stitch superior. and two stitches lateral. Surgical margins are inked as follows: superior anterior margin inked in green and the remaining. margins are inked in black. Serial section through the specimen revealed one suspicious area of pale-pink induration. consistent with previous biopsy site. The indurated area measures approximately 1.1 cm in greatest dimension and is. located in the upper inner quadrant at 11 to 12 o'clock, 0.8 cm from the superficial margin, 0.9 cm from the deep margin,. 3.0 cm from the superior margin, 16.0 cm from the inferior margin, 3.5 cm from the medial margin and 12.0 cm from the. lateral margin. An area of interparenchyma hemorrhage is also identified in the inner upper quadrant, approximately 5.0. cm from the nipple. An additional suspicious area of pale-pink Induration with a granular, cut surface is identified in the. lower outer quadrant at approximately 4 o'clock. The second suspicious area is located 2.6 cm away from the deep. margin, 1.8 cm away from the superficial margin, 10.5 cm away from the superior margin, 8.5 cm away from the inferior. margin, 4.5 cm away from the lateral margin and 13.5 cm away from the medial margin. Cassettes are submitted as. follows: 1. Superficial margin. 2. Deep margin. 3. Superior margin. 4. Inferior margin. 5. Medial margin. 6. Lateral margin. 7-13. Suspicious area and surrounding parenchyma submitted in toto. 14. Section of the hemorrhagic area. 15. Sections of the second suspicious area. 16. Section of the nipple. 17. Representative section of uninvolved breast parenchyma in the upper outer quadrant. 18. Representative section of uninvolved parenchyma in the upper inner quadrant. 19. Representative section of uninvolved parenchyma in the lower inner quadrant. 20. Representative section of uninvolved parenchyma in the lower outer quadrant. C. Received fresh and labeled ""sentinel node #1, right side. is a segment of tan-yellow, fibroadipose tissue. measuring 2.0 x 1.3 x 1.0 cm. Examinations of the specimen revealed two possible lymph nodes. Cassettes are submitted. as follows: 1. One lymph node bisected and submitted for frozen section. 2. One lymph node bisected submitted for frozen section. 3. Remainder of the adipose tissue submitted for frozen section in one cassette. D. Received in formalin and labeled ""non-sentinel lymph node right side""is a segment of tan-white, soft tissue measuring 1.8. x 0.7 x 0.4 cm. The specimen is bisected and submitted in toto in one cassette. SURGICAL PATHOL Report. E. Received fresh and labeled ""sentinel lymph node #2, right side, c' buch prep (FS)"" is a segment of tan-yellow,. fibroadipose tissue measuring 2.1 x 1.1 x 0.6 cm. Examinations of the segment revealed one lymph node. Cassettes are. submitted as follows: 1. One lymph node bisected and submitted for frozen section. 2. F. Received in formalin and labeled ""right breast additional superior flap"" is a segment of tan-yellow, fibroadipose tissue. measuring 6.0 x 3.7 x 1.6 cm. The specimen is received unoriented. One of the surface is rough, irregular and appears. to. face the previous resection site. The surface was inked in orange. The opposite surface was inked in black. Serial. sections through the specimen revealed no suspicious areas. Representative sections submitted in six cassettes. G. Received fresh and labeled ""right breast 1 stitch superior, 2 stitches lateral"" is a mastectomy specimen, which measures. 23.0 x 22.0 x 4.0 cm and weighs 670.0 grams. There is an ellipse of skin with areola and nipple, which measures 9.0 x 3.5. x 0.2 cm. The nipple measures 1.2 x 1.1 cm. The skin is unremarkable. The section margins are inked as follows: superior, green and all other margins are inked in black. Serial section through the specimen revealed an area of pale-. pink induration measuring 2.5 x 1.4 x 1.2 cm and is located in the lower outer quadrant. A firm area is present at the. superficial margin and is located 3.0 cm from the inferior margin, 2.5 cm from the deep margin and 7.0 cm from the. superior margin. The remainder of the parenchyma consists of unremarkable fibroadipose tissue with approximately 70%. adipose tissue and 30% stroma. No other suspicious areas were identified. Cassettes are submitted as follows: 1. Anterior margin. 2. Inferior margin. 3. Deep margin. 4. Lateral margin. 5. Superior margin. 6. Medial margin. 7-13. Area of induration submitted. 14. Representative section of uninvolved parenchyma in the upper outer quadrant. 15. Representative section of uninvolved parenchyma in the upper inner quadrant. 16. Representative section of uninvolved parenchyma in the lower inner quadrant. 17. rative section of uninvolved parenchyma in the lower outer quadrant near the lesion. ICD-9(s): 174.2 174.5.",BRCA,0,"Based on the report, the largest focus of invasive carcinoma in the right breast is measured at 2.5 cm, which falls under the T2 category of tumors that are more than 2.0 cm but not more than 5.0 cm in size. The T stage is not affected by the presence of in situ carcinoma or the number of tumors, and tumor size is measured as the greatest dimension of the invasive component, not including in situ carcinoma or non-invasive components. The left breast tumor is T1a and does not affect the T stage of the patient.",T2,28.0
1225,TCGA-E2-A15R.0F708C6E-0262-46EE-8ED2-67E791D5C379,0,"SPECIMENS: A. SLN 1 RIGHT AXILLA. B. SLN 2 RIGHT AXILLA. C. SLN 3 RIGHT AXILLA. D. SLN 4 RIGHT AXILLA. E. RIGHT BREAST. SPECIMEN(S): A. SLN 1 RIGHT AXILLA. B. SLN 2 RIGHT AXILLA. C. SLN 3 RIGHT AXILLA. D. SLN 4 RIGHT AXILLA. E. RIGHT BREAST. INTRAOPERATIVE CONSULTATION DIAGNOSIS: TPA, Lymph node, sentinel, right axilla, biopsy: Negative for carcinoma. TPB, Lymph node, sentinel, right axilla, biopsy: Negative for carcinoma. TPC, Lymph node, sentinel, right axilla, biopsy: Negative for carcinoma. TPD, Lymph node, sentinel. right axilla, biopsy: Negative for carcinoma. Diagnoses called at. by Dr. GROSS DESCRIPTION: A. SLN 1 RIGHT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node number one right axilla"". is a tan lymph node measuring 2.2 x 1 x 0.8 cm. Touch preparation is performed. Entirely submitted, A1. B. SLN 2 RIGHT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node number two right axilla"". is a tan lymph node measuring 1.5 x 1 x 0.8 cm. Touch preparation is performed. Entirely submitted, B1. C. SLN 3 RIGHT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node number three right axilla"". is a tan lymph node measuring 0.6 x 0.4 x 0.3 cm. Touch preparation is performed. Entirely submitted, C1. D. SLN 4 RIGHT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node number four right axilla"". is a tan lymph node measuring 1 x 0.6 x 0:4 cm. Touch preparation is performed. Entirely submitted, D1. E. RIGHT BREAST. Received fresh labeled with the patient's identification and designated ""right breast"" is an oriented, 27 g, 5.3 x 4.5 x 3. cm lumpectomy specimen. The short suture designates superior, long-lateral. Ink code: Anterior-yellow, posterior-. black, medial-green, lateral-red, superior-blue, inferior-orange. The specimen is serially sectioned from superior to. inferior into 5 slices to reveal a firm lobulated tan mass, 2.2 x 1.5 x 0.9 cm, located 0.1-cm from the nearest anterior. margin. The entire specimen is submitted: E1-E3: Perpendicular sections superior margin. E4-E7: Slice 2, E5 demonstrating mass and nearest anterior margin. E8-E11: Slice 3, E9, E11 demonstrating mass and nearest anterior margin. E12-E15: Slice 4, submitted entirely. E16-E18: Perpendicular sections inferior margin. DIAGNOSIS: A. LYMPH NODE, SENTINEL #1, RIGHT AXILLA, EXCISION: - METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1), MEASURING 0.3-CM WITH EXTRANODAL. EXTENSION, SEE NOTE. B. LYMPH NODE, SENTINEL #2, RIGHT AXILLA, EXCISION: - METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1), MEASURING 0.1-CM WITH EXTRANODAL. EXTENSION, SEE NOTE. C. LYMPH NODE, SENTINEL #3, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). D. LYMPH NODE, SENTINEL #4, RIGHT AXILLA, EXCISION: - METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1), MEASURING 0.6-CM WITH EXTRANODAL. EXTENSION, SEE NOTE. E. BREAST, RIGHT, WIDE LOCAL EXCISION: - INVASIVE DUCTAL CARCINOMA, SBR GRADE 2, MEASURING 1.9-CM. INTERMEDIATE NUCLEAR GRADE, DUCTAL CARCINOMA IN SITU, SOLID TYPE. - INVASIVE TUMOR PRESENT 0.15-CM FROM MEDIAL AND 0.1-CM FROM ANTERIOR SURGICAL RESECTION. MARGINS. - FOCAL LYMPHOVASCULAR INVASION IDENTIFIED. - BIOPSY SITE CHANGES WITH FIBROSIS,. - SEE SYNOPTIC REPORT AND SEE NOTE. NOTE: The touch preparation of SLN #1 and 2 shows no tumor cells. Therefore the false negativity is due to. sampling error. The touch preparation of SLN #4 shows two clusters of atypical cells. Dr. concurs. A few clusters branching out and focally separated from the main tumor mass are identified in a close proximity to. the medial margin (0.15-cm). The main tumor mass is 0.1-cm from the anterior surgical resection margin. SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Yes For mass. Laterality: Right. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 1.9cm. Margins: Negative. Distance from closest margin: Less than 0.15cm. medial and anterior. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 2. Modified Scarff Bloom Richardson Grade: 2. Necrosis: Absent. Vascular/Lymphatic Invasion: Present. Extent: focal. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node. Lymph node status: Positive 3 / 4 Extranodal extension. DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 5%. DCIS Type: Solid. DCIS Location:Associated with invasive tumor. Nuclear grade: Intermediate. Necrosis: Absent. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative by FISH. Performed on Case: Pathological staging (pTN): pT 1c N 1. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. CLINICAL HISTORY: year-old female right breast mass, invasive ductal carcinoma on core bx. Right needle localization excision with. sentinel lymph node biopsy. PRE-OPERATIVE DIAGNOSIS: Carcinoma, right breast. Microscopia/Diagnostic Dictation: Pathologist,. Final Review: Pathologist,. Final: Pathologist,.",BRCA,1,"The report states that the largest focus of invasive carcinoma measures 1.9 cm, which falls within the range for T1 tumors (2.0 cm or less). The further subclassification of T1 tumors (T1a, T1b, T1c) is based on size as well, but the exact size of the largest focus of invasive carcinoma is not provided in the given range (0.1-0.5 cm, 0.5-1 cm, >1 cm but not more than 2 cm). Therefore, we can only determine the T stage as T1.",T1,29.0
1361,TCGA-EW-A1PH.2E77693B-FAAD-4CCC-BD4F-3D2470C25143,0,"F. Pathologic Interpretation: A. BREAST, EXCISIONAL/INCISIONAL BIOPSY: - INVASIVE MAMMARY CARCINOMA, poorly differentiated, Nottingham grade 3 (3+3+2=8), 2.0 cm in greatest. dimension. - Margins are free of tumor. - Tumor cells are reported to be negative for ER, PR and Her2 by immunohistochemistry performed on patient's previous. biopsy. - See tumor summary. B. FS: SENTINEL NODE #1. - No carcinoma seen in one lymph node (0/1). - Keratin immunostain is pending. C. SENTINEL NODE #2. FS: - Metastatic carcinoma in one fymph node (1/1). - Largest metastatic deposit, 2.5 cm. - Perinodal extension is not identified. D. SENTINEL NODE #3. , FS: - No carcinoma seen in one lymph node (0/1). - Keratin immunostain is pending. E. AXILLARY CONTENT RIGHT SIDE: - No carcinoma seen in seven lymph nodes (0/7). Tumor Summary. Specimen: - Partial breast. Procedure: - Excision without wire-guided localization. Lymph Node Sampling: - Sentinel lymph node(s). - Axiliary dissection (partial or complete dissection). Specimen Integrity: - Multiple designated specimen (eg, main excision and identified margins). Specimen Size: - Greatest dimension: 7 cm. Additional dimension: 6 x 4 cm. Laterality: - Right. Tumor Size: Size of Largest Invasive Carcinoma. - Greatest dimension of largest focus of invasion over 0.1 cm: 2 cm. Additional dimensions: 2 x 1.6 cm. Tumor Focality: - Single focus of invasive carcinoma. Macroscopic and Microscopic Extent of tumor: - Skin: Skin is not present. - Skeletal muscle: No skeletal muscle present. Ductal Carcinoma In (DCIS): No DCIS is present. Lobular Carcinoma IN Situ (LCIS): Not identified. Histologic Type of Invasive Carcinoma: - Invasive carcinoma. Histologic Grade: Nottingham Histologic Score. Glandular (Acinar)/Tubular Differentiation: Score 3. Nuclear Pleomorphism: Score 3. SURGICAL PATHOL Report. Mitotic Count: Score 2. Overall Grade: Grade 3: score of 8. Margins: - Margins uninvolved by invasive carcinoma. - Distance from closest margin: 1 mm (anterior, posterior, lateral). Specify margins: Distance from superior margin: 3 mm. Distance from inferior margin: 2.5 mm. Distance from anterior margin: 1 mm. Distance from posterior margin: 1 mm. Distance from medial margin: 2 mm. Distance from lateral margin: 1 mm. Treatment Effect: Response to Presurgical (Neoadjuvant) therapy: - In the Breast: No definite response to presurgical therapy in the invasive carcinoma. - In the Lymph Nodes: No definite response to presurgical therapy in metastatic carcinoma. Lymph-Vascular Invasion: Not identified. Dermal Lymph-Vascular Invasion: No skin present. Lymph Nodes: - Number of sentinel lymph node examined: 3. - Total numbe. S examined (sentinel and Nonsentinel): 10. - Number of. in macrometastases (>0.2 cm): 1. Extrano. identified. Mest. antir vmph Nodes: Hematoxylin and eosin (H&E), one level. -aging: umor: pT1c. .gional Lymph Nodes: pN. Distant Metastasis: Not a. Anciliary Studies: Estrogen Recaptor: - Performed on arother specimen: Results: No immunoreactive tumor cells present. - tarone. ; Results: No immunoreactive tumor cells present. Her. - Performed un a wis er specimer. 1; Results: Negative (Score 0). Preliminary AJCC Classification (7th Edition) pT1c pN1a Mn/a. (Final AJCC c. tion pending evaluation of keratin stain on sentinel nodes). n'' imnohistochemicalann. of if reagents (ASRs) validated by our laboratory. These ASRs are clinirally useful indicators that do not require FDA approval. These clones are used: IDS CA. PRR 636=PR. 1485=HER2, H-. COFR. A. stains are used with formalin or molecular fixed. paraffin embedded tissue. is by Envision Method. The. results are read by a. pathologist us positive or negative. As the attending pathologist, I attest that I: (i) Examined the relevant preparation(s). for the specimen(s); and (ii) Rendered the diagnosis(es). Procedures/Addenda. Addendum. Date Complete: Addendum Diagnosis. B. SENTINEL NODE #1. 1, FS: - Immunohistochemistry for keratin is negative for carcinoma. SURGICAL PATHOL Report. D. SENTINEL NODE #3. ). FS: Immunohistochemistry for keratin is negative for carcinoma. Intraoperative Consultation. B. Sentinel node #1 1. FS: No carcinoma seen. C. Sentinel node #2. FS: Metastatic carcinoma to one lymph node. D. Sentinel node #3. FS: No carcinoma seen. MD. Clinical History: None Provided. Operation Performed. Right breast lumpectomy with sentinel node biopsy and possible node dissection. Pre Operative Diagnosis: Breast cancer. Specimen(s) Received: A: Breast, excisional/incisional blopsy. B: Sentinel node #1. 1, FS. C: Sentinel node #2 (. FS. D: Sentinel node #3 1. 1. FS. E: Axillary content right side. Gross Description: A. Received in formalin is a 43 gram, 7.0 x 6.0 x 4.0 cm lumpectomy specimen, oriented with one stitch superipr, two stitches. lateral and three stitches deep. Resection margins are inked as follows: Superior blue, inferior green, medial red, lateral. orange, anterior yellow, posterior black. On serial sections through the specimen, there is a tan-white indurated mass. with ill-defined borders, measuring 2.0 x 2.0 x 1.6 cm. This lesion is situated less than 1 mm from the anterior resection. margin, 1 mm from the lateral resection margin, 7 mm from the medial margin, 4 mm from the deep margin, and 20 cm. from superior margin and 2.5 cm from the interior margin. No other lesions are identified. Sections submitted as. follows: 1. Lesion in relation to anterior and posterior margin. 2. Lateral margin. 3. inferior and medial margin. 4. Superior margin. 5-8. Lesion submitted in toto. 9&10. Additional sections of the specimen with fibrotic area. B. Received fresh is a segment of tan-grey soft tissue, measuring 1.0 x 1.0 x 0.4 cm. Bisected and submitted in toto in one. cassette for frozen. C. Received fresh is a segment of tan-brown soft tissue, measuring 0.7 x 0.3 x 0.2 cm. Submitted in toto in on e cassette for. frozen. D. Received fresh is a segment of tan-grey soft tissue, measuring 1.5 x 0.7 x 0.4 cm. Submitted in toto in one. cassette for. frozen. SURGICAL PATHOL Report. E. Received in formalin is a tan-yellow fibroadipose tissue, measuring 11.0 x 6.0 x 2.0 cm. Examination of the specimen. reveals multiple possible lymph nodes. Sections submitted as follows: 1-3. One lymph node bisected per cassette. 4&5. Two lymph nodes in toto per cassette. MD (.",BRCA,1,"The T stage is determined by the size of the largest focus of invasive carcinoma. According to the report, the size of the largest focus of invasive carcinoma is 2.0 cm. Therefore, the T stage is T1c, as it is more than 2.0 cm but not more than 5.0 cm in size.",T1c,30.0
651,TCGA-A8-A08L.BC0E0F93-B183-44E8-B551-EA463B2FBCE4,2,"Diagnosis. 1. Left-sided ablated breast tissue with a poorly differentiated invasive ductal breast. carcinoma measuring a maximum of 6 cm with focal invasion of the lymph vessels, extension. to the base of the nipple and the pectoral muscle and excision extending just into the healthy. tissue in the basal epidermis. No pagetoid tumor propagation or skin infiltration. Tumor classification: M-8500/3, G 3, pT3, pN2a (5/13), pMX, stage III A. R0.",BRCA,2,"The report states that the size of the largest focus of invasive carcinoma is 6 cm, which falls in the T3 category of 'tumors more than 5.0 cm in size'. The T stage is determined by the size of the invasive component, and in this case, it is not affected by the presence of in situ carcinoma or the number of tumors. The extension to the base of the nipple, pectoral muscle, and excision into the healthy tissue in the basal epidermis does not affect the T stage.",T3,31.0
1267,TCGA-E2-A574.F3FAB505-03FF-4FAA-ABB6-96AD20F47871,1,"SPECIMEN(S): A. PAPILLOMA MEDIAL LEFT BREAST. B. EXCISION LEFT BREAST CANCER. C. SENTINEL LYMPH NODE #1 LEFT AXILLA. D. SENTINEL LYMPH NODE #2 LEFT AXILLA. CLINICAL HISTORY: 1) Cancer 2 cm in axillary tail left breast. 2) Medial left breast mass - Papilloma by core biopsy. PRE-OPERATIVE DIAGNOSIS: None Given. INTRA-OPERATIVE DIAGNOSIS. B: Lumpectomy, left breast, excision; margins check: Mass is located 0.2 cm from the. posterior margin. Reported to Dr. by Dr. DIAGNOSIS: A. BREAST, LEFT MEDIAL, EXCISION: - INTRADUCTAL PAPILLOMA. - APOCRINE METAPLASIA AND COLUMNAR CELL CHANGE. - BIOPSY SITE CHANGES. - SURGICAL MARGINS NEGATIVE FOR TUMOR. B. BREAST, LEFT, EXCISION: - INVASIVE DUCTAL CARCINOMA, 2.3 CM IN GREATEST DIMENSION, SBR. GRADE 3. - SURGICAL MARGINS NEGATIVE FOR TUMOR. - BIOPSY SITE CHANGES. - SEE SYNOPTIC REPORT. C. LYMPH NODES, SENTINEL #1, LEFT AXILLA: - TWO LYMPH NODES NEGATIVE FOR METASTATIC CARCINOMA (0/2). D. LYMPH NODES SENTINEL #2, LEFT AXILLA: TWO LYMPH NODES NEGATIVE FOR METASTATIC CARCINOMA (0/2). SYNOPTIC REPORT - BREAST. Specimens Involved. Specimens: B: EXCISION LEFT BREAST CANCER. Specimen Type: Excision. Needle Localization: Yes - For mass. Laterality: Left. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 2.3cm. Additional dimensions: 2. 1cm x 2cm. Tumor Site: Not specified. Margins: Negative. Distance from closest margin: 0.3cm. deep. Tubular Score: 2. Nuclear Grade: 3. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Present. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node. Lymph node status: Negative 0/4. DCIS not present. ER/PR/HER2 Results. ER: Negative. PR: Negative. HER2: Negative by FISH. Performed on Case: Pathological staging (pTN): pT 2N0. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. GROSS DESCRIPTION: A. APILLOMA MEDIAL LEFT BREAST. Received fresh/in formalin labeled with the patient's identification and designated. ""papilloma medial left breast"" is an oriented (single anterior, double lateral, triple. superior), previously inked, 14 g, 4.3 x 3.2 x 2.1 cm needle localized excision. Ink code: anterior-yellow, posterior-black, medial-green, lateral-red, superior-blue, inferior-orange. The specimen is serially sectioned from medial to lateral into 7 slices revealing firm,. focally hemorrhagic breast parenchyma. No lesions or nodules are grossly appreciated. Entirely submitted as per the attached diagram: A1: Perpendicular sections medial margin. A2-A3: Slice 2, bisected. A4-A5: Slice 3, bisected. A6-A7: Slice 4, bisected. A8-A9: Slice 5, bisected. A10-A11: Slice 6, bisected. A12-A13: Perpendicular sections lateral margin. B. EXCISION LEFT BREAST CANCER. Received fresh labeled with the patient's identification and designated ""excision left. breast cancer"" is an oriented (triple - superior, double - lateral, single - anterior), 46 g,. (Medial to lateral - 6.5 cm, superior to inferior - 5.4 cm, anterior to posterior - 3.5 cm). lumpectomy specimen. (The specimen is previously inked) Ink code: anterior-yellow,. posterior-black, medial-green, lateral-red, superior-blue, inferior-orange. The specimen is. serially sectioned from medial to lateral into 9 slices revealing a 2.3 x 2.1 x 2 cm, tan-. white to tan-pink, firm to hard mass that is closest to the posterior margin at 0.2 cm, in. slices 6 to 9. Tissue is procured. Representatively submitted in 18 cassettes as per the attached diagram: B1: slice 1 entire, perpendicular sections of the medial margin. B2: slice 2, representative anterior margin. B3: slice 3, representative posterior margin with the mass. B4-B5: slice 4, sections of the mass showing the closest posterior margin,. B6-B7: slice 5, mass with anterior and posterior margins. B8: slice 5, superior margin. B9-B10: slice 6, mass with anterior and posterior margins. B11: slice 6, inferior margin. B12-B13: slice 6, superior margin. B14-B15: slice 7, representative anterior and key and posterior margins. B16: slice 8, posterior margin. B17-B18: slice 9, lateral margin, perpendicular sections. C. SENTINEL LYMPH NODE #1 LEFT AXILLA. Received in formalin with the patient's identification and designated ""sentinel lymph. node #1 left axilla"" is a 3.2 x 1.5 x 1.2 cm fibrofatty tissue within which 2 lymph nodes, 2. x 1.3 x 0.7 cm and 2.5 x 1.2 x 1 cm are identified. The lymph nodes are serially sectioned. and entirely submitted in 2 cassettes, C1-C2. D. SENTINEL LYMPH NODE #2 LEFT AXILLA. Received in formalin with the patient's identification and designated ""sentinel lymph. node #2 left axilla"" is a 3.5 x 2.5 x 0.8 cm fibrofatty tissue within which 2 lymph nodes,. 1.2 x 1 x 0.5 cm and 0.5 x 0.4 x 0.3 cm are identified. The lymph nodes are serially. sectioned and entirely submitted in 2 cassettes, d1-D2.",BRCA,0,"The T stage is determined by the size of the largest focus of invasive carcinoma. The report indicates that the size of the invasive ductal carcinoma is 2.3 cm, which falls within the T2 category of tumors that are more than 2.0 cm but not more than 5.0 cm in size.",T2,32.0
993,TCGA-BH-A0C3.3A54CF6E-AFDB-4609-A827-77D75BB376A7,0,"FINAL DIAGNOSIS: PART 1: LYMPH NODE, LEFT AXILLARY SENTINEL NODE #1, BIOPSY -. TWO SENTINEL LYMPH NODES, NEGATIVE FOR CARCINOMA (0/2). PART 2: LYMPH NODE, LEFT AXILLARY SENTINEL NODE #2, BIOPSY -. TWO SENTINEL LYMPH NODES, NEGATIVE FOR CARCINOMA (0/2). PART 3: BREASI, LEET, 12 O'CLOCK SEGMENTAL MASTECTOMY -. A. INFILTRATING MAMMARY CARCINOMA, WITH MIXED DUCTAL AND LOBULAR PHENOTYPES, NOTTINGHAM. GRADE 2/3 (TUBULE FORMATION: 3, NUCLEAR PLEOMORPHISM. 3, MITOTIC ACTIVITY: 1, TOTAL SCORE: 7/9). B. THE INVASIVE CARCINOMA MEASURES 1.9 CM IN GREATEST DIMENSION (GROSS MEASUREMENT). C. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 2, SOLID TYPE. D. DCIS CONSTITUTES LESS THAN 5% OF THE TOTAL TUMOR MASS, AND IS PRESENT ADMIXED WITH THE. INVASIVE CARCINOMA. E. SURGICAL MARGINS ARE NEGATIVE FOR INFILTRATING CARCINOMA AND DCIS. INFILTRATING CARCINOMA. IS 0.3 CM FROM THE CLOSEST POSTERIOR MARGIN (3I). F. NO LYMPHOVASCULAR INVASION IDENTIFIED. G. FOCAL DUCTAL EPITHELIAL HYPERPLASIA. H. PREVIOUS BIOPSY SITE CHANGES. I. FIBROCYSTIC CHANGES WITH APOCRINE HYPERPLASIA AND SCLEROSING ADENOSIS. J. IMMUNOSTAIN FOR ESTROGEN RECEPTOR IS POSITIVE. NEGATIVE. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Upper outer quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 1.9 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS, Infiltrating lobular carcinoma. HISTOLOGIC TYPE: Classical. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 7. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: Not applicable. CALCIFICATION: TUMOR TYPE, IN SITU: Solid, DCIS admixed with invasive carcinoma. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPH NODES POSITIVE: 0. LYMPH NODES EXAMINED: 4. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: NON-NEOPLASTIC BREAST TISSUE: FCD. T STAGE, PATHOLOGIC: pT1c. N STAGE, PATHOLOGIC: pNO. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: negative. zero or 1+. COMMENT: invasive HER2/NEU: carcinoma show features of lobular carcinoma in H&E sections. ductal carcinoma The immunohistochemical (membranous stains stains for for E-. E-. The tumors cells show the patten of E-cadherin and strong. diffuse cytoplasmic stain for P120.",BRCA,0,"According to the report, the size of the largest focus of invasive carcinoma is 1.9 cm, which falls within the range for T1 tumors (2.0 cm or less). However, since it is more than 1.0 cm, it is specifically a T1c tumor. The presence of in situ carcinoma, the number of tumors, angiolymphatic invasion, involvement of the nipple or overlying skin, and lymph node metastasis do not affect the T stage. Therefore, the T stage for this patient is T1c.",T1c,33.0
953,TCGA-B6-A400.AF83CCA2-3AA4-4933-B6AD-9C11DF501DDD,1,"AP Surgical Pathology: Corrected. CLINICAL HISTORY: Not provided. GROSS EXAMINATION: A. ""Left axilla non-sentinel node (AF1) "". Received fresh for frozen section is. a 1.8 x 1 x 0.6 cm tan-yellow lymph node candidate which is bisected and. frozen as AF1, the frozen section remnant is submitted in block A1. B. ""Left sentinel node number one (BF1) "". Received fresh for frozen section. are three tan-yellow lymph node candidates. The larger lymph node candidate (2. x 1.2 x 1 cm) is bisected and frozen as BF1, and frozen section remnant is. submitted in block B1. The remaining two lymph node candidates (0.5 x 0.5 x. 0.3 cm and 1 x 0.7 x 0.4 cm lymph node candidate) are submitted in toto as. frozen section BF2, and the frozen remnant is submitted in block B2. C. ""Left sentinel node number two (CF1) Received fresh for frozen section is. a 3 x 2.5 x 0.8 cm fragment of tan-yellow fibrofatty tissue. One lymph node. candidate is identified (1.9 x 1 x 0.7 cm) which is bisected and frozen as. CF1. The frozen section remnant is submitted in block C1. D. ""Left breast cancer, 1:00"", received fresh and placed in formalin: Procedure: Wire guided partial mastectomy. Specimen orientation: Suture: long=lateral, short-superior. Clips: two clips. medial, one clip=inferior. Specimen dimensions: Medial to Lateral: 8.5 cm. Anterior to Posterior: 2.5 cm. Superior to Inferior: 9.5 cm. Skin dimensions: 4.3 x 1.3 cm with a 0.4 cm long scar. Margins inked: Superior: Red. Inferior: Yellow. Anterior: Blue. Posterior: Black. Sectioned: Medial to lateral. Gross findings: There is a tan-white indurated ill defined area with. peripheral hemorrhage and fat necrosis. Lateral and superior to this area is a. second focus of white-tan induration with adjacent thick white-tan fibrous. tissue. The remaining parenchyma is tan-yellow lobulated adipose tissue. Gross tumor size: 2.3 x 2.1 x 1.2 cm. Multifocal tumor: Additional lesion is 1.2 x 0.8 x 0.5 cm which directly abuts. the primary focus. Distance of tumor from gross surgical margin for the primary tumor: Superior: 2.1 cm. Inferior: 3.2 cm. Anterior: 0.6 cm. Posterior: 1.2 cm. Medial: 4.2 cm. Lateral: 1 cm. Additional lesion: Superior: 3.1 cm. Inferior: 2 cm. Anterior: 1 cm. Posterior: 1 cm. Medial: 6.9 cm. Lateral: 0.5 cm. Sectioned specimen radiographed? Yes. Radiograph findings: Mass: Yes. Microcalcifications: Yes. Biopsy site microclip: No. Specimen photograph? Yes. Block diagram? Yes. Sections submitted from medial to lateral in blocks D1 through D35. Specimen completely submitted? No. BLOCK SUMMARY: Medial margin-D1. Lateral margin-D34 and D35. Inferior margin: D13. Superior margin: D19. Anterior and posterior margins: D23. Primary tumor: D10, D11, D15, D16, D17, D18, D21, D22, D23, D24, D25, D27,. D28, D31, D33. Secondary lesion: D25, D27, D28, D31, D32, D33. Microcalcifications: D12, D15, D16, D17, D18, D20, D23, D25, D33. E. ""Left axillary mass, long stitch-lateral, short-superior"", received fresh. and placed in formalin: Procedure: Wire guided partial mastectomy. Specimen orientation: Long stitch lateral, short stitch superior. Specimen dimensions: Medial to Lateral: 5.6 cm. Anterior to Posterior: 1 cm. Superior to Inferior: 3.6 cm. Margins inked: Superior: Red. Inferior: Yellow. Anterior: Blue. Posterior: Black. Sectioned: Medial to lateral. Gross findings: A well circumscribed white-brown nodule with an embedded. microclip in the medial portion. Lateral to this first nodule is a second ill. defined firm nodule. The remaining parenchyma is yellow-tan lobulated adipose. tissue. Gross tumor size:1.6 x 0.6 x 0.5 cm. Multifocal tumor: Second lesion is 1.2 x 0.5 x 0.4 cm, and it is 0.7 cm from. the first. Distance of tumor from gross surgical margin: First nodule: Superior: 1.8 cm. Inferior:0. cm. Anterior: 0.2 cm. Posterior: 0.2 cm. Medial: 2 cm. Lateral: 3.6 cm. Second nodule: Superior: 1.7 cm. Inferior: 1 cm. Anterior: 0.2 cm. Posterior 0.3 cm. Medial: 5.9 cm. Lateral: 1.8 cm. Sectioned specimen radiographed?. Radiograph findings: Mass: Yes. Microcalcifications: Yes. Biopsy site microclip: Yes. Specimen photograph? Yes. Block diagram? Yes. Sections submitted from medial to lateral in blocks E1 through E21. Specimen completely submitted? Yes. BLOCK SUMMARY: Medial margin-E1. Lateral margin:E21. Anterior, posterior, inferior margins for first nodule=E8. Anterior, posterior, superior, inferior margin for second nodule-E13. First nodule-E6, E7, E8, E9, E10, E11. Second nodule:E13, E14, E15, E16. Microclip: E11. Microcalcifications: E8, E13, E19. F. ""Left axillary contents"". Received fresh and placed in formalin is a 6.5 x. 6.5 x 2 cm aggregate of multiple fragments of tan-yellow fibrofatty tissue. Fourteen lymph node candidates are identified ranging in size from 0.5 x 0.5 x. 0.4 cm to 3.5 x 1.5 x 1.3 cm. The smallest lymph node candidate is submitted. in blocks F1-F3, and the two largest lymph node candidates are inked blue and. black, bisected and submitted in blocks F4-F6. A. REPORT REVISED ON. INTRA OPERATIVE CONSULTATION: A. ""Non-sentinel node right axilla"": AF1- one lymph node candidate, bisected. (1.3 x 1 x 0.6 cm) - no tumor is seen (Dr. B. ""Sentinel node number one"": BF1 (one lymph node candidate, bisected, 2 x. 1.6 x 1 cm) positive for metastatic cancer (micrometastases) (Dr. BF2 (two lymph node candidates, intact (0.5 x 0.5 x 0.3 cm) and 1 x 0.6 x 0.4. cm, no tumor is seen (Dr. C. ""Sentinel node number two"": CF1- one lymph node candidate, bisected, 1.9 x. 2 x 0.7 cm, positive for metastatic cancer (micrometastases) (Dr. MICROSCOPIC EXAMINATION: Microscopic examination is performed. PATHOLOGIC STAGE: PROCEDURE: Partial mastectomy, sentinel lymph node biopsy with completion. axillary dissection. PATHOLOGIC STAGE (AJCC. Edition) : pT2 pN2a pMX. NOTE: Information on pathology stage and the operative procedure is. transmitted to this Institution's Cancer Registry as required for. accreditation by the Commission on Cancer. Pathology stage is based solely. upon the current tissue specimen being evaluated, and does not incorporate. information on any specimens submitted separately to our Cytology section,. past pathology information, imaging studies, or clinical or operative. findings. Pathology stage is only a component to be considered in determining. the clinical stage, and should not be confused with nor substituted for it. The exact operative procedure is available in the surgeon's operative report. REVISED DIAGNOSIS. A. ""LEFT AXILLA, NON-SENTINEL LYMPH NODE"" (BIOPSY) : ONE LYMPH NODE, NO EVIDENCE OF MALIGNANCY (0/1) . B. ""LEFT AXILLA, SENTINEL LYMPH NODE # 1"" (BIOPSY) : METASTATIC ADENOCARCINOMA IN THREE LYMPH NODES (3/3) . SIZE OF LARGEST METASTASIS: 6 MILLIMETERS. EXTRACAPSULAR INVASION: ABSENT. C. ""LEFT AXILLA, SENTINEL LYMPH NODE # 2"" (BIOPSY) : METASTATIC ADENOCARCINOMA IN ONE LYMPH NODE (1/1) . SIZE OF LARGEST METASTASIS: 4 MILLIMETERS. EXTRACAPSULAR INVASION: ABSENT. D. ""LEFT BREAST CANCER, 1:00"" (WIRE GUIDED PARTIAL MASTECTOMY) : INVASIVE ADENOCARCINOMA OF THE BREAST. HISTOLOGIC TYPE: DUCTAL. NOTTINGHAM COMBINED HISTOLOGIC GRADE: 3 OF 3. TUBULE FORMATION SCORE: 3. NUCLEAR PLEOMORPHISM SCORE: 3. MITOTIC RATE SCORE: 3. GROSS TUMOR SIZE: 2.3 x 2.1 x 1.2 CM. SIZE OF INVASIVE COMPONENT: 2.3 CM. LOCATION OF THE TUMOR: ADJACENT TO PREVIOUS BIOPSY SITE. LYMPHATIC/VASCULAR INVASION: PRESENT. MULTIFOCAL TUMOR: ABSENT (SECOND MASS LESION DESCRIBED GROSSLY IS FAT. NECROSIS) . IN-SITU CARCINOMA: PRESENT. TYPE OF IN-SITU CARCINOMA: COMEDO. NUCLEAR GRADE OF IN-SITU CARCINOMA: 3 OF 3. NECROSIS: PRESENT. DCIS EXTENDING OUTSIDE INVASIVE TUMOR MASS: ABSENT. SIZE OF IN-SITU CARCINOMA: NOT APPLICABLE. SKIN STATUS: FREE OF TUMOR. STATUS OF NON-NEOPLASTIC BREAST TISSUE: NEEDLE CORE BIOPSY SITE, AND FAT. NECROSIS. SURGICAL MARGIN STATUS: NEGATIVE (GREATER THAN 2 MM) . ESTROGEN/PROGESTERONE RECEPTOR, CELL CYCLE, EGFR AND HER2/NEU ANALYSIS: PENDING, PARAFFIN BLOCK NUMBER D11. RESULTS WILL BE ISSUED SEPARATELY FROM THE IMAGE CYTOMETRY LAB. E. ""LEFT AXILLARY MASS"" (EXCISION) : METASTATIC ADENOCARCINOMA IN ONE OF FOUR AXILLARY LYMPH NODES (1/4). SIZE OF METASTASIS: 1.6 CM. EXTRACAPSULAR INVASION: PRESENT. CHANGES CONSISTENT WITH A NEEDLE CORE BIOPSY SITE ARE PRESENT. MARGIN STATUS: NEGATIVE. F. ""LEFT AXILLARY CONTENTS"" (COMPLETION NODE DISSECTION) : METASTATIC ADENOCARCINOMA IN ONE OF TWENTY LYMPH NODES (1/20) . SIZE OF METASTASIS: 0.5 MILLIMETERS. EXTRACAPSULAR INVASION: ABSENT. COMMENT: This report revised. to correct the site for specimens A-C,. which were received labelled as ""right"" Per. the correct site is. left. is notified of this revision. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es). DIAGNOSIS: SEE REVISED REPORT: REPORT REVISED ON. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es) . CI ADDENDUM 1: Please see. for results of supplementary. tests. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es).",BRCA,2,"The report states that the gross tumor size of the primary breast cancer is 2.3 x 2.1 x 1.2 cm, which is larger than 2.0 cm but not more than 5.0 cm. This corresponds to a T2 stage according to the rules provided.",T2,34.0
646,TCGA-A8-A08F.683AAF99-3B91-4501-B701-C3A4E8439647,1,"Diagnosis: 1. Ablated (right) breast sample with a multifocal invasive ductal carcinoma with. intraductal components and focal angioinvasion (focus of a poorly differentiated. invasive ductal carcinoma with a tumor diameter of 2.8 cm and two further foci of. a. moderately invasive ductal carcinoma with tumor diameters of 3.0 cm and 1 cm). Dorsal resection margin tumor-free with minimum margin of 0.5 cm with the first. tumor focus, 1.5 cm with the second and 0.7 cm with the third, other margins are. free. Tumor classification: NOS, G III, pT2(mult)N3aL1V0R0. N. Site. Prior Prigian Noted QUALIFIED. is. (circle): Die.",BRCA,3,"The report mentions a 'focus of a poorly differentiated invasive ductal carcinoma with a tumor diameter of 2.8 cm'. This is the largest focus of invasive carcinoma, which is larger than 2.0 cm but not larger than 5.0 cm, making it a T2 tumor. The T stage is not affected by the presence of in situ carcinoma or the number of tumors, so the multifocal nature of the tumor does not change the T stage.",T2,35.0
785,TCGA-AO-A03T.D5EF8C37-811E-42B7-84E5-E6ED71217971,1,"Clinical Diagnosis & History: Palpable left breast cancer showing IDC on core. Specimens Submitted: 1: SP: Sentinel node #1, level one, left axilla (fs). 2: SP: Sentinel node #2, level one, left axilla (fs). 3: SP: Sentinel node #3, level one, left axilla (fa). 4: SP: Left breast. 5: SP: Level one anu two lymph nodes left axilla. DIAGNOSIS: 1). LYMPH NODE, SENTINEL #1, LEFT AXILLA LEVEL I, BIOPSY: - METASTATIC CARCINOMA INVOLVING ONE OUT OF ONE LYMPH NODE (1/1). - NO EXTRANODAL EXTENSION SEEN. 2). LYMPH NODE. SENTINEL #2, LEFT AXILLA LEVEL I, BIOPSY: - ONE BENIGN LYMPH NODE (0/1). 3). LYMPH NODE, SENTINEL #3, LEFT AXILLA LEVEL I, BIOPSY: - METASTATIC CARCINOMA INVOLVING ONE OUT OF ONE LYMPH NODE (1/1). - NO EXTRANODAL EXTENSION SEEN. 4). BREAST, LEFT, TOTAL MASTECTOMY: - INVASIVE DUCTAL CARCINOMA, NOS TYPE, HISTOLOGIC GRADE III/III (SLIGHT. OR NO TUBULE FORMATION),. NUCLEAR GRADE II/III (MODERATE VARIATION IN. SIZE AND SHAPE), MEASURING 2.5 CM, GROSSLY. - DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID TYPE WITH. INTERMEDIATE NUCLEAR GRADE AND MODERATE NECROSIS. LOBULAR INVOLVEMENT BY DCIS IS PRESENT. - THE DCIS CONSTITUTES <= 25% OF THE TOTAL TUMOR MASS, AND IS PRESENT. ADMIXED WITH AND AWAY. FROM THE INVASIVE COMPONENT. - THE INVASIVE CARCINOMA IS LOCATED NI THE UPPER OUTER QUADRANT AND. CENTRAL AREA. - THE DCIS IS LOCATED IN THE UPPER OUTER QUADRANT AND CENTRAL AREA. - NO INVOLVEMENT OF THE NIPPLE BY EITHER IN SITU OR INVASIVE CARCINOMA. IS IDENTIFIED. VASCULAR INVASION IS PRESENT. - NO INVOLVEMENT OF THE SURGICAL MARGINS BY EITHER INVASIVE OR IN SITU. CARCINOMA IS IDENTIFIED. NO SKIN INVOLVEMENT BY CARCINOMA IS IDENTIFIED. - THE NON-NEOPLASTIC BREAST TISSUE SHOWS BIOPSY SITE CHANGES, STROMAL. FIBROSIS, ADENOSIS. AND FIBROCYSTIC CHANGES. - RESULTS OF SPECIAL STAINS (ARE AS FOLLOWS: Immunohistochemical stains were performed on formalin-fixed tissue with the. following results for invasive carcinoma (block 4 T 11). ESTROGEN RECEPTOR (6F11,. 95% nuclear staining with moderate intensity. PROGESTERONE RECEPTOR (1E2;. 60% nuclear staining with moderate intensity. HER2 (HercepTest; -. Negative (0 ). Controls are satisfactory. Comment: HercepTestTM. ) is an FDA-approved method for assessment of. HER2 protein overexpression in breast cancer tissue routinely processed for. histological evaluation. The HER2 test results are reported in accordance. with the ASCO/CAP guideline recommendations for HER2 testing in breast. cancer (J Clin Oncol 2007; 25 (1) :1-28) . 5). LYMPH NODES, LEFT AXILLA LEVELS I AND II, RESECTION: - NINE BENIGN LYMPH NODES (0/9). I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL), AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Special Studies: Special Stain. Comment. NEG-HER2. Gross Description: 1) The specimen is received fresh for frozen section consultation, labeled. ""sentinel node number one level 1 left axilla"" and consists of a pink-tan. lymph node measuring 1.2 x 1.0 x 0.4 cm. Bisected and entirely submitted. for frozen section. Summary of sections: FSC -- frozen section control. 2) The snecimen is received fresh for frozen section consultation, labeled. ""sentinel node number two level 1 left axilla"" and consists of tan lymph. node measuring 1.0 x 0.5 x 0.5 cm. Bisected and entirely submitted for. frozen section. Summary of sections: FSC frozen section control. 3) The specimen is received fresh for frozen section consultation, labeled. ""sentinel node number three level 1 left axilla"" and consists of a tan lymph. node measuring 1.5 x 0.8 x 0.8 cm. Bisected and entirely submitted for. frozen section. Summary of sections: FSC - frozen section control. 4). The specimen is received fresh, labeled ""left breast stitch marks. axillary tail"" and consists of a breast measuring 21.5 x 17.5 x 4 cm with. overlying skin ellipse measuring 9.5 x 3 cm. Situated centrally on the skin. surface is an everted nipple measuring 1.5 x 1.2 x 0.8 cm and areola. measuring 3.4 x 2.5 cm. A suture demarcates the axillary aspect. The. posterior surface of the breast is inked black and the specimen is serially. sectioned to reveal a centrally located white-tan firm tumor measuring 2.5 x. 2.5 x 2 cm with extension into upper outer quadrant, and located 1.1 cm from. the deep margin. A metal clip marking the previous biopsy site is. identified. Sectioning of the axillary aspect reveals no grossly. identifiable lymph nodes. Representative sections are submitted. TPS. is. taken. Summary of sections: N - nipple. NB - nipple base. D - deep margin. BX - biopsy site with tumor. T - tumor. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. 5) The specimen is received fresh, labeled ""level 1 and 2 lymph nodes left. axilla"" It consists of a 8 x 8 x 1.5 cm fragment of fibroadipose tissue. without orientation. Multiple lymph nodes are identified, ranging in size. from 0.3 cm to 1.2 cm. All identified lymph nodes are submitted. Summary of sections: LN - whole lymph nodes. Summary of Sections: Part. 1: SP: Sentinel node #1, level one, left axilla (fs). Block. Sect. Site. PC's. 1. FSC. 1. Part 2: SP: Sentinel node #2, level one, left axilla (fs). Block. Sect. Site. PCs. 1. FSC. 1. Part 3: SP: Sentinel node #3, level one, left axilla (fs). Block. Sect. Site. PCs. 1. FSC. 1. Part 4: SP: Left breast. Block. Sect. Site. PCs. 5. BX. 5. 1. D. 1. 2. LIQ. 2. 2. LOQ. 2. 2. N. 2. 1. NB. 1. 7. T. 7. 20. TEST. 20. 2. UIQ. 2. 2. UOQ. 2. Part 5: SP: Level one and two lymph nodes left axilla. Block. Sect. Site. PCs. 4. LN. 9. Intraoperative Consultation: Note: The diagnoses given in this section pertain only to the tissue sample. examined at the time of the intraoperative consultation. 1). FROZEN SECTION DIAGNOSIS: METASTATIC DUCT CARCINOMA. PERMANENT DIAGNOSIS: SAME. 2). FROZEN SECTION DIAGNOSIS: BENIGN. PERMANENT DIAGNOSIS: SAME. 3). FROZEN SECTION DIAGNOSIS: METASTATIC DUCT CARCINOMA. PERMANENT DIAGNOSIS: SAME. M.D.",BRCA,1,"The T stage is determined by the size of the largest focus of invasive carcinoma. In this report, the invasive ductal carcinoma measures 2.5 cm, which falls under T2 (more than 2.0 cm but not more than 5.0 cm in size).",T2,36.0
557,TCGA-A2-A3XY.EC1BB6E8-6897-4E70-80A6-5A4E4B9C4E1F,1,"Specimen #: (Age: Race: Physician (s) : AMENDED. SPECIMEN: LEFT BREAST AXILLARY & CONTENTS. FINAL DIAGNOSIS: BREAST, LEFT, MASTECTOMY WITH AXILLARY DISSECTION: - TUMOR TYPE: INVASIVE DUCTAL CARCINOMA (NO SPECIAL TYPE). - TUMOR FOCALITY: UNIFOCAL. - HISTOLOGIC GRADE: GRADE 3. - NOTTINGHAM SCORE: 9/9 (Tubules= 3, Nuclei= 3, Mitoses= 3 mitotic. count 24 PER 10 high power fields). - TUMOR SIZE (GREATEST DIMENSION) : 2.5 CM (GROSS MEASUREMENT) . - TUMOR SIDE (QUADRANT) : LEFT, UPPER OUTER QUADRANT. - TUMOR NECROSIS: PRESENT IN INVASIVE AND IN SITU CARCINOMA. - MICROCALCIFICATIONS: PRESENT IN DUCTAL CARCINOMA IN SITU AND BENIGN. BREAST TISSUE. - VENOUS/LYMPHATIC INVASION: NONE DEFINITELY IDENTIFIED. - INTRADUCTAL COMPONENT: DUCTAL CARCINOMA IN SITU, NUCLEAR GRADE 3,. SOLID TYPE WITH CENTRAL EXPANSIVE ""COMEDO"" NECROSIS. - MARGINS. - DISTANCE OF INVASIVE CARCINOMA FROM CLOSEST MARGIN: 1.2 MM. (SUPERFICIAL MARGIN). DISTANCE OF IN SITU CARCINOMA FROM CLOSEST MARGIN: 1.0 MM. (SUPERFICIAL MARGIN) AND 1.2 MM (DEEP MARGIN). - LYMPH NODES: 3 OF 17 NODES POSITIVE FOR METASTATIC CARCINOMA. - LARGEST METASTATIC FOCUS: 1.2 CM (MICROSCOPIC MEASUREMENT). - EXTRACAPSULAR EXTENSION: ABSENT. - NIPPLE INVOLVEMENT: ABSENT. - SKIN INVOLVEMENT: ABSENT. - PATHOLOGIC STAGE (AJCC. EDITION) : pT2 N1a. - ANCILLARY STUDIES: - ESTROGEN RECEPTORS: NEGATIVE (os NUCLEAR STAINING) . - PROGESTERONE RECEPTORS : NEGATIVE (0% NUCLEAR STAINING). - HER2 BY FISH: NEGATIVE (HER2/CEP17 RATIO: 1.0; PER. PERFORMED ON PRIOR SPECIMEN FROM. - ADDITIONAL PATHOLOGIC CHANGES : - PRIOR BIOPSY SITE CHANGES. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY ACT OF. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY ACT OF. Specimen #: FINAL DIAGNOSIS (continued): - FIBROADENOMA (1.2 CM; MICROSCOPIC MEASUREMENT) . - USUAL DUCTAL HYPERPLASIA, MODERATE. - SMALL PERIPHERAL PAPILLOMA. - FIBROCYSTIC CHANGES. Comment: : This case is amended. to add the results of. immunohistochemical stains for estrogen and progesterone receptors, as. noted above. No other changes are made. Although ER and PR stains were previously performed on the patient's core. biopsy. they were repeated due the greater number of. neoplastic cells in the current specimen and due to the focal staining for. progesterone receptors (reportedly 1%) in the prior biopsy. Estrogen and progesterone receptors were evaluated by immunohistochemical. methods (. estrogen receptor antibody 1D5, progesterone receptor. antibody PgR636) A positive test is defined as easily discernable nuclear. staining in 1% or more of the tumor cells. CLINICAL DIAGNOSIS AND HISTORY: -yearOold. with left breast mass in. Diagnostic. mammography and ultrasound on. confirmed presence of a 2.2 x. 1.4 cm left upper outer quadrant breast mass. PRE-OPERATIVE DIAGNOSIS: Left breast mass; breast cancer. POST-OPERATIVE DIAGNOSIS: None provided. GROSS DESCRIPTION: Received fresh, labeled with the patient's name. and. designated, ""Left Breast Axillary and Contents"" and consists of a left. mastectomy oriented with a short stitch superior; two short stitches. posterior; one long lateral; and two long on an axillary lymph node. The. specimen weighs 381 grams and measures 17.0 cm medially to laterally; 15.0. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY ACT OF. FOR OFFICIAL USE ONLY - PERSONAL DATA - FRIVACY ACT of. Specimen #: GROSS DESCRIPTION (continued) : cm superiorly to inferiorly; and 2.5 cm anterior to posterior. The darkly. pigmented superficial skin ellipse measures 15.5 x 5.5 cm and displays a. 1.5 x 1.0 x 1.0 cm centrally located, everted nipple, free of discharge. The deep margin is inked black and the superficial margin is inked blue. Serial sections reveal a fairly well defined, firm pink-tan mass in the. upper outer quadrant. The mass measures 2.5 x 1.4 x 0.4 cm, comes to. within 0.4 cm of the deep margin and abuts the superficial margin. Immediately adjacent to, and continuous with the mass, is a 0.4 cm. centrally located, red-brown probable biopsy cavity. A 1.2 x 1. 2 x. 0.5. cm. ell-circumscribed, rubbery fibrous nodule is noted in the lower mid. breast which is consistent with a fibroadenoma. The remainder of the. specimen is composed of markedly dense tan-white fibrous tissue with. minimal admixed adipose tissue. No additional lesions are identified. The attached axillary tail measures 8. x 6.5 x 2.0 cm. Sectioning. reveals 11 lymph nodes ranging in size from 0.3 cm in greatest dimension. to 2.5 x 2.0 x 1.7 cm. On sectioning, the two largest lymph nodes, one of. which is tagged with a suture, are tan-white and moderately firm,. consistent with involvement by metastatic lesion. Representative sections are submitted as follows: 1- nipple; 2- mass with. deep margin; 3. - mass with superficial margin; 4- mass with deep margin;. 5-. mass with superficial margin; 6-7- mass with deep margin; 8-9- mass with. superficial margin; 10- mass; 11- biopsy cavity; 12- - biopsy cavity; 13- -. lower mid nodule; 14- UIQ; 15- LIQ; 16- LOQ; 17; central (adjacent to. mass) i 18- - one lymph node (marked with suture) ; 19- five lymph nodes; 20-. one lymph node; 21- one lymph node, bisected; 22- one lymph node; 23 - one. lymph node; 24-25- one lymph node, sectioned. Matched sections of 1,5,8-10, 12-18, 20 and 22-24 are submitted in. OCT/Paraffin per. Time in formalin: >80 hours. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY ACT OF.",BRCA,1,"The T stage is determined by the size of the largest focus of invasive carcinoma. In this report, the size of the largest focus of invasive carcinoma is 2.5 cm, which falls in the T2 category (T2 tumors are more than 2.0 cm but not more than 5.0 cm in size).",T2,37.0
1350,TCGA-EW-A1P5.82771A56-81CA-4414-949F-EFBCAE1C98D4,1,"F. Pathologic Interpretation: A. Sentinel node # 1 count. - Metastatic carcinoma to one lymph node, (0/1). - Metastatic deposit: 0.6 cm. NOTE: Metastatic deposit is only present on permanent slides. B. Sentinel node # 2 count. - No carcinoma seen in one lymph node (0/1). - Immunohistochemistry for keratin to follow. C. Right breast 1 short superior, 1 long lateral: - Invasiye and in situ moderately differentiated ductal carcinoma, Nottingham grade 2 (3+2+1), 2.5 cm in greatest. dimension. - Resection margins are free of tumor (closest margin at 1.0 cm: inferior). - Lymphovascular invasion is not present. - DCIS, intermediate nuclear grade without necrosis, cribriform type, present in 2 of 15 slides examined. - See Tumor Summary. Tumor Summary: Specimen: - Total breast. Procedure: - Total mastectomy. Lymph Node Sampling: - Sentinel lymph node. Specimen Integrity: - Single intact specimen. Specimen Laterality: - Right. Tumor Size: - Greatest dimension of largest focus of invasion: 2.5 cm. Tumor Focality: - Single focus of invasive carcinoma. Macroscopic and Microscopic Extent of Tumor: - Skin: Invasive carcinoma does not invade into the dermis or epidermis. - Skeletal Muscle: No skeletal muscle present. Ductal Carcinoma in Situ (DCIS): - DCIS is present: - Extensive intraductal component (EIC) negative. - Size (Extent) of DCIS: - Number of blocks with DCIS: 2. - Number of blocks examined: 15. Architectural Pattern: - Cribriform. Nuclear Grade: - Grade II (Intermediate). Necrosis: - Not identified. Lobular Carcinoma in Situ: - Not identified. Histologic Type of Invasive Carcinoma: - Invasive ductal carcinoma. Histologic Grade: SURGICAL PATHOL Report. - Glandular (Acinar)/Tubular Differentiation: - Score 3: <10 of tumor area forming glandular/tubular structures. - Nuclear Pleomorphism: - Score 2: Cells larger than no9rmal with open vesicular nuclei, visible nucieoli, and moderate variability. in both size and shape. - Mitotic Count: - Score 1. - Overall Grade: - Grade 2. Margins: - Margins uninvolved by invasive carcinoma: Distance from closest margin: 10 mm (Inferior). Lymph-Vascular Invasion: - Not identified. Dermal Lymph-Vascular Invasion: - Not identified. Lymph Nodes: Number of sentinel lymph nodes examined: 2. Total number of lymph nodes examined (sentinei and nonsentinel): 2. Number of lymph nodes with macrometastases (>0.2 cm): 1. Number of lymph nodes with micrometastases (>0.2 mm to 0.2 cm and /or > 200 cells): 0. Number of lymph nodes with Isolated tumor cells (1.2 mm and <200 cells): 0. Size of largest Metastatic deposit: 0.6 cm. Extranodal Extension: Not identified. Method of Evaluation of Sentinel Lymph Nodes: - Hematoxylin and eosin (H&E), one level. - Immunohistochemistry. Ancillary Studies: Estrogen Receptor: Pending. Progesterone Receptor: Pending. Her2/neu FISH: Performed on another specimer. Results: Not amplified (HER2 gene copy <4.0 or ratio < 1.8). Pathologic Staging: Primary Tumor (Invasive Carcinoma) (pT): pT2. Regional Lymph Nodes (pN) Modifier: (sn) pN1a. Distant Metastasis (M): Not applicable. Pathologic Staging: pT2, pN1a, MX. NOTE: Some FDA approval. These clones antibodies are used: are ID5=ER, analyte specific PgR 636=PR, reagents A485-HER2, (ASRs) validated H-11=EGFR, by our leboretory CCH2/DOG9=CMV, (Her 2, Parvo, F39.4. H. pylort, 1=AR and HBcore). HPV by Thase ISH. ASRs AI immunohistochertic are cilinically uselui indicators stains are that used. do. not with require formalin or molecular fixed, paraffin embedded tissue. Detection is by LSAB. The results are read by . pathologist as positive or negative. As the attending pathologist, , attest that I: (1) Exemined the relevent. preparation(s) for the specimen(s); and (4) Renderedithe diagnosis(es). Procedures/Addenda. Addendum. Date Complete: Addendum Diagnosis. ""B"" Immunohistochemistry for keratin is negative for carcinoma. SURGICAL PATHOL Report. ""C"" The tumor cells are positive for ER and PR and negative for HER-2 by Immunohistochemistry. MD. Intraoperative Consultation. AFS. Sentinel node # 1 count. ) fs: Negative for carcinoma. BFS. Sentinel node # 2 count : fs: Lymph node; negative for tumor. CFS. Right breast 1 short superior, 1 long lateral fs. Inferior margin; negative for tumor (grossly and microscopically 1.0 cm from margin). Superficial margin-negative for tumor (gross and microscopic microscopically 3 cm from tumor). :, MD. Clinical History: Patient is a. I female with right breast cancer. Pre Operative Diagnosis: Right breast cancer, tissue study patient. Specimen(s) Received: A: Sentinel node # 1 count. fs. B: Sentinel node # 2 count : fs. C: Right breast 1 short superior, 1 long lateral fs. Gross Description: A. Received in formalin and labeled ""sentinel node # 1 count. fs"" consists of irregular shaped, adipose tissue fragment,. 1.5 x 1.1 x 0.6 cm. Specimen submitted as follows. 1. Section for frozen. 2&4. The reminders of the specimen in toto. B. Received in formalin and labeled ""sentinel node # 2 count. fs"" consists of irregular shaped, adipose tissue fragment,. 2.6 x 1.8 x 0.5 cm. Specimen submitted as follows. 1. Sections for frozen. 2&3. Reminders of specimen in toto. C. Received in formalin and labeled ""right breast 1 short superior, 1 long lateral fs"" consists of a mastectomy specimen. weighing 6.63 grams and measures 20.0 x 16.0 x 4.0 cm. Specimen is oriented with a short stitch superior and a long. stitch lateral. There is an ellipse of skin present, 10.0 x 5.5 cm the nipple and areola are present. The areola complex. measure 5.0 cm in greatest dimension. The nipple is inverted, distracted and measures 0.7 cm in greatest dimension. For. gross purpose the specimen is inked as follow: Superior resection margin inked blue, inferior resection margin inked. green, medial resection margin inked red, lateral resection margin inked orange, anterior margin inked yellow and. posterior surgical resection margin inked black. Sectioning of the specimen reveals an ill-defined, pale-tan, firm mass, 2.5. x 1.5 x 1.5 cm. This mass is grossly located 1.0 cm from inferior resection margin and 3.0 cm from lateral resection. margin. It is located 2.0 cm from the anterior resection margin and 1.0 cm from the deep resection margin. upon. sectioning the stroma is composed of yellow, lobulated adipose tissue. The firm, white area is closely associated with the. skin. No other lesions are identified. Specimen submitted as follows. 1. Inferior margin for frozen sections. SURGICAL PATHOL Report. 2. Lateral margin for frozen sections. 3. Nipple. 4-6. Sections of mass. 7. Prior biopsy site with clip. 8. Closest deep margin. 9. Mass with skin. 10. Medial margin. 11. Superior margin. 12. lower inner quadrant. 13. Upper inner quadrant. 14. Upper outer quadrant. 15. Lower outer quadrant. ICD-9(s): 196.3 174.8. Anatomic Pathology Consult Report. F. Client: Interpretation: RIGHT BREAST: INFILTRATING DUCTAL CARCINOMA, INTERMEDIATE NUCLEAR GRADE. IMMUNOHISTOCHEMISTRY IS REPORTED TO BE POSITIVE FOR ESTROGEN RECEPTOR AND. PROGESTERONE RECEPTOR (IN THE ORIGINAL LABORATORY). HER2-FISH IS REPORTED TO BE NEGATIVE (IN THE ORIGINAL LABORATORY). NOTE: Some are amalyses spectic reagents (ASRe) by our Inboratury (Her 2 Parvo, H. Thear ASRs are clinically - indicators that - not require FDA appreval Then clanes. IDS-ER. PgR 6J6-PR, 1485-HER2. H.II-EGFR. CCH2DDG9-CMV, F39 4. /-AR and HPV by ISH A# - are ased - formalia - moleculer Delection is by Method The resulte are - tya. patholagiar or - or -. MD. As the pathologiaz, I Offest that I: (4) the relevant. preparation(s) for the speciman(s); and (ii) Rendered the dagnosts(es). Clinical History: Right breast core biopsy from a. female. Specimen(s) Received: SP consult, slides only. Slide(s)/Block(s) Received: RECEIVED 1 SLIDE LABELED.",BRCA,1,"The T stage is determined by the size of the largest focus of invasive carcinoma. T2 tumors are more than 2.0 cm but not more than 5.0 cm in size. According to the report, the greatest dimension of the largest focus of invasion is 2.5 cm, which falls within the T2 category.",T2,38.0
566,TCGA-A2-A4S3.351D8E38-6E04-4F54-8CB1-975AEB7DB552,1,"M.D. Specimen: Req# : Sp type: SURGICAL P. is M.D. PREOPERATIVE DIAGNOSIS. LEFT BREAST CANCER WITH POSITIVE NODE. OPERATION PERFORMED. DOCTOR (S) : PROCEDURE: MASTECTOMY MODIFIED RADICAL/TOTAL MASTECTOMY. TISSUE REMOVED. A. RIGHT BREAST @. B. LEFT BREAST AND AXILLARY CONTENTS. C. HIGHEST LEFT AXILLARY LYMPH NODE. GROSS DESCRIPTION. RECEIVED IN 3 PARTS. PART A RECEIVED LABELED. RIGHT BREAST STITCH AT 12. O'CLOCK, IS A 1435.5 GRAM MASTECTOMY. SECTIONING REVEALS THE MAJORITY. OF THE SPECIMEN TO CONSIST OF BLAND YELLOW FATTY TISSUE WITH FINE. FIBROUS BANDS. CENTRALLY, THE FIBROUS BANDS BECOME BROADER BUT NO. MASSES ARE IDENTIFIED. REPRESENTATIVE SECTIONS ARE SUBMITTED AS. FOLLOWS: A1--NIPPLE, A2--CENTRAL DEEP MARGIN, A3 AND 4--UPPER INNER. QUADRANT, A5 AND 6--UPPER OUTER QUADRANT, A7 AND 8--LOWER OUTER. QUADRANT, A9 AND 10--LOWER INNER QUADRANT. NOTE: MIRROR IMAGE SECTIONS FROM THE NIPPLE AND RANDOM QUADRANT. SECTIONS (Al, A3, A5, A7, AND A9) ARE SUBMITTED PER CLINICAL BREAST CARE. PROJECT RESEARCH PROTOCOL, FROZEN IN. PART B RECEIVED LABELED. LEFT BREAST AND AXILLARY. CONTENTS DOUBLE STITCH AT 12 O'CLOCK LONG STITCH AT AXILLARY CONTENTS, IS. A 2170 GRAM LEFT MODIFIED RADICAL MASTECTOMY SPECIMEN WHICH MEASURES 34.5. CM FROM MEDIAL TO LATERAL, 24 CM FROM SUPERIOR TO INFERIOR, AND UP TO 6.5. CM FROM ANTERIOR TO THE DEEP MARGIN. THE NIPPLE IS UNREMARKABLE WITHIN A. 30 x 15 CM SKIN ELLIPSE. A SUTURE DENOTES 12 O'CLOCK. THERE IS A MASS. PALPABLE AT THE 3 O'CLOCK AND 12 O'CLOCK POSITIONS AND A MASS PALPABLE. TOWARDS THE AXILLARY TAIL. THE ANTERIOR MARGIN IS MARKED WITH BLUE INK,. THE DEEP IS MARKED WITH BLACK. THE AXILLARY TAIL IS REMOVED AND WHERE IT. IS CUT FROM THE MASTECTOMY SPECIMEN, THE MARGIN IS MARKED WITH RED INK. Specimen. Req# : Sp type: SURGICAL P. M.D. GROSS DESCRIPTION. AND DOES NOT REPRESENT TRUE MARGIN. IN THE LOW AXILLARY TAIL, THERE IS A. 3.5 x 3.2 x 2.3 CM LYMPH NODE. A RIBBON CLIP IS IDENTIFIED. A CENTRAL. CROSS-SECTION IS SUBMITTED IN B2 AND 3. SECTIONING REVEALS 4 MASSES. WITHIN THE UPPER OUTER QUADRANT BETWEEN 300 AND 1200. THE MOST LATERAL AT. 3 O'CLOCK IS A SMALL IRREGULAR AREA MEASURING 1 X 0.8 x 0. 6 CM. THIS IS. 0. TO THE -LATERAL EDGE OF THE. MASS GROSSLY SEPARATED BY 2 CM. THE SECOND MASS MEASURES 3.5 X 2.7 x 3.5. CM FROM MEDIAL TO LATERAL. THE SECOND MASS IS INFERIOR TO THE THIRD AND. FOURTH MASSES WHICH ARE AT 12 O'CLOCK. THE DEEPEST IS A 1.6 x 1.3 x 1 CM. MASS GROSSLY 2 CM DEEP TO THE FOURTH MASS WHICH MEASURES 4 CM FROM. SUPERIOR TO INFERIOR, 3 CM FROM ANTERIOR TO POSTERIOR, AND 4 CM FROM. MEDIAL TO LATERAL. THE DEEPEST OF THESE LESIONS IS 2 CM FROM THE DEEP. MARGIN. THIS LAST LESION IS 1.5 CM BENEATH THE SKIN. THE REMAINING. BREAST TISSUE CONSISTS OF BLAND YELLOW FATTY TISSUE. THE 2 LARGEST. MASSES, ALTHOUGH GROSSLY SEPARATE, APPEAR TO ABUT EACH OTHER AND ANTERIOR. TO THIS AREA IS AN ADDITIONAL 0.6 CM IN DIAMETER MASS (B4) A RIBBON. CLIP IS FOUND AT THE INFERIOR EDGE OF MASS 2. A COIL CLIP IS ALSO. IDENTIFIED WITHIN MASS 2. SECTIONS ARE SUBMITTED AS FOLLOWS: B1--NIPPLE, B2 AND 3--LOW AXILLARY LYMPH NODE, B4-SMALL LESION ANTERIOR. TO THE AREA OF THE 2 LARGER MASSES, B5--THE TISSUE ADJACENT MEDIALLY TO. THE SECOND-DESCRIBED MASS AND INFERIOR TO THE FOURTH-DESCRIBED MASS,. B6--DEEP MARGIN TO MASS 1 AND 2, B7--MASS 1, B8--AREA BETWEEN MASS 1 AND. MASS 2, B9 AND 10--FULL CROSS-SECTION OF MASS 2, B11--HHE MOST MEDIAL. EDGE OF MASS 2, B12--THE MOST LATERAL EDGE OF TUMOR 2, B13--DEEP MARGIN. TO MASS 3 AND 4, B14--TISSUE BETWEEN MASS 3 AND MASS 4 WITH THE RED INK. ALONG THE EDGE ADJACENT TO MASS 4, B15-MASS 3 WITH ADJACENT SMALL. NODULE, B16 THROUGH 18--A LONGITUDINAL SECTION THROUGH MASS 4 FROM. SUPERIOR TO INFERIOR, B19--THE MOST LATERAL AREA OF MASS 4, B20--THE MOST. MEDIAL ASPECT OF MASS 4, 321--HHE ANTERIOR MARGIN TO MASS 4 SUPERIOR TO. THE SKIN ELLIPSE. NOTE: SECTIONS ARE SUBMITTED FROZEN IN. PER THE CLINICAL BREAST CARE. PROJECT RESEARCH PROTOCOL WITH A MIRROR IMAGE OF THE NIPPLE AND RANDOM. QUADRANT SECTIONS (B1 AND B22-B25) IN ADDITION, SECTIONS OF THE LARGE. LYMPH NODE #1 ARE SUBMITTED AS P1-2 WITH TISSUE ALSO FROZEN IN. TISSUE FROM THE FIRST TUMOR (B7) IS SUBMITTED AS P3, OF THE SECOND TUMOR. AS P4-5 AND P10 WITH TISSUE ALSO FROZEN IN. OF THE THIRD TUMOR AS P6. AND THE FOURTH TUMOR AS P7 THROUGH p9 WITH ADDITIONAL TISSUE FROZEN IN. TISSUE TAKEN BETWEEN MASS 3 AND 4 (B14) IS SUBMITTED AS P11. FURTHER EXAMINATION OF THE AXILLARY TAIL REVEALS 6 ADDITIONAL LYMPH. NODES, ONE OF WHICH IS GROSSLY POSITIVE. THESE ARE SUBMITTED AS. FOLLOWS: B26-GROSSLY POSITIVE NODE BISECTED, B27- NODE BISECTED,. B28--1 VERY SMALL NODE BISECTED, B29--2 NODES, B30 THROUGH B32--1 NODE. Specimen. Req# : Sp type: SURGICAL P. M.D. GROSS DESCRIPTION. TOTAL, SECTIONED. PART C RECEIVED LABELED. HIGHEST LEFT AXILLARY. NODE, ARE 4 FRAGMENTS OF YELLOW FATTY TISSUE TOGETHER MEASURING 16 x 2.8. X 1.2 CM. THIS IS EXAMINED FOR LYMPH NODES OF WHICH 6 ARE IDENTIFIED. THESE ARE SUBMITTED AS. FOLLOWS: NODE SECTIONED, C2 4. NODES,. C3--1 NODE BISECTED. COMMENT: THIS CASE IS IN COMPLIANCE WITH CAP/ASCO GUIDELINE OF 6-48. HOURS FORMALIN FIXATION TIME. PATH PROCEDURES. PROCEDURES: 88305, 88307, 88309, A BLK/10, B BLK/32, C BLK/3. FINAL DIAGNOSIS. PART A RIGHT BREAST, MASTECTOMY: BREAST TISSUE WITH FIBROCYSTIC CHANGE. WITH DUCT HYPERPLASIA OF THE USUAL TYPE, APOCRINE METAPLASIA AND CYST. FORMATION. CALCIFICATIONS ARE PRESENT. NO EVIDENCE OF ATYPIA OR. MALIGNANCY. NIPPLE WITH HYPERKERATOSIS OF THE EPIDERMIS. PART B LEFT BREAST, MODIFIED RADICAL MASTECTOMY: 1. MULTICENTRIC IN SITU AND INFILTRATING DUCT CARCINOMAS GRADE 3 WITH. NUCLEAR GRADE 2 AND HIGH MITOTIC INDEX. I DC 3/2/3 X 5. 2. MULTIPLE INVASIVE TUMORS ARE PRESENT MEASURING 4, 10, 12, 35 AND 40. MM IN GREATEST DIMENSION. 3. LYMPHATIC INVASION IS PRESENT. 4. METASTATIC CARCINOMA TO 2 OF 7 AXILLARY LYMPH NODES. 5. THE POSTERIOR AND ANTERIOR MARGINS AND NIPPLE ARE FREE OF NEOPLASM. 6. FIBROCYSTIC CHANGE. TUMOR. (8), NEGATIVE FOR % LN. PART C HIGHEST AXILLARY LEFT LYMPH NODES: LYMPH NODES. Discrepancy. noted. QUALIFIED. onte Ke liewed.",BRCA,1,"The report mentions 'multiple invasive tumors are present measuring 4, 10, 12, 35 and 40 mm in greatest dimension.' The largest tumor measures 40 mm, which is greater than 5.0 cm and falls under T3 classification according to the rules provided.",T3,39.0
1153,TCGA-D8-A1XT.99050E48-8DFE-4405-B8D8-7649CE2C9CFF,0,"page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breast. !. Expected time of examination: up to 8 working days. Clinical diagnosis: Bifocal cancer of the right breast. Results of immunohistochemical examination: Tumour 1. No estrogen receptors found in neoplastic cell nuclei. No progesterone receptors found in neoplastic cell nuclei. HER2 protein. stained using rabbit antibody Ventana PATHWAY HER-2/neu (485). Positive reaction in invasive cancerous cells (Score = 3+). Tumour 2. No estrogen receptors found in neoplastic cell nuclei. No progesterone receptors found in neoplastic cell nuclei. HER2 protein. stained using rabbit antibody Ventana PATHWAY HER-2/neu (4B5). Positive reaction in invasive cancerous cells (Score = 3+). validated by: I. Macroscopic description: Right breast sized 26 x 19 x 5 cm with axillary tissues sized 11 x 8 x 2 and a skin flap of 24 x 2.5 cm. Tumour sized 1.6 x 1.5 x I.3 cm found on the boundary of lower quadrants, located 1.3 cm from the lower boundary, 1 cm from. the base and 4 cm from the skin. The other tumour present in the upper outer quadrant, sized 1.6 x 1.5 x 1.2 cm, removed by 0.1 cm from the base, 0.6 cm from. the skin and 3 cm from the upper boundary. Microscopic description: Both tumours: Carcinoma ductale invasivum NHG3 (3+3+2/ 12 mitoses /10 HPF, visual area diameter: 0.55mm). Few. foci of carcinoma ductale in situ (DCIS) (papillary type, with medium nuclear atypia and comedo necrosis of 5% of. the tumour). In situ lesions of the type carcinoma intraductale mamillae. Glandular tissue showing parenchymal atrophy. AXILLARY LYMPH NODES:Metastases carcinomatosae in lymphonodis (No III/X). page 2 / 2. Examination: Histopathological examination. Gender: F. Infiltratio telae perinodalis. Test result: Carcinoma ductale invasivum bifocale et ductale in situ mammae dextrae. Invasive bifocal ductal carcinoma and ductal. carcinoma in situ of the right breast. Metastases carcinomatosae in lymphonodis axillae (No III/X). Cancer metastases in axillary. lymph nodes (NHG3, pTlc, pNIa). Compliance valida.",BRCA,1,"The report mentions two invasive tumors with the largest focus being 1.6 x 1.5 x 1.3 cm, which is more than 2.0 cm but not more than 5.0 cm. This indicates a T2 stage according to the rules provided.",T2,40.0
1506,TCGA-S3-AA15.DD2B9E47-8C67-4599-B0B6-0D30DE727B55,1,"Female. Admission Date: Discharge Date: Collected Date/Time: Received Date/Time: Final Diagnosis. A. RIGHT SENTINEL LYMPH NODE, EXCISION: - METASTATIC CARCINOMA TO ONE LYMPH NODE (1/1). - THE FROZEN SECTION DIAGNOSIS IS CONFIRMED. SEE SPECIAL STAINS AND SYNOPTIC REPORT. B. RIGHT BREAST, MASTECTOMY WITH AXILLARY LYMPH NODES DISSECTION: - INVASIVE DUCTAL CARCINOMA, GRADE 3, MEASURING 1.1 CM, EXTENDING TO 5 MM FROM THE CLOSEST. POSTERIOR RESECTION MARGIN, WITH ILYMPHOVASCULAR INVASION. - DUCTAL CARCINOMA IN-SITU, NUCLEAR GRADE 3, WITH FOCAL NECROSIS, EXTENDING TO MORE THAN 5. MM FROM THE CLOSEST POSTERIOR RESECTION MARGIN. - MICROMETASTATIC CARCINOMA (0.21 MM) TO 1 OF 12 AXILLARY LYMPH NODES (1/12). - HEALING BIOPSY SITE WITH ORGANIZING HEMATOMA. - SKIN AND NIPPLE WITH SCLEROSING ADENOSIS. - SEE SYNOPTIC REPORT AND SPECIAL STAINS. (Electronic signature). Verified: Synoptic Report. SPECIMEN: Total breast (including nipple and skin). PROCEDURE: Total mastectomy (including nipple and skin). LYMPH NODE SAMPLING: Axillary dissection (partial or complete dissection). SPECIMEN INTEGRITY: Single intact specimen (margins can be evaluated). SPECIMEN SIZE: Greatest dimension: 30 cm. Print Date/Time: Distribute to: Patient Locations: surgical Pathology Report. Collected Date/Time: Received Date/Time: Additional dimensions: 22 X 7 cm. SPECIMEN LATERALITY: Right. TUMOR SITE: INVASIVE CARCINOMA: Upper inner quadrant. TUMOR SIZE: SIZE OF LARGEST INVASIVE CARCINOMA: Microinvasion only (<=0.1 cm). Greatest dimension of largest focus of invasion over 0.1 cm: 1.1 cm. TUMOR FOCALITY: Single focus of invasive carcinoma. MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR: Skin: Invasive carcinoma does not invade into the dermis or epidermis. DUCTAL CARCINOMA IN SITU (DCIS): DCIS is present. Extensive intraductal component (EIC) negative. NUCLEAR GRADE: Grade III (high). NECROSIS: Present, focal (small foci or single cell necrosis). HISTOLOGIC TYPE OF INVASIVE CARCINOMA: Invasive ductal carcinoma (no special type or not otherwise specified). GLANDULAR (ACINAR)/TUBULAR DIFFERENTIATION: Score- 3: <10% of tumor area forming glandular/tubular structures. NUCLEAR PLEOMORPHISM: Score 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very. large and bizarre forms. MITOTIC COUNT: Score 2. Number of mitoses per 10 high-power fields: 17. Diameter of microscope field: 0.55 mm. OVERALL GRADE: Grade 3: scores of 8 or 9. MARGINS: Margins uninvolved by invasive carcinoma. Distance from closest margin: POSTERIOR 5 mm. Distance from anterior margin: >5 mm. Margins uninvolved by DCIS (if present). Distance from anterior margin: >5 mm. Distance from posterior margin: >5 mm. TREATMENT EFFECT: RESPONSE TO PRESURGICAL THERAPY: IN THE BREAST: No known presurgical therapy. TREATMENT EFFECT: RESPONSE TO PRESURGICAL THERAPY: IN THE LYMPH NODES: No known presurgical therapy. LYMPH-VASCULAR INVASION: Present. Print Date/Time: Collected Date/Time: Received Date/Time: DERMAL LYMPH-VASCULAR INVASION: Not identified. LYMPH NODES: Number of sentinel lymph nodes examined: 1. Total number of lymph nodes examined (sentinel and nonsentinel): 13. Number of lymph nodes with macrometastases (>0.2 cm): 1. Number of lymph nodes with micrometastases (>0.2 mm to 0.2 cm and/or >200 cells): 1. Number of lymph nodes with isolated tumor cells (less than or equal to 0.2 mm and less than or equal to 200 cells): 0. Size of largest metastatic deposit: 0.9 CM. EXTRANODAL EXTENSION: Not identified. METHOD OF EVALUATION OF SENTINAL LYMPH NODES: Hematoxylin and eosin (H&E), one level. PRIMARY TUMOR (INVASIVE CARCINOMA (pT): pT1c: Tumor >10 mm but less than or equal to 20 mm in greatest dimension. REGIONAL LYMPH NODES (pN): pN1a: Metastases in 1 to 3 axillary lymph nodes, at least 1 metastasis greater than 2.0 mm. DISTANT METASTASIS (M): Not applicable. ESTROGEN RECEPTOR: Performed on another specimen. Specimen (accession number): PROGESTERONE RECEPTOR: Performed on another specimen. Specimen (accession number): HER2/NEU IMMUNOPEROXIDASE STUDIES: Performed on another specimen. Specimen (accession number): MICROCALCIFICATIONS. Not identified. CLINICAL HISTORY: Mass or architectural distortion. Source of Specimen. A. Lymph Nodes, Rt. Sentinel. B. RT Breast and Axillary Nodes I & II. Clinical Information. African American female with right breast cancer, silk marks axilla upper inner quadrant. PRE-OP DIAGNOSIS: Right breast cancer. POST-OP DIAGNOSIS: Same. TYPE OF PROCEDURE: Right breast mastectomy and Sentinel node biopsy. Gross Description. Print Date/Time: Female. Collected Date/Time: Received Date/Time: Specimen is received in 2 parts: A. The specimen is labeled ""RIGHT SENTINEL NODE"" and is received unfixed for frozen section diagnosis. (The specimen is in the. formalin. more. than 6 hours and less than 48 hours). It consists of a large lymph node measuring 3.5 x 2 x 2 cm. Sectioned and. entirely submitted in cassettes FSA 1-FSA3. Time specimen was removed from the patient: Time specimen was placed in formalin : Ischemic time: 27 minutes. B. The specimen is labeled ""RIGHT BREAST AND AXILLARY NODES I AND II"" and is received in formalin. (The specimen is. in the formalin more than 6 hours and less than 48 hours). It consist of mastectomy specimen with lymph nodes weighing 1150. grams and measuring 30 x 22 x 7 cm with brown skin ellipse measuring 21 x 10 cm, containing grossly unremarkable 2.0 cm in. diameter nipple. The skin is tagged with a black stitch designating the axilla The posterior margin is composed of smooth fascia. which is inked black. The breast is sliced in sagittal planes revealing a 5 x 5 x 4 cm hemorrhagic cavity within the upper inner-central. quadrants which is 0.7 cm away from the closest deep fascial margin of resection. The remaining parenchyma reveals unremarkable. yellow mammary fat with streaks of white-gray mammary parenchyma. Representative sections are submitted as follows: B1 = one lymph node, bisected. B2 = one lymph node, bisected. B3 = one lymph node, bisected. B4 = 5 lymph nodes. B5 = 2 lymph nodes, one bisected. B6 = one lymph node, bisected. B7 = one lymph node, bisected. B8 = one lymph node, bisected. B9-E = upper inner quadrant-central mass. B13 = mass closest to deep fascial margin of resection. B14 = nipple. B15 = upper inner quadrant. B16 = upper outer quadrant. B17 = lower outer quadrant. B18 = lower inner quadrant. B19-28= additional sections from biopsy cavity. Time specimen was removed from the patient: Time specimen was placed in formalin : Ischemic time: 18 minutes. Intra Operative Consultation. Right sentinel lymph node: one lymph node, positive for carcinoma (1/1). Special Stains/Slides. Immunohistochemical studies were performed on formalin fixed, paraffin-embedded tissue (Block B2, B5, B6) with adequate positive. and negative control sections. Immunostains for keratins AE1/AE3 are negative for carcinoma. Print Date/Time: Collected Date/Time: Received Date/Time: The performance characteristics of these antibodies were determined by the. They have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such. clearance or approval is not necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research. This laboratory is. certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high-complexity clinical laboratory testing. Tissue Code.",BRCA,1,"The report states that the 'SIZE OF LARGEST INVASIVE CARCINOMA: Microinvasion only (<=0.1 cm). Greatest dimension of largest focus of invasion over 0.1 cm: 1.1 cm.', which indicates that the largest focus of invasive carcinoma is 1.1 cm. According to the rules provided, T1 tumors are 2.0 cm or less in size, and T1c specifically refers to tumors that are greater than 10 mm but less than or equal to 20 mm in greatest dimension. Therefore, the T stage for this patient is T1c.",T1c,40.0
975,TCGA-BH-A0BC.9714A9F8-B507-43E6-9D56-1852F5D1F675,1,"FINAL DIAGNOSIS: PART 1: BREAST, LEFT, 12 O'CLOCK, NEEDLE LOCALIZED EXCISIONAL BIOPSY -. A. ATYPICAL DUCTAL EPITHELIAL HYPERPLASIA (see comment). B. COMPLEX PAPILLARY PROLIFERATIVE LESIONS. C. DUCTAL EPITHELIAL HYPERPLASIA. D. ADENOSIS AND SCLEROSING ADENOSIS. E. COLUMNAR CELL CHANGES AND HYPERPLASIA WITH ASSOCIATED MICROCALCIFICATIONS. F. FIBROCYSTIC CHANGES WITH APOCRINE METAPLASIA. G. DUCT ECTASIA. H. MICROSCOPIC RADIAL SCARS. I. MARKED CAUTERY ARTIFACT. J. BIOPSY RELATED CHANGES. PART 2: BREAST. RIGHT. 9 O'CLOCK, NEEDLE LOCALIZED SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA WITH LOBULAR FEATURES, 3.2 CM (GROSS), NOTTINGHAM GRADE 2/3. (COMBINED NOTTINGHAM SCORE 6/9: TUBULE FORMATION 3/3, NUCLEAR ATYPIA 2/3, MITOTIC ACTIVITY. 1/3) (see comment). B. DEFINITIVE DUCTAL CARCINOMA IN SITU is NOT IDENTIFIED. C. EXTENSIVE LYMPHOVASCULAR INVASION. D. MARGINS FREE, CLOSEST MEDIAL, ANTERIOR, DEEP AND INFERIOR WITHIN 0.5 CM. E. ATYPICAL DUCTAL EPITHELIAL HYPERPLASIA. F. FIBROCYSTIC CHANGES. G. INTRADUCTAL PAPILLOMA. H. BIOPSY SITE CHANGES. I. MARKED CAUTERY ARTIFACT. J. PATHOLOGIC STAGE (see comment). PART 3: BREAST, RIGHT, NEW MARGIN, EXCISION -. A. COMPLEX PAPILLARY PROLIFERATIVE LESION. B. DUCTAL EPITHELIAL HYPERPLASIA. C. ADENOSIS AND SCLEROSING ADENOSIS. D. COLUMNAR CELL CHANGES AND HYPERPLASIA. E. FIBROCYSTIC CHANGES WITH APOCRINE METAPLASIA. F. DUCT ECTASIA. G. MARKED CAUTERY ARTIFACT. PART 4: SENTINEL LYMPH NODE # 1, RIGHT, BIOPSY -. A. METASTATIC CARCINOMA INVOLVING ONE LYMPH NODE. B. METASTATIC FOCUS, 1.2 CM IN GREATEST DIAMETER (ENTIRE LYMPH NODE). C. EXTRACAPSULAR EXTENSION IS IDENTIFIED, 0.5 CM X 0.2 CM. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Segmental. Not specified. SIZE OF TUMOR: Maximum dimension invasive component: 3.2 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 6. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPH NODES POSITIVE: 1. LYMPH NODES EXAMINED: 1. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SIZE OF NODAL METASTASES: Diameter of largest lymph node metastasis: 15.0 mm. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: NON-NEOPLASTIC BREAST TISSUE: ADH. T STAGE, PATHOLOGIC: pT2. N STAGE, PATHOLOGIC: pN1. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: zero or 1+.",BRCA,3,"According to the report, the maximum dimension of the invasive component of the tumor is 3.2 cm. Based on the rules provided, T2 tumors are more than 2.0 cm but not more than 5.0 cm in size. Therefore, the T stage for this patient is T2.",T2,41.0
938,TCGA-B6-A0WV.506BFD3B-240B-440E-B7A0-E596FC0B7F72,1,"Gurgical. Patho. CLINICAL HISTORY: S/P tru cut biopsy of 3.5 cm breast self detected lesion. Moderately. differentiated NSABP II, grade adenocarcinoma. Breast carcinoma. GROSS EXAMINATION: A. ""Right breast mass"", in formalin. A 4 x 3 x 1.5 cm piece of yellow-white. fibrofatty breast tissue containing a 3.5 x 3 x 2 cm firm, gritty, white-pink,. infiltrating tumor. Margins are not an issue for this specimen per Dr. therefore, the specimen is not inked. Representative sections of. the tumor are submitted in Blocks A1-A3. B. ""Right breast"", unfixed. A 22 x 15 x 5 cm mastectomy specimen with. axillary tail. The breast has a 19 x 13 cm skin ellipse containing nipple and. areola with a 6 cm long horizontal sutured biopsy site located directly above. the nipple. The external surface of the breast is inked in black. The skin surface, nipple and areola are grossly unremarkable. Cross sectioning through the breast specimen reveals a soft yellow-white. fibrofatty breast parenchyma along with an 8 x 6 x 5 cm hollow biopsy cavity. running in a horizontal direction beneath the nipple which is lined by pink,. thin, smooth, membranous tissue. No residual tumor is identified. The edges. of the biopsy cavity lie 3 cm, 1 cm, 7 cm and 7 cm from the superior,. deep/posterior and inferior inked tissue margins. No other lesions are noted. BLOCK SUMMARY: B1 representative section of nipple. B2 biopsy cavity and corresponding inked deep/posterior surface. B3-B4 additional sections of biopsy cavity. B5-B6 representative sections of upper lateral portion of breast. B7-B8 representative sections of lower lateral portion of breast. B9-B10 representative sections of upper medial portion of breast. B11-B12 representative sections of lower medial portion of breast. B13 1 bisected lymph node candidate from most medial portion of axillary. tail. B14. 2 lymph node candidates from most medial portion of axillary tail. B15. 3 lymph node candidates from the middle portion of the axillary tail. B16. 2 lymph node candidates from the middle portion of the axillary tail. B17. 1 bisected lymph node candidate from the middle portion of the axillary. tail. B18 2 lymph node candidates from the middle portion of the axillary tail. B19 2 lymph node candidates from the most lateral portion of. tail. Dr. DIAGNOSIS: A. ""RIGHT BREAST"", (BIOPSY) : INFILTRATING DUCTAL CARCINOMA. 3.5 x 3 x 2. NSABP HISTOLOGIC GRADE 2 OF 3, NUCLEAR GRADE MODERATELY DIFFERENTIATED. VASCULAR INVASION IDENTIFIED. B. ""RIGHT BREAST"", (MASTECTOMY WITH AXILLARY TAIL) : BREAST: NO RESIDUAL CARCINOMA. BENIGN PROLIFERATIVE CHANGES, INCLUDING EPITHELIAL HYPERPLASIA OF USUAL. TYPE AND BLUNT DUCT ADENOSIS. RECENT BIOPSY CAVITY WITH NO EVIDENCE OF MALIGNANCY. SKIN AND NIPPLE WITH NO HISTOLOGIC ABNORMALITY. AXILLARY LYMPH NODES. METASTATIC CARCINOMA IN 4 OF 7 LYMPH NODES. EXTRACAPSULAR SPREAD PRESENT. LARGEST LYMPH NODE 2.1 CM. M.D. Pager ID#. COMMENT:",BRCA,1,"The T stage is determined by the size of the largest focus of invasive carcinoma. In this report, the largest focus of invasive carcinoma is measured as 3.5 x 3 x 2 cm, which falls in the T2 category of being more than 2.0 cm but not more than 5.0 cm in size.",T2,42.0
1463,TCGA-MS-A51U.58D54D1A-3A8D-40DD-A643-846CAF242494,1,"pN: Regional nodes (pN). pN1  total positive nodes). M: Distant metastases (M). M0 (clinically absent). SPECIMEN(S): A: Left sentinel lymph node #1. B: Left sentinel lymph node #2. C: Left breast with axillary lymph nodes. D: Right breast. FINAL DIAGNOSIS: Amended Microscopic Breast Carcinoma Checklist (see below). A. Lymph nodes, ""left sentinel lymph node #1,"" biopsy (including AFS1). - Metastatic carcinoma in one lymph node consistent with breast. primary (1/1). - Metastatic deposit measures 6mm in greatest dimension. - No extracapsular extension. B. Lymph nodes, ""left sentinel lymph node #2,"" biopsy (including BFS1). - Two lymph nodes with no evidence of malignancy (0/2). C. Breast left, modified radical mastectomy. - Invasive lobular carcinoma. - Multifocal with largest tumor 3.2 cm in greatest dimension in. upper outer quadrant; additional foci in retroareolar area and lower. outer quadrant up to 1.1cm in greatest dimension. - Histological grade = 2/3 (score: tubules 3 + nucleus 2 + mitoses 1 =. 6/9) by. criteria. - Mitotic index = <1/hpf (low). - Margins negative for invasive carcinoma (nearest = 1.2 cm; location: deep margin). - Lobular carcinoma in situ (LCIS). - LCIS comprises 5% of total carcinoma in specimen. - Nuclear grade 1/3 by SBR criteria (low). - Margins negative for LCIS. - Metastatic carcinoma present in one of fifteen lymph nodes (1/15). - Tumor deposit measures 4mm in greatest dimension, with no. extracapsular extension. - Nevus cell aggregate also identified. D. Breast, right, prophylactic simple mastectomy. - Fibrocystic changes. - Columnar cell hyperplasia. - Usual ductal hyperplasia. - No evidence of atypical hyperplasia, in situ carcinoma, or invasive. carcinoma. - Skin, nipple, and resection margins unremarkable. COMMENT: This report was amended to correct the number of positive nodes in the. microscopic section, in the ""Breast Carcinoma Checklist."" The Diagnosis. above is unchanged, and is correct, with a total of 2 positive nodes;. that count has been re-verified by review of the microscopic slides. The microscopic checklist section has now been corrected, to indicate. that a total of 2 nodes are positive. The ""N"" stage has thus been. corrected to pN1, as well. This case was discussed with. it a recent. conference, and he in fact pointed out this discrepancy. I informed him. at that time that I would make these corrections to the report. CLINICAL HISTORY: The patient is a. year-old woman with biopsy proven infiltrating. lobular cancer of the left breast (ER+ PR+ Her2/neu-). Operative. procedure: Sentinel lymph node biopsies, left modified radical. mastectomy and right simple mastectomy. GROSS: Received are four fresh containers each labeled with the patient's name. A. The first container is additionally labeled ""A - left. sentinel lymph node #1."" The specimen consists of a 2.1 X 2.06 cm. fragment of pale, yellow-tan, fibrofatty tissue. A single potential. lymph node is identified measuring 1.8 cm in greatest dimension. The. node is serially sectioned and entirely submitted for frozen section. analysis as AFS1. B. The next container is labeled ""B - left sentinel lymph node. #2."" The specimen consists of a 1.8 x 1.5 x 0.4 cm fragment of. yellow-tan, fibrofatty tissue. Two potential lymph nodes are identified. measuring 0.8 X 0.4 cm in greatest dimension. The smaller node is inked. black. The nodes are serially sectioned and entirely submitted for. frozen section analysis as BFS1. The remaining adipose tissue is. submitted for permanent sections in cassette B2. Summary of Sections: BFS1 - two potential sentinel lymph nodes, entirely submitted. B2 - remaining soft tissue. C. The next container is labeled ""C - left breast at 12 o'clock. with left axillary node dissection."" The specimen consists of a 613 gm. modified radical mastectomy with axillary tail. The breast measures 17. cm medial to lateral, 15.5 cm superior to inferior and 3.9 cm. superficial to deep. The attached axillary tail measures 8 X 7.5 x 2. cm. There is an attached ovoid portion of skin measuring 4 X 3.5 cm. with an everted, freely mobile nipple which measures 2.5 X 2.5 cm with. the areolar complex. The deep fascial plane is inked black, the. remaining superior half is inked blue with the remaining inferior half. inked green. The specimen is serially sectioned from medial to lateral. A gray-white, firm, irregularly-bordered mass is identified in the. upper outer quadrant measuring 3.2 X 2.2 X 1.3 cm in greatest dimension. This mass is consistent with a bilobed single mass. However, it could. represent two separate masses. The central area of the mass is. submitted which could represent normal parenchyma in between the two. masses. The mass is 1.8 cm to the deep margin and 2.5 cm to the nipple. A dumbbell-shaped biopsy clip is identified near the medial portion of. the mass. There are firm, indurated possibly calcified areas located. posteriorly to the nipple. The axillary tail is dissected to reveal 19. potential lymph nodes ranging in size from 0.3 to 2.6 cm in greatest. dimension. The nodes are entirely submitted. The specimen is sectioned. and laced in formalin. Summary of Sections: C1 - middle portion of mass. C2-C3 - medical portion of tumor. C4 - lateral portion of tumor with deep margin. C5 - lateral portion of tumor. C6 - representative upper inner quadrant. C7 - representative upper outer quadrant. C8 - representative lower outer quadrant. C9 - representative lower inner quadrant. C10 - representative retroareolar areas of induration. C11 - nipple. C12 - one potential lymph node, bisected, entirely submitted. C13 - one potential lymph node, bisected, entirely submitted. C14 - one potential lymph node, bisected, entirely submitted. C15 - six potential lymph nodes, submitted intact. C16 - six potential lymph nodes, submitted intact. C17 - four potential lymph nodes, submitted intact. D. The next container is additionally labeled ""D - right. breast."" The specimen consists of a 510 gm simple mastectomy measuring. 20 X 17x2.8 cm. Attached roughly ovoid portion of skin measures 3.9 X. 2.5 cm which is pale tan without lesions identified. The attached. nipple is everted and freely mobile and measures 2.7 x 2.0 cm with the. areolar complex. The deep fascial plane is inked black. The remaining. specimen is inked blue. The specimen is unoriented. It is serially. sectioned to reveal yellow-tan, lobulated parenchyma with interspersed,. dense and gray-white fibrosis and fibrocystic change. A small 0.6 cm. area of hemorrhage is identified located at the periphery. Masses or. lesions suspicious for malignant process are not grossly identified. The specimen is arbitrarily divided into quadrants and representative. sections are submitted. The specimen is sectioned and placed in. formalin . Summary of Sections: D1 nipple. D2-D3 - representative of quadrant 1. D4-D5 - representative of quadrant 2. D6-D7 - representative of quadrant 3. D8-D9 - representative of quadrant 4. INTRAOPERATIVE CONSULTATION: FROZEN SECTION DIAGNOSIS: AFS1: Left sentinel lymph node #1 - ""Metastatic breast carcinoma in. one lymph node."". FROZEN SECTION DIAGNOSIS: BFS1: Left sentinel lymph node #2 - ""Two lymph nodes with no evidence. of malignancy."". MICROSCOPIC: Microscopic examination is performed. Permanent sections confirm the. frozen section diagnoses. Breast carcinoma checklist: Operative procedure: mastectomy. Specimen size: 17 x 15.5 X 3.9 cm. Specimen integrity: Intact. Tumor location: Upper outer quadrant, lower outer quadrant, and. sub-areolar. Tumor focality: Multifocal. Tumor size: 3.2 x 2.2x1.3 cm, with other nodules as large as 1.1 cm. Tumor extent: tumor limited to breast, without invasion of skin or. muscle. Tumor type: Infiltrating lobular carcinoma. Histologic grade: 2/3 (score: tubules 3 + nucleus 2 + mitoses 1 = 6/9). by ESBR criteria. Mitotic index: <1/hpf (low). Lymphovascular invasion: Present. Perineural invasion: Absent. Margins of invasive carcinoma: Negative (nearest = 12 mm; location;. deep). In situ carcinoma: Present; Lobular carcinoma in situ (LCIS). Extent of in situ carcinoma: Non-extensive, comprises 5% of total. carcinoma. Grade of in situ carcinoma: 1/3 by SBR criteria (low). Margins of in situ carcinoma: Negative. Paget's disease: Absent. Number of Lymph nodes examined: 18. Number of Lymph nodes positive: 2 (1/3 sentinel nodes, and 1/15. nodes from mastectomy). Size of largest metastatic focus: 6 mm. Extracapsular extension: Absent. Receptor studies (performed on prior biopsy). ER +. PR:+. her2/neu:-. AJCC Cancer Staging: pT: Primary tumor (pT). pT2.",BRCA,1,"The T stage is determined by the size of the largest focus of invasive carcinoma. In this report, the largest tumor is located in the left breast and measures 3.2 cm in greatest dimension. Therefore, the T stage is T2.",T2,43.0
